Gene,Mutation_Remark,System/Pathway_info,Drug_Name_and_Combination,Phases,Primary Phenotype Measures,Primary/Secondary_Hypertension,Drug_Class,Source
ACE,homozygous or compound heterozygous mutation in genes encoding components of the angiotensin-converting enzyme (106180) on chromosome 17q23,Renin-angiotensin system,DRUG: Olmesartan medoxomil+ Hydrochlorothiazide|DRUG: Benazepril+ Amlodipine,PHASE4,Change in systolic blood pressure from the start of the study,"Hypertension, Primary",Renin-angiotensin system inhibitor,NCT00185120
ACE,homozygous or compound heterozygous mutation in genes encoding components of the angiotensin-converting enzyme (106180) on chromosome 17q23,Renin-angiotensin system,DRUG: Perindopril+Amlodipine,PHASE4,"systolic Blood pressure control, reduction in mmHg, 3 months|Diastolic Blood pressure control, reduction in mmHg, 3 months","Hypertension, Primary",Renin-angiotensin system inhibitor,NCT02995954
ACE,homozygous or compound heterozygous mutation in genes encoding components of the angiotensin-converting enzyme (106180) on chromosome 17q23,Renin-angiotensin system,DRUG: Ramipril,PHASE3,"Time interval to renal 'loss' as defined by an absolute decrease in creatinine clearance by 50 % or attainment of renal replacement therapy., two-monthly",Children|Chronic Renal Failure|Hypertension|Acquired Kidney Disease|Congenital Kidney Disease,"Antihypertensive, Angiotensin-converting enzyme inhibitor",NCT00221845
ACE,homozygous or compound heterozygous mutation in genes encoding components of the angiotensin-converting enzyme (106180) on chromosome 17q23,Renin-angiotensin system,DRUG: losartan|DRUG: ramipril,PHASE4,"Fatal and nonfatal stroke, two years|Progression of silent brain infarction or white matter lesion on magnetic resonance imaging, two years",Brain Infarction|Hypertension,"Antihypertensive, Angiotensin II receptor antagonist, Angiotensin-converting Enzyme Inhibitors",NCT00126516
ACE,homozygous or compound heterozygous mutation in genes encoding components of the angiotensin-converting enzyme (106180) on chromosome 17q23,Renin-angiotensin system,DRUG: Ramipril,PHASE3,"The main outcome variable will be a combined end-point of cardiovascular death (including sudden death and cardiac arrest resuscitation) and myocardial infarction or non-fatal stroke., Baseline, 1st and 2nd year",Left Ventricular Hypertrophy|Hypertension,"Antihypertensive, Angiotensin-converting enzyme inhibitor",NCT00985322
ACE,homozygous or compound heterozygous mutation in genes encoding components of the angiotensin-converting enzyme (106180) on chromosome 17q23,Renin-angiotensin system,DRUG: esaxerenone (CS-3150),PHASE3,"Change from baseline in sitting systolic and diastolic blood pressure, Change from baseline in sitting systolic and diastolic blood pressure, Baseline to end of Week 12",Hypertension With Moderate Renal Impairment,"Antihypertensive, Aldosterone antagonist",NCT02807987
ACE,homozygous or compound heterozygous mutation in genes encoding components of the angiotensin-converting enzyme (106180) on chromosome 17q23,Renin-angiotensin system,DRUG: Hydrochlorothiazide+Indapamide,PHASE4,"Better metabolic effects of indapamide SR 1.5 mg+quinapril by comparison with hydrochlorothiazide 25 mg+quinapril, in patients with hypertension and type 2 diabetes mellitus., 6 months",Hypertension|Type 2 Diabetes Mellitus,"Antihypertensive, Diuretic, Na+-Cl- symport inhibitor",NCT00980187
ACE,homozygous or compound heterozygous mutation in genes encoding components of the angiotensin-converting enzyme (106180) on chromosome 17q23,Renin-angiotensin system,DRUG: Enalapril 5mg|DRUG: Enalapril 10mg|DRUG: Sitagliptin,PHASE4,"Change in MAP During Placebo, The change in mean arterial pressure (MAP) in response to placebo or enalapril after pretreatment with 5 days of placebo, just prior to drug administration and 8 hours after drug administration|Change in MAP During Sitagliptin, Mean change in mean arterial pressure in response to placebo or enalapril in the presence of 5 days of sitagliptin 100mg/day, just prior to drug administration and 8 hours following treatment",Metabolic Syndrome|Hypertension,"Antihypertensive, Vasodilator, Angiotensin-converting enzyme inhibitor",NCT00666848
ACE,homozygous or compound heterozygous mutation in genes encoding components of the angiotensin-converting enzyme (106180) on chromosome 17q23,Renin-angiotensin system,DRUG: Aliskiren+ Valsartan|DRUG: Telmisartan+ Ramipril,PHASE2,"Compare the effects of aliskiren + valsartan vs ramipril + telmisartan on 24-hour urinary aldosterone, 56 days","Hypertension, Primary","Antihypertensive, Angiotensin-converting enzyme inhibitor",NCT00939588
ACE,homozygous or compound heterozygous mutation in genes encoding components of the angiotensin-converting enzyme (106180) on chromosome 17q23,Renin-angiotensin system,DRUG: Fosinopril,PHASE2,NaN,Cardiovascular Diseases|Heart Diseases|Hypertension,"Antihypertensive, Angiotensin-converting enzyme inhibitor",NCT00051389
ACE,homozygous or compound heterozygous mutation in genes encoding components of the angiotensin-converting enzyme (106180) on chromosome 17q23,Renin-angiotensin system,DRUG: Dapagliflozin with patient undergoing ACE Inhibitor,PHASE3,"Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure for 12 Week Double-Blind Treatment Period - Randomized Participants, Systolic blood pressure (SBP) was measured in millimeters of mercury (mmHg) on Day -1, Day 1, Weeks 2, 4, 8, and 12 of the Double Blind Period. Blood pressure (BP) values were obtained after the participant was seated for quietly for 10 minutes; a mean of 3 replicate measurements was taken at least 1 minute apart. However, if the 3 consecutive seated BP readings were not within 8 mm Hg of each other, an additional 2 BP readings were obtained (total = 5) and incorporated into the calculated mean. BP was measured in both arms. If the BP was higher in one arm than the other, then this arm was used; if no difference, the participant's dominant arm was used for all future BP measurements. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. Participants refrained from ingestion of caffeine, alcohol, or nicotine at least 10 hours prior to their visit and having their BP measured., Baseline to Week 12|Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) for 12 Week Double-Blind Treatment Period - Randomized Participants, Adjusted mean change in glycosylated hemoglobin ( HbA1c) from baseline at Week 12 was calculated. HbA1c was measured as percent of hemoglobin by a central laboratory. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. HbA1c values were obtained at enrollment and lead-in (Day -28) periods, and at Day 1, Weeks 4, 8, and 12, in the double-blind period., Baseline to Week 12",Type 2 Diabetes,"Antidiabetic, SGLT-2 inhibitor",NCT01195662
ACE,homozygous or compound heterozygous mutation in genes encoding components of the angiotensin-converting enzyme (106180) on chromosome 17q23,Renin-angiotensin system,DRUG: pyridoxal-5'-phosphate with and without ACE inhibitor,PHASE2,"Effects on blood pressure:|Determine the efficacy of MC-1 and of the combination of MC-1/ACE inhibitor on blood pressure as measured by mean daytime ambulatory systolic blood pressure.|Effects on metabolic function:|Determine the efficacy of MC-1 and of the combination of MC-1/ACE inhibitor on metabolic function as measured by insulinemia, fasting serum glucose, glycated hemoglobin, and triglycerides.",Diabetes Mellitus Type 2|Hypertension|Metabolic Syndrome,naturally occurring metabolite of vitamin B6,NCT00157729
ACE,homozygous or compound heterozygous mutation in genes encoding components of the angiotensin-converting enzyme (106180) on chromosome 17q23,Renin-angiotensin system,DRUG: Perindopril|DRUG: Losartan|DRUG: hydrochlorothiazide,PHASE2,"Gait speed, Self-paced gait speed over 4m distance, 32 weeks",Hypertension|Aging|Sedentary Lifestyle,Renin-angiotensin system inhibitor,NCT03295734
AGTR1,homozygous or compound heterozygous mutation in genes encoding components of the angiotensin II receptor type 1 (106165) on chromosome 3q24,Renin-angiotensin system,DRUG: Angiotensin type II receptor antagonists,PHASE4,"Acute pain after cough, Intensity of pain after cough measured with the Visual Analogue Scale (VAS 0-100 mm), 24 hours postoperatively",Hypertension,NaN,NCT02513979
AGTR1,homozygous or compound heterozygous mutation in genes encoding components of the angiotensin II receptor type 1 (106165) on chromosome 3q24,Renin-angiotensin system,DRUG: IRBESARTAN|DRUG: Atenolol,PHASE4,"Endothelial function in vivo qualification: brachial artery flow mediated vasodilation (FMV%) determined by high resolution ultrasound., at baseline and at the end of the study-12th wk",Hypertension,"Antihypertensive, Angiotensin II receptor antagonist",NCT00529750
AGTR1,homozygous or compound heterozygous mutation in genes encoding components of the angiotensin II receptor type 1 (106165) on chromosome 3q24,Renin-angiotensin system,DRUG: losartan | DRUG: Ramipril,PHASE4,"Fatal and nonfatal stroke, two years|Progression of silent brain infarction or white matter lesion on magnetic resonance imaging, two years",Brain Infarction|Hypertension,"Antihypertensive, Angiotensin II receptor antagonist, Angiotensin-converting Enzyme Inhibitors",NCT00126516
AGTR1,homozygous or compound heterozygous mutation in genes encoding components of the angiotensin II receptor type 1 (106165) on chromosome 3q24,Renin-angiotensin system,DRUG: intravenous (IV) administration of Angiotensin II,PHASE1,"Mean dose required to increase the SBP, The mean dose required to increase the SBP in these 3 cohorts with essential hypertension (ACE inhibitor, ARB, or those on another class of hypertensive agents) to within 5% of baseline or higher will be calculated., up to 1 hour",Hypertension,NaN,NCT03733145
AGTR1,homozygous or compound heterozygous mutation in genes encoding components of the angiotensin II receptor type 1 (106165) on chromosome 3q24,Renin-angiotensin system,DRUG: Metoprolol succinate|DRUG: Nebivolol,PHASE4,"Forearm Blood Flow, 12 weeks after each specified medication",Hypertension,"Antihypertensive, Vasodilator, beta1-Adrenergic receptor antagonist",NCT01502787
AGTR1,homozygous or compound heterozygous mutation in genes encoding components of the angiotensin II receptor type 1 (106165) on chromosome 3q24,Renin-angiotensin system,DRUG: Olmesartan medoxomil,PHASE4,"Insulin Sensitivity by Intravenous Glucose Tolerance Testing (Change Over Time), Data collected from the intravenous glucose tolerance tests included blood concentrations of glucose and insulin. Glucose was measured immediately on a YSI glucose analyzer and insulin was measured via ELISA colormetric kits once all study samples were collected. To analyze changes in insulin sensitivity, the MINMOD software was used. The MINMOD software uses Bergman's minimal model to determine insulin sensitivity during an intravenous glucose tolerance test. Both glucose and insulin values were inserted at each timepoint collected (33 in total over the 3-hour protocol) and the software was run to generate the insulin sensitivity value at baseline and post-test. This information was then used to calculate the change of insulin sensitivity from baseline to post-testing after each 8-week intervention., Baseline testing to post-testing after 8-week intervention",Overweight|Obese|Prehypertension|Hypertension,"Antihypertensive, Angiotensin II receptor antagonist",NCT01684748
AGTR1,homozygous or compound heterozygous mutation in genes encoding components of the angiotensin II receptor type 1 (106165) on chromosome 3q24,Renin-angiotensin system,DRUG: Sacubitril + Valsartan Oral Tablet [Entresto],PHASE3,"Change in mPAP With Sacubitril/Valsartan compared to Standard therapy, Change in Mean Pulmonary Artery Pressure With Sacubitril/Valsartan compared to Standard therapy., Time Frame: 0-18 weeks",Pulmonary Hypertension,"Antihypertensive, Angiotensin-converting enzyme inhibitor",NCT04753112
AGTR1,homozygous or compound heterozygous mutation in genes encoding components of the angiotensin II receptor type 1 (106165) on chromosome 3q24,Renin-angiotensin system,DRUG: Micardis,PHASE3,"Change from baseline in seated systolic blood pressure at trough (24 hours post-dose), after 6 weeks of treatment|Change from baseline in urine albumine excretion rate, after 6 weeks of treatment|Change from baseline in pulse wave velocity, after 6 weeks of treatment",Hypertension,"Antihypertensive, Angiotensin II receptor antagonist",NCT02175355
AGTR1,homozygous or compound heterozygous mutation in genes encoding components of the angiotensin II receptor type 1 (106165) on chromosome 3q24,Renin-angiotensin system,DRUG: Amlodipine 10 mg or Losartan 100 mg + Amlodipine 5 mg,PHASE4,Insulin sensitivity assessed with hyperinsulinaemic isoglycaemic glucose clamp(GDR),Hypertension,"Antihypertensive, Vasodilator, Calcium channel blocker",NCT00237588
AGTR1,homozygous or compound heterozygous mutation in genes encoding components of the angiotensin II receptor type 1 (106165) on chromosome 3q24,Renin-angiotensin system,"DRUG: Amlodipine, Telmisartan, Amiloride Compound , Simvastatin",PHASE4,"The primary study outcomes are composite of non-fatal stroke, non-fatal myocardial infarction and cardiovascular death., 3-4 years",Essential Hypertension,Dihydropyridine calcium channel blocker,NCT01011660
AGTR1,homozygous or compound heterozygous mutation in genes encoding components of the angiotensin II receptor type 1 (106165) on chromosome 3q24,Renin-angiotensin system,DRUG: Losartan|DRUG: Captopril,PHASE1,"Changes in plasma renin activity and subsequent components of the circulating renin-angiotensin system, Changes in supine plasma renin activity and aldosterone following drug administration, 0 - 6 hours post administration",Hypertension|Pure Autonomic Failure|Multiple System Atrophy,"Antihypertensive, Angiotensin II receptor antagonist, Angiotensin-converting enzyme inhibitor",NCT01292694
AGTR1,homozygous or compound heterozygous mutation in genes encoding components of the angiotensin II receptor type 1 (106165) on chromosome 3q24,Renin-angiotensin system,DRUG: Salsalate Oral Tablet,EARLY_PHASE1,"change in endothelial function following salsalate treatment compared to placebo treatment, Endothelium-dependent vasodilation assessed by reactivity to exogenous acetylcholine, a total of 2 times throughout the study (approximately 4 weeks): 1) at the completion of 5 days of oral salsalate treatment, and 2) at the completion of 5 days of placebo treatment",Preeclampsia,"Analgesic, Anti-inflammatory, COX inhibitor",NCT03482440
AGTR1,homozygous or compound heterozygous mutation in genes encoding components of the angiotensin II receptor type 1 (106165) on chromosome 3q24,Renin-angiotensin system,DRUG: Dapagliflozin,PHASE4,"Change in Blood Pressure From Baseline to 6 Weeks Measured by ABPM, Blood pressure was measured at baseline with a 24 hour ambulatory blood pressure machine (ABPM), and again after 6 weeks of treatment., Baseline to 6 weeks",Type 2 Diabetes|Hypertension,"Antidiabetic, SGLT-2 inhibitor",NCT02796170
AGTR1,homozygous or compound heterozygous mutation in genes encoding components of the angiotensin II receptor type 1 (106165) on chromosome 3q24,Renin-angiotensin system,"DRUG: Angiotensin II receptor antagonists, Calcium channel blocker",PHASE4,"Changes in blood pressure level at home after getting up.|The rate of the blood pressure levels at home after getting up, which effected the target levels (systolic blood pressure < 125 mm Hg, diastolic blood pressure < 80 mm Hg).|Adverse events, adverse drug reactions|Clinical laboratory data","Hypertension|Diabetes Mellitus, Type 2",NaN,NCT00144144
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: bosentan,PHASE4,"Change from baseline (BL) to 6 mths in the IVUS-derived measurement of pulmonary artery wall thickness., Baseline to 6 months|Change from BL to 6 mths in pulmonary microvascular circulation dilator responses to actylcholine (Ach)., Baseline to 6 months","Hypertension, Pulmonary, Primary","Antihypertensive, Endothelin receptor antagonist",NCT00595049
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Beraprost Sodium|DRUG: Sildenafil Citrate,PHASE4,"Efficacy of Beraprost, Sildenafil and comparison between both drugs in lowering pulmonary arterial pressure, Measuring mPAP (pre-post therapy) via echocardiography before and after consuming sildenafil or beraprost, 12 weeks","Pediatric Pulmonary Hypertension, Primary","Antihypertensive, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT03431649
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Oral Treprostinil,PHASE3,"Change in Exercise Capacity at Month 12, Assess the effect of continued therapy with oral treprostinil on exercise capacity as assessed by the change from Baseline in 6-Minute Walk Test (6MWT) after 1 year of treatment. The 6MWT is the clinical standard for assessing subject functional status in the treatment of PAH and has been considered an objective measure of subject functional status by the American Thoracic Society. The distance a subject can walk in 6 minutes is recorded in meters., From First Visit (Visit 1) to Month 12","Pulmonary Arterial Hypertension, Primary","Anticoagulant, Antihypertensive, Vasodilator, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT01027949
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Iloprost,PHASE2,NaN,Pulmonary Arterial Hypertension|Ayerza Syndrome|Pulmonary Hypertension,"Antihypertensive, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT00086463
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Ambrisentan,PHASE4,"Change From Baseline in Pulmonary Vascular Resistance (PVR), Last Observation Carried Forward (LOCF), The primary objective of this study is to evaluate the change from baseline in PVR, and other hemodynamic parameters, following the addition of ambrisentan to background PDE-5i therapy in subjects with PAH who have demonstrated a sub-optimal response to PDE-5i monotherapy. A decrease in measurement value (dynes sec/cm\^5) indicates improvement for this patient population., Baseline to Week 24","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Endothelin receptor type A antagonist",NCT00617305
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: sitaxentan,PHASE1,"Time to Reach Maximum Observed Plasma Concentration (Tmax), Day 6 (predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours post dose)|Trough Plasma Concentrations (Ctrough), Minimum or ""trough""concentrations, Day 6 (predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours post dose)|Maximum Observed Plasma Concentration (Cmax), Day 6 (predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours post dose)|Area Under the Curve of the 24 Hour Dosing Interval (AUC24), Day 6 (predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours post dose)|Apparent Oral Clearance (CL/F), Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood., Day 6 (predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours post dose)|Volume of Distribution at Steady State (Vss), Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state., Day 6 (predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours post dose)","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Endothelin receptor type A antagonist",NCT01244620
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Dimethyl Fumarate (DMF),PHASE1,"6 Minute Walk Distance (6MWD), The primary outcome of clinical efficacy in this study is improvement in 6-minute walk distance (6MWD). Data depict the mean change (%) at end-of-study-treatment (Week 24) from baseline in both treatment groups, utilizing the Last Observation Carried Forward of withdrawn subjects., Baseline to Week 24",Systemic Sclerosis|Pulmonary; Hypertension,Immunomodulator,NCT02981082
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Selexipag (JNJ-67896049),PHASE4,"Change from Baseline to Week 26 in Right Ventricular Stroke Volume (RVSV) Assessed by Pulmonary Artery Flow Magnetic Resonance Imaging (MRI), Change from baseline to week 26 in RVSV in participants will be assessed by pulmonary artery flow MRI., Baseline and week 26","Pulmonary Arterial Hypertension, Primary","Vasodilator, Prostaglandin I2 receptor agonist",NCT04435782
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Beraprost Sodium Modified Release,PHASE2,"Change From Baseline in Pulmonary Vascular Resistance at Week 12, The change in Pulmonary Vascular Resistance (PVR) was evaluated from Baseline to Week 12. PVR is expressed in Wood Units or millimeters of Mercury per Liter per minute (mmHG/L/min), Week 12|Change From Baseline in Cardiac Output (CO) at Week 12, The change in Cardiac Output was evaluated from Baseline to Week 12., Week 12|Change From Baseline in Pulmonary Arterial Pressure at Week 12, The change in mean Pulmonary Arterial Pressure (mPAP) was evaluated from Baseline to Week 12., 12 weeks","Pulmonary Arterial Hypertension, Primary","Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT00989963
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Sotatercept,PHASE3,"Time to First Confirmed Morbidity or Mortality Event, Events are defined as all-cause death, lung transplantation, or PAH worsening-related hospitalization of ΓëÑ 24 hours. All events will be adjudicated by a blinded, independent committee of clinical experts., Up to approximately 46 months","Pulmonary Arterial Hypertension, Primary","Anti-anemic, Bone anabolic",NCT04896008
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Bosentan,PHASE1,"AUClast, 0-24h|Cmax, 0-24h","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Endothelin receptor antagonist",NCT01864863
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Spironolactone,PHASE2,"Change in placebo corrected 6-minute walk distance, Change in placebo corrected 6-minute walk distance., 6 months","Pulmonary Arterial Hypertension, Primary",Aldosterone antagonist,NCT01712620
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Pemziviptadil (PB1046),PHASE2,"Incidence and severity of AEs, 172 days - Starting up to 30 days prior to first dose and completing 28 days after last dose.|Incidence of Clinical Laboratory Abnormalities, 172 days - Starting up to 30 days prior to first dose and completing 28 days after last dose.|Changes in Diastolic Blood Pressure, 172 days - Starting up to 30 days prior to first dose and completing 28 days after last dose.|Changes in Systolic Blood Pressure, 172 days - Starting up to 30 days prior to first dose and completing 28 days after last dose.|Changes in Oral Body Temperature, 172 days - Starting up to 30 days prior to first dose and completing 28 days after last dose.|Changes in Respiratory Rate, 172 days - Starting up to 30 days prior to first dose and completing 28 days after last dose.|Changes in Heart Rate, 172 days - Starting up to 30 days prior to first dose and completing 28 days after last dose.|12-Lead ECG - Incidence of clinically significant findings, 172 days - Starting up to 30 days prior to first dose and completing 28 days after last dose.|Immunogenicity, 172 days - Starting up to 30 days prior to first dose and completing 8 weeks after last dose. May be extended in the event that result does not return to baseline in time allotted.|Change in baseline in pulmonary vascular resistance (PVR), 142 days - Pre-dose (up to 30 days prior to first dose) and post-dose 16.","Pulmonary Arterial Hypertension, Primary",NaN,NCT03556020
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: UT-15C SR|DRUG: treprostinil diethanolamine,PHASE3,"To Assess the Pharmacokinetics (Mean AM Dose) in Subjects During Twice Daily (BID) Dosing (up to 14 Days Prior to Transitioning to Three Times Daily [TID] Dosing Regimen at PK Visit 1) and up to 35 Days After Transitioning to TID Dosing (at PK Visit 2)., The PK sampling occurred over a 12-hour period in subjects during BID dosing (PK Visit 1) and during TID dosing (PK Visit 2). Prior to each PK sampling day, subjects must have been receiving a stable dose for at least 5 days., Up to 14 days prior to transitioning to TID dosing regimen (PK Visit 1) and up to 35 days after transitioning to TID dosing regiment (PK Visit 2)|To Assess the Pharmacokinetics (Cmax, Cmin) in Subjects During Twice Daily (BID) Dosing (up to 14 Days Prior to Transitioning to Three Times Daily [TID] Dosing Regimen at PK Visit 1) and up to 35, The PK sampling occurred over a 12-hour period in subjects during BID dosing (PK Visit 1) and during TID dosing (PK Visit 2). Prior to each PK sampling day, subjects must have been receiving a stable dose for at least 5 days., Up to 14 days prior to transitioning to TID dosing regimen (PK Visit 1) and up to 35 days after transitioning to TID dosing regiment (PK Visit 2)|To Assess the Pharmacokinetics (AUClast) in Subjects During Twice Daily (BID) Dosing (up to 14 Days Prior to Transitioning to Three Times Daily [TID] Dosing Regimen at PK Visit 1) and up to 35 Days After Transitioning to TID Dosing (at PK Visit 2)., The PK sampling occurred over a 12-hour period in subjects during BID dosing (PK Visit 1) and during TID dosing (PK Visit 2). Prior to each PK sampling day, subjects must have been receiving a stable dose for at least 5 days., Up to 14 days prior to transitioning to TID dosing regimen (PK Visit 1) and up to 35 days after transitioning to TID dosing regiment (PK Visit 2)","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Prostaglandin I2 receptor agonist",NCT01934582
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: rodatristat ethyl (RVT-1201) ,PHASE2,"Adverse events (AEs) and discontinuations due to AEs, Incidence of treatment-emergent adverse events (TEAEs), drug-related adverse events (AEs), and discontinuations due to AEs, 8 weeks","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Tryptophan hydroxylase inhibitor",NCT03924154
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Imatinib Mesylate,PHASE2,"Identifying the highest tolerated dose, Part 1: Discontinuation of the drug for more than 5 consecutive days due to Grade 2 or above Adverse Events, defined by NCI criteria (version 5.0, 2017) adapted for the study., 12 months|Change in pulmonary vascular resistance (PVR), Part 2: The primary efficacy endpoint is a binary variable. For patients with a baseline pulmonary vascular resistance (PVR) \>1000 dynes┬╖s┬╖cm-5, success is defined by an absolute reduction in PVR of ΓëÑ300 dynes┬╖s┬╖cm-5 at 24 weeks. For patients with a baseline PVR Γëñ1000 dynes┬╖s┬╖cm-5, success is a 30% reduction in PVR at 24 weeks., 24 months","Pulmonary Arterial Hypertension, Primary","Antineoplastic, Tyrosine kinase inhibitor",NCT04416750
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: PLX-PAD,PHASE1,"Incidence of treatment-emergent AEs (frequency and severity at each dose level), 12 weeks|Incidence of SAEs, 1 year","Pulmonary Arterial Hypertension, Primary",Cell transplant therapies,NCT01795950
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Iloprost,PHASE3,"Adverse events, Throughout the whole study","Hypertension, Pulmonary","Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT00185315
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: GSK2586881,PHASE2,"Change From Baseline in Pulmonary Vascular Resistance (PVR), PVR is the resistance generated by pulmonary circulation. Pulmonary arterial catheters were placed in participants and PVR values were recorded from the right heart catheterization. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was measured as ratio of post-dose visit value to Baseline value., Baseline (Day 1, Pre-dose); 1 hour, 2 hours and 4 hours post-dose (Day 1)|Change From Baseline in Cardiac Output (CO), CO is the amount of blood pumped by the heart per minute. Pulmonary arterial catheters were placed in participants and CO values were recorded from the right heart catheterization. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was measured as ratio of post-dose visit value to Baseline value., Baseline (Day 1, Pre-dose); 1 hour, 2 hours and 4 hours post-dose (Day 1)|Change From Baseline in Mean Pulmonary Artery Pressure (mPAP), The pulmonary artery pressure is a measure of the blood pressure found in the main pulmonary artery. Pulmonary arterial catheters were placed in participants and mPAP values were recorded from the right heart catheterization. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was measured as ratio of post-dose visit value to Baseline value., Baseline (Day 1, Pre-dose); 1 hour, 2 hours and 4 hours post-dose (Day 1)","Hypertension, Pulmonary",Protein Based Therapies,NCT03177603
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Dapagliflozin 10 MG [Farxiga],PHASE2,"Change in VO2 max from baseline to follow up, 3 months",Pulmonary Arterial Hypertension|Chronic Thromboembolic Pulmonary Hypertension," Antidiabetic, SGLT-2 inhibitor",NCT05179356
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Macitentan,PHASE3,"Evaluation of the Reliability and the Construct Validity of the Cardiopulmonary Symptoms Domain of the PAH-SYMPACT, The Cardiopulmonary Symptoms domain consists of 6 items reported on a 5-point Likert scale (from 0 to 4). The value 0 means ""no symptom"" and value 4 corresponds to ""very severe symptoms"".The symptoms part of the PAH-SYMPACT was administered daily over a 7 day period. The recall period of symptom items is the last 24 hours. An average Cardiopulmonary Symptoms domain score is determined based on the daily scores of the 6 items. It was administered two times (daily during 7 days each time) prior to administration of Macitentan (Visit 2, Baseline) and daily during the 7-day period in the treatment period prior to Visit 3 (Week 8) and Visit 4 (Week 16)., From Screening Visit (Visit 1) to End of Treatment (EOT) Visit (Visit 4, Week 16)|Evaluation of the Reliability and the Construct Validity of the Cardiovascular Symptoms Domain of the PAH-SYMPACT, The Cardiovascular Symptoms domain consists of 5 items reported on a 5-point Likert scale (from 0 to 4). The value 0 corresponds to ""no symptoms"" and value 4 corresponds to ""very severe symptoms"". The symptoms part of the PAH-SYMPACT was administered daily over a 7 day period. The recall period of symptom items is the last 24 hours. An average Cardiovascular Symptoms domain score is determined based on the daily scores of the 5 items. It was administered two times (daily during 7 days each time) prior to administration of Macitentan (Visit 2, Baseline) and daily during the 7-day period in the treatment period prior to Visit 3 (Week 8) and Visit 4 (Week 16)., From Screening Visit (Visit 1) to End of Treatment (EOT) Visit (Visit 4, Week 16)|Evaluation of the Reliability and the Construct Validity of the Physical Impacts Domain of the PAH-SYMPACT, The Physical Impacts domain consists of 7 items reported on a 5-point Likert scale (from 0 to 4). The value 0 corresponds to ""not at all""/""with no difficulty at all"" and value 4 corresponds to ""very much""/""extremely""/ ""not able at all"". The impacts part of the PAH-SYMACT was administered on Day 7 of the symptoms part administration. Items in the impact part have a 7 day recall period. An average Physical Impacts domain score is determined based on the 7 items in the domain. It was administered two times prior to administration of Macitentan (Visit 2, Baseline) and during the 7-day period in the treatment period prior to Visit 3 (Week 8) and Visit 4 (Week 16)., From Screening Visit (Visit 1) to End of Treatment (EOT) Visit (Visit 4, Week 16)|Evaluation of the Reliability and the Construct Validity of the Cognitive/Emotional Impacts Domain of the PAH-SYMPACT, The Cognitive/Emotional Impacts domain consists of 4 items reported on a 5-point Likert scale (from 0 to 4). The value 0 corresponds to ""not at all""/""with no difficulty at all"" and value 4 corresponds to ""very much""/""extremely""/ ""not able at all"". The impacts part of the PAH-SYMACT was administered on Day 7 of the symptoms part administration. Items in the impact part have a 7 day recall period. An average Cognitive/Emotional Impacts domain score is determined based on the 4 items in the domain. It was administered two times prior to administration of Macitentan (Visit 2, Baseline) and during the 7-day period in the treatment period prior to Visit 3 (Week 8) and Visit 4 (Week 16)."", From Screening Visit (Visit 1) to End of Treatment (EOT) Visit (Visit 4, Week 16)","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Endothelin receptor antagonist",NCT02081690
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: spironolactone,PHASE1,Dyspnoea score|Exercise capacity (six-minute walk)|NYHA/WHO functional class|Change of acropachy|Blood gas test|Pulmonary artery pressure (measured by echocardiogram or catheter),"Hypertension, Pulmonary","Antihypertensive, Diuretic, Aldosterone antagonist",NCT00240656
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Iloprost+Bosentan,PHASE3,"change from baseline in 6-min-walk distance (6-MWD), 12 weeks","Pulmonary Arterial Hypertension, Primary",Platelet aggregation inhibitor + Antihypertensive,NCT01712997
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Selexipag,PHASE4,"Change From Baseline to Week 24 in Actigraphy Assessed Daily Life Physical Activity (DLPA) for Variables Expressed in Minutes, Change from baseline to Week 24 of the DLPA activity parameters for daily time spent in non-sedentary activity (NSA) (as defined by Freedson '98 and Koster '16) and daily time spent in moderate-to-vigorous physical activity (MVPA) as defined by Freedson '98 were reported. These variables were assessed by actigraphy and were expressed in minutes. Freedson 1998 established ranges of activity counts obtained from a hip worn accelerometer corresponding to commonly employed MET categories. Based on this work, threshold between sedentary and NSA was defined. This threshold is often referred to as Freedson's 1998 publication. Koster 2016 defined the threshold between sedentary and NSA based on wrist-worn accelerometers on non-dominant hand, respectively. Positive change from baseline means improvement., Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)|Change From Baseline to Week 24 in Actigraphy DLPA for Variables Expressed in Percentage (%), Change from baseline to Week 24 of the DLPA activity parameters for daily time spent in non-sedentary activity (NSA) (Freedson '98), daily time spent in moderate-to-vigorous physical activity (MVPA) (Freedson '98) and dailytime spent in NSA (Koster '16) were reported. These variables were assessed by actigraphy and were expressed in percentage (%). Freedson 1998 established ranges of activity counts obtained from a hip worn accelerometer corresponding to commonly employed MET categories. Based on this work, threshold between sedentary and NSA was defined. This threshold is often referred to as Freedson's 1998 publication. Koster 2016 defined the threshold between sedentary and NSA based on wrist-worn accelerometers on non-dominant hand, respectively. Positive change from baseline means improvement., Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)|Change From Baseline to Week 24 in Actigraphy DLPA for Variables Expressed in Counts Per Minute (Counts/Minute), Change from baseline to Week 24 of the DLPA activity parameter for total daily activities and NSA (Koster '16) were reported. These variables were assessed by actigraphy and were expressed in counts/minutes. Koster 2016 defined the threshold between sedentary and NSA based on wrist-worn accelerometers on non-dominant hand, respectively. Positive change from baseline means improvement., Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)|Change From Baseline to Week 24 in Actigraphy DLPA for Variables Expressed in Counts, Change from baseline to Week 24 of the DLPA activity parameters for volume of non-sedentary activity (Koster '16)were reported. These variables were assessed by actigraphy and were expressed in counts. Koster 2016 defined the threshold between sedentary and NSA based on wrist-worn accelerometers on non-dominant hand, respectively. Positive change from baseline means improvement., Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)|Change From Baseline to Week 24 in Actigraphy DLPA for Variable Expressed in Step Counts, Change from baseline to Week 24 of the DLPA activity parameters for number of steps during awake time were reported. These variables were assessed by actigraphy and were expressed in step counts. Positive change from baseline means improvement., Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)|Change From Baseline to Week 24 in Actigraphy DLPA for Variables Expressed in Step Counts/Minute, Change from baseline to Week 24 of the DLPA activity parameters for number of steps during awake time were reported. These variables were assessed by actigraphy and were expressed in step counts/minute. Positive change from baseline means improvement., Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)|Change From Baseline to Week 24 in Total Sleep Time (TST), TST (in minutes) was assessed by actigraphy., Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)|Change From Baseline to Week 24 in Wake After Sleep Onset (WASO), WASO (in minutes) was assessed by actigraphy., Baseline and Week 24 (data collection was done during 14-Days each for Baseline and for Week 24)|Change From Baseline to Week 24 in Number of Awakenings, Number of awakenings was assessed by actigraphy., Baseline and Week 24 (data collection was done during 14-Days each for Baseline and for Week 24)|Change From Baseline to Week 24 in Sleep Efficiency (SE), SE (in percentage) was assessed by actigraphy. Sleep efficiency was defined as the TST divided by the time in bed (minutes) multiplied by 100. TST was the duration in minutes including REM sleep plus NREM sleep during the time spent in bed., Baseline and Week 24 (data collection was done during 14-Days each for Baseline and for Week 24)","Pulmonary Arterial Hypertension, Primary","Vasodilator, Prostaglandin I2 receptor agonist",NCT03078907
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Bosentan,PHASE2|PHASE3,"Improvement in six minute walk distance, 16 weeks",Sarcoidosis|Pulmonary Arterial Hypertension,"Antihypertensive, Endothelin receptor antagonist",NCT00581607
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Sildenafil,PHASE4,"Change From Baseline in Pulmonary Vascular Resistance Index (PVRI) at Week 16, PVRI equals pulmonary vascular resistance (PVR) times body surface area (BSA) (PVRI = PVR\*BSA). PVR is the resistance to blood flow through the pulmonary circulation and it was measured in Wood units. Wood unit =80 dyne\*seconds per centimetre\^5 (dyne\*sec/cm\^5)., Baseline, Week 16|Change From Baseline in Mean Pulmonary Artery Pressure (mPAP) at Week 16, It was a hemodynamic parameter and measured using a pressure transducer positioned at the mid-axillary line with the participant in the supine position., Baseline, Week 16|Change From Baseline in World Health Organization (WHO) Functional Class in Participants With Pulmonary Arterial Hypertension (PAH) at Week 4, WHO functional classification for PAH range from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest). The change from baseline in WHO functional class was classified into ""Improved"", ""No change"" and ""Worsened"". Improvement = reduction in functional class, worsened = increase in functional class and no change = no change in functional class. Change from baseline in number of participants in each functional class were reported., Baseline, Week 4|Change From Baseline in World Health Organization (WHO) Functional Class in Participants With Pulmonary Arterial Hypertension (PAH) at Week 8, WHO functional classification for PAH range from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest). The change from baseline in WHO functional class was classified into ""Improved"", ""No change"" and ""Worsened"". Improvement = reduction in functional class, worsened = increase in functional class and no change = no change in functional class. Change from baseline in number of participants in each functional class were reported., Baseline, Week 8|Change From Baseline in World Health Organization (WHO) Functional Class in Participants With Pulmonary Arterial Hypertension (PAH) at Week 16, WHO functional classification for PAH range from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest). The change from baseline in WHO functional class was classified into ""Improved"", ""No change"" and ""Worsened"". Improvement = reduction in functional class, worsened = increase in functional class and no change = no change in functional class. Change from baseline in number of participants in each functional class were reported., Baseline, Week 16|Change From Baseline in Brain Natriuretic Peptide (BNP) at Week 16, BNP is produced by ventricular cardiomyocytes. It causes reduction in preload and blood pressure by vasodilatation., Baseline, Week 16|Change From Baseline in N-terminal Pro Brain Natriuretic Peptide (NT Pro-BNP) at Week 16, NT pro-BNP is a cardiac marker, having the prognostic value for participants with heart failure or left ventricular dysfunction. Higher level of the marker was indicative of heart damage., Baseline, Week 16","Pulmonary Arterial Hypertension|Hypertension, Pulmonary","Vasodilator, Impotence therapy, Phosphodiesterase V inhibitor",NCT01642407
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Riociguat Oral Product,PHASE4,"Pulmonary Vascular resistance, Change from baseline to month 4 and month 12 in pulmonary vascular resistance (PVR) as assessed by Right Heart Catheterization., 4 and 12 months",Pulmonary Hypertension,"Vasodilator, Guanylate cyclase activator",NCT03809156
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Tadalafil,PHASE3,"Period 1: Change From Baseline to Week 24 in a 6 Minute Walk (MW) Distance in Meters, 6MWD in meters assessed in a subset of participants who are ΓëÑ6 to \<18 years of age who are developmentally capable of performing a 6MW test. Change from baseline was derived using mixed model repeated measures (MMRM) with terms for treatment group, visit, baseline 6MWD, and treatment-by-visit interaction., Baseline, Week 24","Hypertension, Pulmonary","Antihypertensive, Impotence therapy, Phosphodiesterase V inhibitor",NCT01824290
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Zamicastat,PHASE2,"Area under the curve 0-24h (AUC0-24h) - 50 mg, This PK parameters (24-hour profile) for zamicastat and its metabolites will be derived after a single dose of 50 mg zamicastat, Day 1 (0 hours and then 1, 2, 4, 8, 16 and 24 hours after IMP intake)|Area under the curve 0-24h (AUC0-24h) - HTD, This PK parameter (24-hour profile) for zamicastat and its metabolites will be derived at steady-state at the individual highest tolerated dose (HTD), 1, 2, 4, 8, 16 and 24 hours after IMP intake|Maximum plasma concentration (Cmax) - 50 mg, This PK parameters (24-hour profile) for zamicastat and its metabolites will be derived after a single dose of 50 mg zamicastat, Day 1 (0 hours and then 1, 2, 4, 8, 16 and 24 hours after IMP intake)|Maximum plasma concentration (Cmax) - HTD, This PK parameter (24-hour profile) for zamicastat and its metabolites will be derived at steady-state at the individual highest tolerated dose (HTD), 1, 2, 4, 8, 16 and 24 hours after IMP intake|Time until Cmax (tmax) - 50 mg, This PK parameters (24-hour profile) for zamicastat and its metabolites will be derived after a single dose of 50 mg zamicastat, Day 1 (0 hours and then 1, 2, 4, 8, 16 and 24 hours after IMP intake)|Time until Cmax (tmax) - HTD, This PK parameter (24-hour profile) for zamicastat and its metabolites will be derived at steady-state at the individual highest tolerated dose (HTD), 1, 2, 4, 8, 16 and 24 hours after IMP intake|Minimum plasma concentration at the end of the dosing interval (Cmin,SS) - HTD, This PK parameter (24-hour profile) for zamicastat and its metabolites will be derived at steady-state at the individual highest tolerated dose (HTD), 1, 2, 4, 8, 16 and 24 hours after IMP intake","Pulmonary Arterial Hypertension, Primary",dopamine β-hydroxylase inhibitor,NCT04316143
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Sitaxentan,PHASE3,"Number of Participants With Adverse Events, Number of participants with any adverse events, severe adverse events, serious adverse events, Up to 22 days (last participant discontinuation)","Hypertension, Pulmonary","Antihypertensive, Endothelin receptor type A antagonist",NCT01210443
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: sitaxsentan sodium,PHASE2|PHASE3,,Pulmonary Hypertension,"Antihypertensive, Endothelin receptor type A antagonist",NCT00034307
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Bosentan,PHASE3,"Area under the plasma concentration-time curve during a dose interval (AUCt) for bosentan, AUCt was assessed at steady state (i.e., after at least 2 weeks of treatment with a same dose of the study drug) over 12 hours ., At pre-dose and 0.5h, 1h, 3h, 7.5h, and 12h post-dose","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Endothelin receptor antagonist",NCT00319267
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Tezosentan,PHASE2,"Absolute change in supine SBP from Baseline to 30 minutes at each visit (Visit 1 and Visit 2) - in mmHg, 30 days","Pulmonary Arterial Hypertension, Primary","Vasodilator, ETB receptor antagonist",NCT01094067
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Albuterol,PHASE2,"End-expiratory lung volume:total lung capacity (EELV/TLC) ratio at matched metabolic isowork., Determined by measuring inspiratory capacity every 2 minutes during cardiopulmonary exercise test (CPET), up to 3 days",Idiopathic Pulmonary Arterial Hypertension.,"Bronchodilator, beta2-Adrenergic receptor agonist",NCT02108743
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Epoprostenol sodium,PHASE4,"Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE), An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, important medical events which may require medical or surgical interventions. Intention-to-Treat (ITT) population: comprised of all participants who have received at least one dose of the thermostable formulation of FLOLAN., Up to Week 4|Number of Participants With Mild, Moderate or Severe AEs, Intensity for an AE and SAE is categorized as mild if an event is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities; moderate if an event is sufficiently discomforting to interfere with normal everyday activities; severe if that prevents normal everyday activities., Up to Week 4|Percentage of Basophils, Eosinophils, Lymphocytes, Monocytes, and Total Neutrophils in Blood at Baseline and Week 4, Blood samples were collected for the measurement of percentage of basophils, eosinophils, lymphocytes, monocytes, and total neutrophils in blood at Baseline (BL) and Week 4 (W4). The Baseline values are those collected within 0.5 hour (hr) prior to the first dose of the new diluent formulation ('Visit 2 - Baseline'), Baseline and Week 4|Absolute Values of Hemoglobin at Baseline and Week 4, Blood samples were collected for measurement of hemoglobin values at Baseline (BL) and Week 4 (W4). The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline'), Baseline and Week 4|Absolute Values of Hematocrit at Baseline and Week 4, Blood samples were collected for measurement of hematocrit values at Baseline (BL) and Week 4 (W4). The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline'), Baseline and Week 4|Absolute Values of Platelet Count and White Blood Cell Count at Baseline and Week 4, Blood samples were collected for measurement of platelets and white blood cells (WBC) at Baseline (BL) and Week 4 (W4). The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline'), Baseline and Week 4|Absolute Values of Red Blood Cell Count at Baseline and Week 4, Blood samples were collected for measurement of red blood cells at Baseline (BL) and Week 4 (W4). The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline'), Baseline and Week 4|Absolute Values of Albumin and Total Protein at Baseline and Week 4, Blood samples were collected for measurement of albumin and total protein at Baseline (BL) and Week 4 (W4). The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline'), Baseline and Week 4|Absolute Values of Total and Direct Bilirubin, Creatinine, and Uric Acid at Baseline and Week 4, Blood samples were collected for measurement of total and direct bilirubin, creatinine (CRT), and uric acid (UA) at Baseline (BL) and Week 4 (W4). The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline'), Baseline and Week 4|Absolute Values of Alanine Aminotransferase, Aspartate Aminotransferase, Alkaline Phosphatase, Gamma Glutamyltransferase, Lactate Dehydrogenase and Creatine Kinase at Baseline and Week 4, Blood samples were collected for measurement of Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP), Gamma Glutamyltransferase (GGT), Lactate Dehydrogenase (LDH) and Creatine Kinase (CK) at Baseline (BL) and Week 4 (W4). The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline'), Baseline and Week 4|Absolute Values of Urea/Blood Urea Nitrogen, Glucose, Chloride, Sodium, Potassium, Magnesium, Phosphorus (Inorganic), and Calcium at Baseline and Week 4, Blood samples were collected for measurement of urea/Blood Urea Nitrogen (Urea/BUN), glucose, chloride, sodium, potassium, magnesium, phosphorus, inorganic, and calcium at Baseline (BL) and Week 4 (W4). The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline'), Baseline and Week 4|Absolute Values of Free Triiodothyronine and Free Thyroxine at Baseline and Week 4, Blood samples were collected for measurement of Free Triiodothyronine (FT3) and Free Thyroxine (FT4) at Baseline (BL) and Week 4 (W4). The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline'), Baseline and Week 4|Absolute Values of Thyroid Stimulating Hormone at Baseline and Week 4, Blood samples were collected for measurement of Thyroid Stimulating Hormone (TSH) at Baseline (BL) and Week 4 (W4). The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline'), Baseline and Week 4|Number of Participants With the Indicated Urinalysis Findings, Urine protein, urine glucose, and occult blood were assessed at Baseline (BL) and Week 4 (W4). Dipstick test was performed for routine urinalysis. Abnormal values such as trace, 1+, 2+, 3+ and positive have been reported. The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline')., Baseline and Week 4|Number of Participants With the Indicated Electrocardiogram (ECG) Findings, A safety 12-lead ECG was performed at Baseline (BL), 24 hr after switching to the new Flolan diluent and Week 4 (W4). Any abnormal clinically significant (CS) and not clinically significant (NCS) findings were reported. ECG abnormaility with respect to CS and NCS findings were judged by the investigator. The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline'), Baseline, 24 hour and Week 4|Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP), SBP and DBP were measured at Baseline, 1 hr, 3 hr, 24 hr, Week 4 (W4). The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline'). Change from Baseline is defined as the difference between the post-dose visit value and the Baseline value., Baseline, 1 hour, 3 hour, 24 hour and Week 4|Change From Baseline in Heart Rate, Heart rate was measured at Baseline, 1 hr, 3 hr, 24 hr, Week 4 (W4). The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline'). Change from Baseline is defined as the difference between the post-dose visit value and the Baseline value., Baseline and up to Week 4|Change From Baseline in Body Weight, Body weight was measured at Baseline (BL) and Week 4 (W4). The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline'). Change from Baseline is defined as the difference between the post-dose visit value and the Baseline value. Participants with body weight outside and within the clinical concern reference range (\<50kg) has been presented., Baseline and Week 4|Absolute Values of Oxygen Saturation, Oxygen saturation was measured by pulse oximetry at Baseline (BL), 1 hr, 3 hr, 24 hr, Week 4 (W4). The Baseline values are those collected within 0.5 hr prior to the first dose of the new diluent formulation ('Visit 2 - Baseline')., Baseline and up to Week 4",Cardiovascular Disease,"Antihypertensive, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT02705807
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Famotidine 20 MG,PHASE2,"Six-minute walk distance, To determine whether famotidine increases six-minute walk distance at 24 weeks in men and women with pulmonary arterial hypertension, 0 to 24 weeks",Pulmonary Arterial Hypertension|Right Heart Failure,"Anti-ulcerative, H2 receptor antagonist",NCT03554291
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: cyclic pentapeptide (BQ-123),PHASE2,"Pulmonary Vascular Resistance (PVR), PVR will be measured at these 5 time points: 1) Baseline, 2) Hypoxia induced and maintained for 15 min post-baseline at which time the measurement is taken again, 3) Baseline oxygen saturation (Normoxia) reestablished 15 min post-hypoxia period, at which time the measurement is taken again 4) Normoxia measurement taken after BQ-123 administered for 60 min after time point 3, 5) Hypoxia induced and maintained for 15 min after BQ-123 normoxia period, at which time the measurement is taken again., Baseline and time points 2, 3, 4, and 5 (as described in Outcome Measure Description)",Pulmonary Hypertension,endothelin subtype A-receptor antagonist,NCT00759408
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Ranolazine,PHASE1,"Change in pulmonary vascular resistance (PVR), 12 weeks","Pulmonary Arterial Hypertension, Primary",Metabolizing enzyme inhibitor,NCT01757808
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Fluoxetine,PHASE2,"Change in Pulmonary Vascular Resistance (PVR) at Three Months, PVR will be measured by right heart catheterization at baseline and 3 months. Change in PVR will be determined by baseline value minus 3 month value., Change in PVR at 3 mos (Baseline - 3 months)","Pulmonary Arterial Hypertension, Primary","Antidepressant, Selective serotonin reuptake inhibitor (SSRI)",NCT00942708
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Vardenafil,PHASE3,"The change in exercise capacity, as measured by the total distance walked in six minutes, at week 12 and week 24",Pulmonary Hypertension,"Vasodilator, Impotence therapy, Phosphodiesterase V inhibitor",NCT00718952
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Nebulized ipratropium bromide,PHASE3,"Reduction of 1.0 unit of dyspnoea intensity (on a Borg scale) between pre-dose and post-dose BD measured at a standardized time (iso-time) or V'E (iso-V'E), At the end of CWR-CPET, the sensory-perceptual and affective dimensions of dyspnoea will be evaluated with Multidimensional Dyspnoea Profile (MDP) questionnaire., At two month (V3), three month (V4) and three months (V5)","Pulmonary Arterial Hypertension, Primary","ronchodilator, Muscarinic acetylcholine receptor antagonist",NCT02782052
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Ambrisentan,PHASE2,"Number of Participants With Non-serious Treatment-emergent Adverse Events (Non-STEAEs) and Serious Treatment-emergent Adverse Events (STEAEs), AE was defined as any untoward medical occurrence in participant or clinical investigation participant,temporally associated with use of medicinal product, whether or not considered related to medicinal product.SAE was defined as any untoward medical occurrence that, at any dose: results in death,is life threatening, requires hospitalization or prolongation of existing hospitalization,results in disability or incapacity,or is congenital anomaly or birth defect, important medical events that may not immediately life threatening or result in death or hospitalization but may jeopardize participant or may require medical or surgical intervention as per medical or scientific judgement or associated with drug-induced liver injury.TEAE is any event that was not present prior to initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. TEAEs which were not serious TEAEs were considered as non serious TEAEs., Up to 10 years and 11 months|Change From Baseline in Liver Function Parameters: Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Total Bilirubin, Blood samples were collected from participants for analysis of following clinical chemistry parameters: ALT, AST, GGT, total bilirubin. Baseline was the last value recorded prior to start of study treatment from AMB112529. Change from Baseline was calculated by subtracting the Baseline value from the end of study post-dose visit value., Baseline (Day 1) and up to 10 years and 11 months|Change From Baseline in Chemistry Parameters: Calcium, Chloride, Carbon Dioxide (CO2) Content, Glucose, Potassium, Magnesium, Sodium, Phosphorus Inorganic, Blood Urea Nitrogen (BUN), Blood samples were collected from participants for analysis of following clinical chemistry parameters: Calcium, chloride, CO2 content, glucose, potassium, magnesium, sodium, phosphorus inorganic, and BUN. Baseline was the last value recorded prior to start of study treatment from AMB112529. Change from Baseline was calculated by subtracting the Baseline value from the end of study post-dose visit value., Baseline (Day 1) and up to 10 years and 11 months|Change From Baseline in Chemistry Parameters: Alkaline Phosphatase (ALP), Creatine Kinase (CK), Lactate Dehydrogenase (LDH), Blood samples were collected from participants for analysis of following clinical chemistry parameters: ALP, CK, LDH. Baseline was the last value recorded prior to start of study treatment from AMB112529. Change from Baseline was calculated by subtracting the Baseline value from the end of study post-dose visit value., Baseline (Day 1) and up to 10 years and 11 months|Change From Baseline in Chemistry Parameters: Creatinine, Uric Acid, Blood samples were collected from participants for analysis of following clinical chemistry parameters: Creatinine, uric acid. Baseline was the last value recorded prior to start of study treatment from AMB112529. Change from Baseline was calculated by subtracting the Baseline value from the end of study post-dose visit value., Baseline (Day 1) and up to 10 years and 11 months|Change From Baseline in Chemistry Parameters: Albumin, Total Protein, Blood samples were collected from participants for analysis of following clinical chemistry parameters: Albumin, total protein. Baseline was the last value recorded prior to start of study treatment from AMB112529. Change from Baseline was calculated by subtracting the Baseline value from the end of study post-dose visit value., Baseline (Day 1) and up to 10 years and 11 months|Change From Baseline in Hematology Parameters: Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC), Blood samples were collected from participants for analysis of following hematology parameters: Hemoglobin and MCHC. Baseline was the last value recorded prior to start of study treatment from AMB112529. Change from Baseline was calculated by subtracting the Baseline value from the end of study post-dose visit value., Baseline (Day 1) and up to 10 years and 11 months|Change From Baseline in Hematology Parameters: Hematocrit, Blood samples were collected from participants for analysis of following hematology parameters: Hematocrit. Baseline was the last value recorded prior to start of study treatment from AMB112529. Change from Baseline was calculated by subtracting the Baseline value from the end of study post-dose visit value., Baseline (Day 1) and up to 10 years and 11 months|Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, White Blood Cells (WBC), Platelet Count, Blood samples were collected from participants for analysis of following hematology parameters: Basophils, eosinophils, lymphocytes, monocytes, total neutrophils, WBC, platelet count. Baseline was the last value recorded prior to start of study treatment from AMB112529. Change from Baseline was calculated by subtracting the Baseline value from the end of study post-dose visit value., Baseline (Day 1) and up to 10 years and 11 months|Change From Baseline in Hematology Parameter: Mean Corpuscle Hemoglobin, Blood samples were collected from participants for analysis of following hematology parameter: Mean Corpuscle Hemoglobin. Baseline was the last value recorded prior to start of study treatment from AMB112529. Change from Baseline was calculated by subtracting the Baseline value from the end of study post-dose visit value., Baseline (Day 1) and up to 10 years and 11 months|Change From Baseline in Hematology Parameter: Mean Corpuscle Volume, Blood samples were collected from participants for analysis of following hematology parameter: Mean Corpuscle Volume. Baseline was the last value recorded prior to start of study treatment from AMB112529. Change from Baseline was calculated by subtracting the Baseline value from the end of study post-dose visit value., Baseline (Day 1) and up to 10 years and 11 months|Change From Baseline in Hematology Parameters: Red Blood Cell Count, Reticulocytes, Blood samples were collected from participants for analysis of following hematology parameters: Red Blood Cell count, reticulocytes. Baseline was the last value recorded prior to start of study treatment from AMB112529. Change from Baseline was calculated by subtracting the Baseline value from the end of study post-dose visit value., Baseline (Day 1) and up to 10 years and 11 months|Number of Participants With Abnormal Values for Physical Examination Parameter: Liver Size, Physical examination included measurement of liver size. Any abnormal enlargement or reduction in the size of the liver is reported. Liver size was assessed as normal or abnormal. Data for abnormal (improved, worsened and unchanged) liver size is presented. End of study visit data is presented., Up to 10 years and 11 months|Number of Participants With Abnormal Values for Physical Examination Parameter: Jugular Venous Pressure, Physical examination included measurement of Jugular venous pressure. Jugular venous pressure was assessed as normal or abnormal. Data for abnormal (improved, worsened and unchanged) jugular venous pressure is presented. End of study visit data is presented., Up to 10 years and 11 months|Number of Participants With Abnormal Values for Physical Examination Parameters: Ascites, Physical examination included measurement of ascites. Ascites were assessed as present or absent. Data for ascites present with improved, worsened and unchanged is presented. End of study visit data is presented., Up to 10 years and 11 months|Number of Participants With Abnormal Values for Physical Examination Parameter: Peripheral Edema, Physical examination included measurement of peripheral edema. Peripheral edema were assessed as present or absent. Data for peripheral edema present with improved, worsened and unchanged is presented. End of study visit data is presented., Up to 10 years and 11 months|Percentage of Saturated Oxygen Level (Physical Examination Parameter), Physical examination included measurement of saturated oxygen. End of study visit data is presented., Up to 10 years and 11 months|Change From Baseline in Vital Signs Parameter: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP), SBP and DBP was measured for the participants at indicated time points. Baseline was the last value recorded prior to start of study treatment from AMB112529. Change from Baseline was calculated by subtracting the Baseline value from the end of study post-dose visit value., Baseline (Day 1) and up to 10 years and 11 months|Change From Baseline in Vital Signs Parameter: Heart Rate, Heart rate was measured for the participants at indicated time points. Baseline was the last value recorded prior to start of study treatment from AMB112529. Change from Baseline was calculated by subtracting the Baseline value from the end of study post-dose visit value., Baseline (Day 1) and up to 10 years and 11 months|Change From Baseline in Vital Signs Parameter: Weight, Weight was measured for the participants at indicated time points. Baseline was the last value recorded prior to start of study treatment from AMB112529. Change from Baseline was calculated by subtracting the Baseline value from the end of study post-dose visit value., Baseline (Day 1) and up to 10 years and 11 months|Change From Baseline in Vital Sign Parameter: Height, Height was measured for the participants at indicated time points. Baseline was the last value recorded prior to start of study treatment from AMB112529. Change from Baseline was calculated by subtracting the Baseline value from the end of study post-dose visit value., Baseline (Day 1) and up to 10 years and 11 months|Change From Baseline in Vital Sign Parameter: Body Mass Index, Body mass index was measured for the participants at indicated time points. Body mass index was calculated as weight in kilograms (kg) divided by the square of their height in meters (m\^2). Baseline was the last value recorded prior to start of study treatment from AMB112529. Change from Baseline was calculated by subtracting the Baseline value from the end of study post-dose visit value., Baseline (Day 1) and up to 10 years and 11 months|Change From Baseline in Vital Sign Parameter: Body Surface Area, Body surface area was measured for the participants at indicated time points. Baseline was the last value recorded prior to start of study treatment from AMB112529. Change from Baseline was calculated by subtracting the Baseline value from the end of study post-dose visit value., Baseline (Day 1) and up to 10 years and 11 months|Number of Participants With Abnormal Electrocardiogram (ECG) Findings, 12-lead ECG was measured in a semi-supine position using an automated ECG machine. Abnormal findings were categorized as clinically significant (CS) and not clinically significant (NCS). Data for any time till end of study were presented., Up to 10 years and 11 months|Change From Baseline in Plasma Endocrine Parameters - Female: Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) at End of Study, FSH and LH level of participants were measured. Only those parameters having status as overall were presented. Baseline was the last value recorded prior to start of study treatment from AMB112529. Change from Baseline was calculated by subtracting the Baseline value from the end of study post-dose visit value., Baseline (Day 1) and up to 10 years and 11 months|Change From Baseline in Plasma Endocrine Parameters - Female: Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) at 20 Years of Age of Participants, FSH and LH level of participants were measured. Only those parameters having status as overall were presented. Baseline was the last value recorded prior to start of study treatment from AMB112529.Change from Baseline was calculated by subtracting the Baseline value from the specified time point value. Only participants with data at 20 year visit is presented. When participants reached pubertal maturity prior to being 20 years of age then these tests were not repeated at 20-years of age of participants., Baseline (Day 1) and at 20 years of age of participants|Change From Baseline in Plasma Endocrine Parameters - Female: Inhibin B at End of Study, Inhibin B level of participants was measured. Only those parameters having status as overall were presented. Baseline was the last value recorded prior to start of study treatment from AMB112529. Change from Baseline was calculated by subtracting the Baseline value from the end of study post-dose visit value., Baseline (Day 1) and up to 10 years and 11 months|Change From Baseline in Plasma Endocrine Parameters - Female: Inhibin B at 20 Years of Age of Participants, Inhibin B level of participants was measured. Only those parameters having status as overall were presented. Baseline was the last value recorded prior to start of study treatment from AMB112529.Change from Baseline was calculated by subtracting the Baseline value from the specified time point value. Only participants with data at 20 year visit is presented. When participants reached pubertal maturity prior to being 20 years of age then these tests were not repeated at 20-years of age of participants., Baseline (Day 1) and at 20 years of age of participants|Change From Baseline in Plasma Endocrine Parameters - Female: Sex Hormone Binding Globulin at End of Study, Sex hormone binding globulin level of participants was measured. Only those parameters having status as overall were presented. Baseline was the last value recorded prior to start of study treatment from AMB112529. Change from Baseline was calculated by subtracting the Baseline value from the end of study post-dose visit value., Baseline (Day 1) and up to 10 years and 11 months|Change From Baseline in Plasma Endocrine Parameters - Female: Sex Hormone Binding Globulin at 20 Years of Age of Participants, Sex hormone binding globulin level of participants was measured. Only those parameters having status as overall were presented. Baseline was the last value recorded prior to start of study treatment from AMB112529. Change from Baseline was calculated by subtracting Baseline value from the specified time point value. Only participants with data at 20 year visit is presented. When participants reached pubertal maturity prior to being 20 years of age then these tests were not repeated at 20-years of age of participants., Baseline (Day 1) and at 20 years of age of participants|Change From Baseline in Plasma Endocrine Parameters - Female: Estrone at End of Study, Estrone level of female participants was measured. Only those parameters having status as overall were presented. Baseline was the last value recorded prior to start of study treatment from AMB112529. Change from Baseline was calculated by subtracting the Baseline value from the end of study post-dose visit value., Baseline (Day 1) and up to 10 years and 11 months|Change From Baseline in Plasma Endocrine Parameters - Female: Estrone at 20 Years of Age of Participants, Estrone level of female participants was measured. Only those parameters having status as overall were presented. Baseline was the last value recorded prior to start of study treatment from AMB112529.Change from Baseline was calculated by subtracting the Baseline value from the specified time point value. Only participants with data at 20 year visit is presented. When participants reached pubertal maturity prior to being 20 years of age then these tests were not repeated at 20-years of age of participants., Baseline (Day 1) and at 20 years of age of participants|Change From Baseline in Plasma Endocrine Parameters - Female: Estriol at End of Study, Estriol level of female participants will be measured. Only those parameters having status as overall will be presented. Baseline is the last value recorded prior to start of study treatment from AMB112529. Change from Baseline is calculated by subtracting the Baseline value from the end of study post-dose visit value. Data for this endpoint will be available for this endpoint by June 2023, Baseline (Day 1) and up to 10 years and 11 months|Change From Baseline in Plasma Endocrine Parameters - Female: Estriol at 20 Years of Age of Participants, Estriol level of female participants will be measured. Only those parameters having status as overall will be presented. Baseline is the last value recorded prior to start of study treatment from AMB112529.Change from Baseline is calculated by subtracting the Baseline value from the specified time point value. Only participants with data at 20 year visit is presented. When participants reached pubertal maturity prior to being 20 years of age then these tests were not repeated at 20-years of age of participants. Data for this endpoint will be available for this endpoint by June 2023, Baseline (Day 1) and at 20 years of age of participants|Change From Baseline in Plasma Endocrine Parameters - Female: Estradiol at End of Study, Estradiol level of female participants was measured. Only those parameters having status as overall were presented. Baseline was the last value recorded prior to start of study treatment from AMB112529. Change from Baseline was calculated by subtracting the Baseline value from the end of study post-dose visit value., Baseline (Day 1) and up to 10 years and 11 months|Change From Baseline in Plasma Endocrine Parameters - Female: Estradiol at 20 Years of Age of Participants, Estradiol level of female participants was measured. Only those parameters having status as overall were presented. Baseline was the last value recorded prior to start of study treatment from AMB112529.Change from Baseline was calculated by subtracting the Baseline value from the specified time point value. Only participants with data at 20 year visit is presented. When participants reached pubertal maturity prior to being 20 years of age then these tests were not repeated at 20-years of age of participants., Baseline (Day 1) and at 20 years of age of participants|Change From Baseline in Plasma Endocrine Parameters - Male: FSH and LH at End of Study, FSH and LH level of participants were measured. Only those parameters having status as overall were presented. Baseline was the last value recorded prior to start of study treatment from AMB112529. Change from Baseline was calculated by subtracting the Baseline value from the end of study post-dose visit value., Baseline (Day 1) and up to 10 years and 11 months|Change From Baseline in Plasma Endocrine Parameters - Male: FSH and LH at 20 Years of Age of Participants, FSH and LH level of participants were measured. Only those parameters having status as overall were presented. Baseline was the last value recorded prior to start of study treatment from AMB112529.Change from Baseline was calculated by subtracting the Baseline value from the specified time point value. Only participants with data at 20 year visit is presented. When participants reached pubertal maturity prior to being 20 years of age then these tests were not repeated at 20-years of age of participants., Baseline (Day 1) and at 20 years of age of participants|Change From Baseline in Plasma Endocrine Parameters - Male: Inhibin B at End of Study, Inhibin B level of participants was measured. Only those parameters having status as overall were presented. Baseline was the last value recorded prior to start of study treatment from AMB112529. Change from Baseline was calculated by subtracting the Baseline value from the end of study post-dose visit value., Baseline (Day 1) and up to 10 years and 11 months|Change From Baseline in Plasma Endocrine Parameters - Male: Inhibin B at 20 Years of Age of Participants, Inhibin B level of participants was measured. Only those parameters having status as overall were presented. Baseline was the last value recorded prior to start of study treatment from AMB112529.Change from Baseline was calculated by subtracting the Baseline value from the specified time point value. Only participants with data at 20 year visit is presented. When participants reached pubertal maturity prior to being 20 years of age then these tests were not repeated at 20-years of age of participants., Baseline (Day 1) and at 20 years of age of participants|Change From Baseline in Plasma Endocrine Parameters - Male: Sex Hormone Binding Globulin at End of Study, Sex hormone binding globulin level of participants was measured. Only those parameters having status as overall were presented. Baseline was the last value recorded prior to start of study treatment from AMB112529. Change from Baseline was calculated by subtracting the Baseline value from the end of study post-dose visit value., Baseline (Day 1) and up to 10 years and 11 months|Change From Baseline in Plasma Endocrine Parameters - Male: Sex Hormone Binding Globulin at 20 Years of Age of Participants, Sex hormone binding globulin level of participants was measured. Only those parameters having status as overall were presented. Baseline was the last value recorded prior to start of study treatment from AMB112529.Change from Baseline was calculated by subtracting the Baseline value from the specified time point value. Only participants with data at 20 year visit is presented. When participants reached pubertal maturity prior to being 20 years of age then these tests were not repeated at 20-years of age of participants., Baseline (Day 1) and at 20 years of age of participants|Change From Baseline in Plasma Endocrine Parameters - Male: Total Testosterone at End of Study, Total Testosterone level of participants was measured. Only those parameters having status as overall were presented. Baseline was the last value recorded prior to start of study treatment from AMB112529. Change from Baseline was calculated by subtracting the Baseline value from the end of study post-dose visit value., Baseline (Day 1) and up to 10 years and 11 months|Change From Baseline in Plasma Endocrine Parameters - Male: Total Testosterone at 20 Years of Age of Participants, Total Testosterone level of participants was measured. Only those parameters having status as overall were presented. Baseline was the last value recorded prior to start of study treatment from AMB112529.Change from Baseline was calculated by subtracting the Baseline value from the specified time point value. Only participants with data at 20 year visit is presented. When participants reached pubertal maturity prior to being 20 years of age then these tests were not repeated at 20-years of age of participants., Baseline (Day 1) and at 20 years of age of participants|Change From Baseline of Pubertal Development in Male: Testicular Volume at End of Study, Testicular volume was assessed by Prader's orchiodometer and the assessment was performed by a pediatric endocrinologist using the Tanner's criteria. Only those parameters having status - overall were presented. Baseline was the last value recorded prior to start of study treatment from AMB112529. Change from Baseline was calculated by subtracting the Baseline value from the end of study post-dose visit value. Data reported for left and right testicular volume., Baseline (Day 1) and up to 10 years and 11 months|Change From Baseline of Pubertal Development in Male: Testicular Volume at 20 Years of Age of Participants, Testicular volume was assessed by Prader's orchiodometer and the assessment was performed by a pediatric endocrinologist using the Tanner's criteria. Only those parameters having status as overall were presented. Baseline was the last value recorded prior to start of study treatment from AMB112529.Change from Baseline was calculated by subtracting the Baseline value from the specified time point value. Only participants with data at 20 year visit is presented. When participants reached pubertal maturity prior to being 20 years of age then these tests were not repeated at 20-years of age of participants. Data reported for left and right testicular volume., Baseline (Day 1) and at 20 years of age of participants|Time to Change in Dose of Ambrisentan or Other Targeted PAH Therapeutic Agents (Prostanoids, Phosphodiesterase Type 5 [PDE-5] Inhibitors) Due to Tolerability Issues, Time to change in dose of ambrisentan or other targeted PAH therapeutic agents (prostanoids, Phosphodiesterase type 5 \[PDE-5\] inhibitors) due to tolerability issues was defined as the time from randomization to the first occurrence of a dose change due to tolerability issues., Baseline (Day 1) and up to 10 years and 11 months","Hypertension, Pulmonary","Antihypertensive, Endothelin receptor type A antagonist",NCT01342952
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Zamicastat (BIA 5-1058),PHASE1,"time-matched change from baseline in placebo-adjusted QT interval corrected for heart rate based on an individual correction method after BIA 5-1058 dosing., In each treatment period, continuous 12-lead digital ECG recording will be performed by Holter monitor for at least 24 hours prior to dose until approximately 24 hours postdose., Day 1 at -1.25, -1, and -0.75 hours predose, Day -1 (baseline) at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, and 24 hours and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, and 23 hours postdose.",Cardiovascular Disease|Pulmonary Arterial Hypertension|Heart Failure,dopamine β-hydroxylase inhibitor,NCT03489005
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Treprostinil Palmitil,PHASE2,"Change from Baseline in Pulmonary Vascular Resistance at Week 16, Baseline to Week 16","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Prostaglandin I2 receptor agonist",NCT05147805
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Subcutaneous Treprostinil,PHASE4,"Incidence of Adverse Events Among Subjects through Study Completion, Adverse events among participants will be recorded throughout participation in the study. The incidence of adverse events among subjects through study completion, an average of 3 years, will be described by the number of subjects analyzed and the percentage of those subjects who experienced an adverse event until study completion., Study Completion, an Average of 3 Years|Change in 6-minute Walk Distance (6MWD) From Baseline to Month 12, The intent of the 6MWD test is to evaluate exercise capacity associated with carrying out activities of daily living. Change in 6MWD from Baseline to Month 12, correlates with the current clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status. Subjects will be instructed to walk down a corridor at a comfortable speed as far as they can manage for six minutes. Distance \<500 meters suggests considerable exercise limitation; Distance 500-800 meters suggests moderate limitation; Distance \>800 meters (with no rests) suggests mild or no limitation., Baseline and Month 12|Change in Borg Dyspnea Score (following 6MWT) from Baseline to Month 12, The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea (difficulty in breathing) experienced during the six-minute walk test (6MWT). The Borg dyspnea score will be assessed immediately following the 6MWT. Scores range from 0 (for no shortness of breath) to 10 (for the greatest shortness of breath ever experienced). Changes from Baseline to Month 12 will be summarized and compared between treatment groups using descriptive statistics. No formal hypothesis testing will be performed., Baseline and Month 12|Number of Participants with a Change from Baseline World Health Organization (WHO) Functional Classification at Month 12, The WHO Functional Class of pulmonary hypertension is a physical activity rating scale as follows: Class I: No limitation of physical activity. Class II: Slight limitation of physical activity. Class III: Marked limitation of physical activity. Class IV: Inability to carry out any physical activity without symptoms. Changes from Baseline to Month 12 will be summarized and compared between treatment groups using descriptive statistics. No formal hypothesis testing will be performed., Change from Baseline at Month 12","Pulmonary Arterial Hypertension, Primary","Anticoagulant, Antihypertensive, Vasodilator, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT02882126
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: oral Treprostinil diolamine (UT-15C),PHASE3,"Change in six-minute walk distance from Baseline to Week 12, 12 weeks",Pulmonary Hypertension,"Antihypertensive, Prostaglandin I2 receptor agonist",NCT00760916
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Esomeprazole on patients taking Oral Treprostinil,PHASE1,"Treprostinil pharmacokinetics in healthy volunteers following a single oral dose of a 1 mg treprostinil diethanolamine sustained release tablet before and after repeated dosing with esomeprazole., Within 10 minutes prior to through 36 hours post treprostinil diethanolamine dosing|Adverse event monitoring, Time Frame: From the first dose of treprostinil diethanolamine through study end (Study Day 9/10)","Hypertension, Pulmonary|Pulmonary Arterial Hypertension","Antisecretory (gastric acid), Anti-ulcerative, Proton pump inhibitor",NCT00963027
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: ACT-385781A (Actelion Epoprostenol),PHASE4,"Dose Normalized Pharmacokinetics of 6,15-diketo-13,14-dihydro-Prostacyclin F1alpha at 2 ng/kg/Min, The plasma concentration for the epoprostenol metabolite 6,15-diketo-13,14-dihydro-Prostacyclin F1alpha was measured at 2 ng/kg/min just prior to the next up-titration. Dose-normalized concentrations are used to summarize the results., Day 1|Dose Normalized Pharmacokinetics of 6,15-diketo-13,14-dihydro-Prostacyclin F1alpha at 4 ng/kg/Min, The plasma concentration for the epoprostenol metabolite 6,15-diketo-13,14-dihydro-Prostacyclin F1alpha was measured at 4 ng/kg/min just prior to the next up-titration. Dose-normalized concentrations are used to summarize the results., Day 1|Dose Normalized Pharmacokinetics of 6-keto-Prostacyclin F1alpha at 2 ng/kg/Min, The plasma concentration for the epoprostenol metabolite 6-keto-Prostacyclin F1alpha was measured at 2 ng/kg/min just prior to the next up-titration. Dose-normalized concentrations are used to summarize the results., Day 1|Dose Normalized Pharmacokinetics of 6-keto-Prostacyclin F1alpha at 4 ng/kg/Min, The plasma concentration for the epoprostenol metabolite 6-keto-Prostacyclin F1alpha was measured at 4 ng/kg/min just prior to the next up-titration. Dose-normalized concentrations are used to summarize the results., Day 1|Six-minute Walk Distance (6MWD) - Baseline and Day 28, The 6-minute walk test (6MWT) was to be performed prior to initiating study treatment either during the screening visit or on Day 1 prior to drug initiation, and Day 28 (End of treatment (EOT)). This assessment is a non-encouraged test that measures the distance walked for a duration of 6 minutes. The 6MWD was recorded in the Case Report Form (CRF)., Baseline and 28 days (+3 days)|Patients With New York Heart Association (NYHA) Functional Class Change (Improved or Worsened) From Baseline to Day 28, Disease severity was assessed by NYHA classification of PAH criteria: Class I: no limitation of physical activity (PA). Ordinary PA: no undue dyspnea/fatigue, chest pain, near syncope. Class II: slight limitation of PA. Comfortable at rest. Ordinary PA: undue dyspnea/fatigue, chest pain, near syncope. Class III: marked limitation of PA. Comfortable at rest. Less than ordinary PA: undue dyspnea/fatigue, chest pain, near syncope. Class IV: inability to carry out PA without symptoms. Right heart failure. Dyspnea/fatigue may even have been present at rest. Discomfort increased by any PA., From baseline to 28 days (+3 days)|Percentage Central Venous Blood Oxygen Saturation (ScVO2) - Baseline and Day 28, Central venous blood oxygen saturation assessment was performed only in specific centers. Measurements for ScVO2 were performed during the inpatient hospitalization period on Day 1 (prior to drug initiation) and on Day 28 (EOT). Samples for ScVO2 were obtained by aspirating blood from the indwelling central venous catheter. After the sample had been drawn, the catheter was primed with study drug in order to refill the lumen to avoid interruption in treatment and sudden decompensation., Baseline and 28 days|Blood Pressure - Baseline and Day 28, Blood pressure (systolic and diastolic) were measured indirectly using an automatic oscillometric device, on the same arm for each measurement. The Blood Pressure was assessed at baseline and at Day 28 (End of Study Treatment visit)., Baseline and 28 days|Heart Rate - Baseline and Day 28, Heart rate was measured indirectly using an automatic oscillometric device, on the same arm for each measurement. The Heart Rate was assessed at Baseline and at Day 28 (End of Study Treatment visit)., Baseline and 28 days|Body Weight - Baseline and Day 28, Body weight was measured both at baseline and day 28., Baseline and 28 days","Pulmonary Arterial Hypertension, Primary","Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT01105091
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Carvedilol,PHASE1,"Mean change in RVEF, 1. The primary efficacy outcome is the mean change in RVEF as measured by cardiac MRI before and after 6 months of carvedilol treatment. An improvement of 5% will be considered to be clinically significant. Assessment of the RV is challenging due to its complex geometry. Cardiac MRI offers the ability to acquire 3-dimensional datasets that do not require geometric modeling. In addition to being highly reproducible40, RVEF measured by cardiac MRI can be used to identify PAH patients that are likely to have clinical worsening41. The prognostic ability of cardiac MRI-measurements of RVEF is similar to that as mean pulmonary artery pressure and exercise capacity, Baseline and 6 months",Pulmonary Hypertension|Cardiac MRI <40,"Antihypertensive, alpha1/beta-Adrenergic receptor antagonist",NCT02120339
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Vardenafil,PHASE4,"Change in 6 minute walk or New York Heart Association functional class., 14 weeks",Pulmonary Arterial Hypertension,"Vasodilator, Impotence therapy, Phosphodiesterase V inhibitor",NCT01649739
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: treprostinil sodium,PHASE4,"Change in Six Minute Walk Distance, Baseline and Week 8","Hypertension, Pulmonary","Anticoagulant, Vasodilator, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT00643604
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: ACT-385781A (Actelion Epoprostenol),PHASE4,"Safety and Tolerability of ACT-385781A and Flolan in Injectable Prostanoid Treatment-na├»ve Patients With Pulmonary Arterial Hypertension (PAH) - Number of Patients With Adverse Events Leading Discontinuation of Study Treatment, Up to 39 days. Day 1 - until patients transition from study medication to commercially-obtained medication|Safety and Tolerability of ACT-385781A and Flolan in Injectable Prostanoid Treatment-na├»ve Patients With PAH - Number of Deaths, Up to 39 days. Day 1 - until patients transition from study medication to commercially-obtained medication","Pulmonary Arterial Hypertension, Primary","Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT01105117
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Apabetalone,EARLY_PHASE1,"Change in Pulmonary Vascular Resistance (PVR), dyn┬╖s┬╖cm-5, Right heart catheterization: Measuring PVR is performed in a standardized manner in catheterization laboratories of the participating centres, according to recommendations. Printed copies of waveforms will be kept for monitoring visits and documentation of the accuracy of the pressures and calculations., Baseline,and 16 weeks later","Pulmonary Arterial Hypertension, Primary","Anti-inflammatory, BET inhibitor",NCT03655704
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: LIQ861 Inhaled Treprostinil,PHASE3,"Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events, Treatment-Emergent Adverse Events and Serious Adverse Events will be grouped by MedDRA System Organ Class, dose level, time on drug, and relationship to dose titration, Baseline, Week 2, Month 1, Month 2 Visits, with bimonthly follow up for up to 30 months.",Primary Pulmonary Hypertension,"Antihypertensive, Prostaglandin I2 receptor agonist",NCT03399604
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Selexipag|DRUG: Riociguat,PHASE4,"Right Ventricular Stroke Volume (RVSV) flow on each therapy measured by MRI RSVS (flow) on each therapy measured by MRI, This provides a robust, objective assessment of clinical efficacy which, if met, will mean that a change in therapy has provided a clinically meaningful change in physiology, Baseline to Week 12","Pulmonary Arterial Hypertension, Primary","Vasodilator, Prostaglandin I2 receptor agonist | Vasodilator, Guanylate cyclase activator",NCT05825417
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: GB002 (seralutinib),PHASE2,"Number of Participants With Treatment Emergent Adverse Events, From first dose of study drug up to 148 weeks","Pulmonary Arterial Hypertension, Primary",Receptor tyrosine kinase inhibitor,NCT04816604
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: HypotonicTreprostinil Solution|DRUG: Eutonic Treprostinil Solution,PHASE4,"Daily Pain Diary, 2 weeks","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Prostaglandin I2 receptor agonist",NCT01615627
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: MK-8892,PHASE1,"Area Under the Concentration Time-curve From Hour 0 to 24 Hours (AUC0-24hr) of MK-8892 at Day 1 and Day 28, Blood samples taken at Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, and 24 hours postdose on Days 1 and 28 to determine the AUC0-24hr., Predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours postdose on Days 1 and 28|Number of Participants Who Experienced an Adverse Event (AE), An AE was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. The number of participants that reported at least 1 AE was summarized., Up to 42 days|Number of Participants Who Had Study Drug Discontinued Due to an Adverse Event, An AE was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. The number of participants who had study drug discontinued due to an AE was summarized., Up to 28 days","Pulmonary Arterial Hypertension, Primary",Soluble guanylate cyclase (sGC) modulator,NCT01926509
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: oral sildenafil,PHASE4,"Arterial pulmonary resistance index, 6 months","Pulmonary Arterial Hypertension, Primary","Vasodilator, Impotence therapy, Phosphodiesterase V inhibitor",NCT00483626
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Treprostinil Inhalation Powder,PHASE1,"Number of subjects with treatment-emergent adverse events [Safety and Tolerability], The safety and tolerability of TreT in subjects with PAH currently treated with Tyvaso will be evaluated by the number of subjects with treatment-emergent adverse events, 3 weeks","Pulmonary Arterial Hypertension, Primary","Anticoagulant, Vasodilator, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT03950739
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Sildenafil 20mg and Bosentan 62.5mg,PHASE4,"Change in Pulmonary artery pressures, Change in Pulmonary artery pressures measured by echocardiography at baseline and 6 months in patients of systemic sclerosis with PAH when treatment with Single(PDE-5inhibitors at dose of 20 mg maximum upto 60mg) versus Dual therapy(PDE-5inhibitors and ER antagonist 62.5 mg maximum upto 125mg) for 6 months, Baseline and 6 months",Associated Pulmonary Arterial Hypertension,"Vasodilator, Impotence therapy, Phosphodiesterase V inhibitor + Antihypertensive, Endothelin receptor antagonist",NCT03053739
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Sitaxsentan,PHASE3,"Change From Baseline in Total Distance Walked During 6 Minute Walk Distance (6MWD) at Week 12, 6 MWD was the distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed. Continuous pulse oximetry was conducted during the test for safety. Change is Week 12 results minus baseline results., Baseline/Day 1 and Week 12","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Endothelin receptor type A antagonist",NCT00795639
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Intestinal microbiota transplant (IMT),PHASE1,"Frequency of Serious Adverse Events, In order to assess the safety of the trial, the frequency of adverse events will be reported. Outcome will be reported as the mean number of serious adverse events per participant., 6 months|Proportion of IMT Compliance, In order to assess the feasibility of the trial, the proportion of subjects taking 100% of the intestinal microbiota transplantation (IMT) doses per protocol will be reported. Outcome is reported as the percent of participants who consume 100% of IMT doses., 6 months","Pulmonary Arterial Hypertension, Primary",Intestinal microbiota transplant (IMT),NCT04884971
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Fluoxetine,PHASE2,"Pulmonary Vascular Resistance (PVR), Change in PVR between baseline and follow-up will be utilized. PVR is calculated as \[(Pulmonary Artery mean - wedge) / Fick Cardiac Output\]. Fick CO will be used in computing PVR over thermodilution because Fick appears to have greater precision (but not accuracy). The calculation of PVR above is measured in woods unit. Change is derived by getting the difference between baseline and week 24 PVR (Week 24 minus Baseline). mean is then computed by getting the average of the change, Baseline and Week 24","Pulmonary Arterial Hypertension, Primary","Antidepressant, Selective serotonin reuptake inhibitor (SSRI)",NCT03638908
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: ambrisentan,PHASE4,"Number of Subjects Not Able to Tolerate Ambrisentan, If a subject was not able tolerate ambrisentan, subject was returned to use of bosentan and ambrisentan was withdrawn within first 12 weeks of start. A subject was considered to not be able to tolerate ambrisentan if they experienced an adverse event or side effect that was not acceptable to the subject., baseline to 12 weeks","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Endothelin receptor type A antagonist",NCT01330108
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Beraprost Sodium Modified Release,PHASE2,"Number of Participants Reporting at Least One Treatment-Emergent Adverse Event (TEAE), A treatment-emergent adverse event (TEAEs) is defined as an event not present prior to the initiation of the treatments or any event already present that worsens in either intensity or frequency following exposure to the treatments. AEs occurring more than 3 days after the last day study drug is taken in the study will not be included in the statistical analyses or summaries (except for subjects with adverse events leading to study drug withdrawn). Only treatment-emergent adverse events occurring during the treatment period of the BPS-MR-PAH-202 study will be summarized. Any adverse event starting prior to the first dose of study drug will be excluded from the summary analyses and only presented in the data listings. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module., Up to 56 months|Number of Treatment Emergent Adverse Events Reported During The Study, A treatment-emergent adverse event (TEAE) is defined as an event not present prior to the initiation of the treatment or any event already present that worsens in either intensity or frequency following exposure to the treatment. AEs occurring more than 3 days after the last day study drug was taken in the study was not included in the statistical analyses or summaries (except for participants with adverse events leading to study drug withdrawn). Only TEAEs that occurred during the treatment period of the BPS-MR-PAH-202 study were summarized. Any adverse event starting prior to the first dose of study drug was excluded from the summary analyses and only presented in the data listings. All efficacy results are descriptive; no statistical analysis was conducted. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module., Up to 56 months","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT00792571
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Empagliflozin 10 MG,PHASE2,"Tolerability: the number of patients who have to prematurely discontinue treatment due to intolerability or adverse events., 12 weeks|Feasibility: time needed to include all patients and number of patients needed to screen., 12 weeks|Safety: the number of adverse events (AEs), severe adverse events (SAEs), adverse event of special interest (AESI) and suspected unexpected serious adverse reactions (SUSARs)., 12 weeks",Idiopathic Pulmonary Arterial Hypertension,"Antidiabetic, SGLT-2 inhibitor",NCT05493371
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Spironolactone,PHASE4,"Change in biomarker levels in the spironolactone treated as compared to placebo treated group., 50 participants will be enrolled in a 16-week study, and each subject will receive placebo or active drug in a random order. At the end of week 8, treatment arm for each subject will be blindly switched. Biomarker levels will be drawn 3 times (baseline, week 8, and week 16) during the study period for each subject., 16 week",Pulmonary Hypertension,"Antihypertensive, Diuretic, Aldosterone antagonist",NCT01468571
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Aspirin+clopidogrel,PHASE2,Plasma P-selectin level|Aggregometry|Serum thromboxane B2|Urinary Tx-M|Urinary prostaglandin I2 (PGI-M),Idiopathic pulmonary arterial hypertension,Antiplatelet,NCT00105209
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: sildenafil,PHASE4,"6 minute walk distance (6MWD) change from Baseline, ATS guideline based 6MW distance, 6 months",Pulmonary Arterial Hypertension|Idiopathic Pulmonary Fibrosis|Interstitial Lung Disease|Pulmonary Hypertension,"Vasodilator, Impotence therapy, Phosphodiesterase V inhibitor",NCT00625079
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Sodium Nitrite Inhalation Solution| and AIR001 Inhalation Solution (Expansion arm),PHASE1,"The measurement of pulmonary arterial pressures by echocardiography., Pretreatment and up to 2 hours post treatment","Pulmonary Arterial Hypertension, Primary",Antidote (cyanide poisoning),NCT00814645
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: UT-15C SR (treprostinil diethanolamine),PHASE1,"Treprostinil pharmacokinetics in volunteers with varying degrees of renal function following a single oral dose of a 1 mg treprostinil diethanolamine sustained release., 48hrs post dose (60 hours for ESRD)",Pulmonary Arterial Hypertension|Renal Dysfunction,"Antihypertensive, Prostaglandin I2 receptor agonist",NCT01131845
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Macitentan 10 mg|DRUG: Macitentan 37.5 mg|DRUG: Macitentan 75 mg|,PHASE3,"Double-blind Treatment Period: Time to First Clinical Events Committee (CEC)-adjudicated Morbidity or Mortality (M/M) Events, Time to first CEC-adjudicated M/M event on-treatment (ie.,up to 7 days after last dose of DB study intervention) is defined as time from randomization to first of following events: All-cause death, including death caused by on-treatment adverse event that occur within 4 weeks of study DB treatment discontinuation;non-planned Pulmonary Arterial Hypertension(PAH)-related hospitalization(including for worsening of PAH, atrial septostomy, lung transplantation with or without heart transplantation, or initiation of parenteral prostacyclins);PAH-related disease progression, defined as worsening of World Health Organization(WHO) Functional Class(FC) from baseline or deterioration by at least 15% in exercise capacity, as measured by 6-minute walk distance(6MWD), from baseline and confirmed by second 6MWD test performed on different day within 2 week of initial test or appearance or worsening of signs or symptoms of right-sided heart failure that require initiation of intravenous diuretics., Up to 4 years","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Endothelin receptor antagonist",NCT04273945
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Seralutinib (GB002),PHASE1,"Number of participants with Treatment-Related Adverse Events GB002 (Main study), To evaluate the safety and tolerability of GB002, Up to 45 days|Number of participants with Treatment-Related Adverse Events GB002 (OLE study), To evaluate the long-term safety and tolerability and efficacy of GB002, Up to 200 days","Pulmonary Arterial Hypertension, Primary",Receptor tyrosine kinase inhibitor,NCT03926793
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: saquinavir+ritonavir,EARLY_PHASE1,"HMGB1 level, 14 days","Pulmonary Arterial Hypertension, Primary","Antiviral, HIV protease inhibitor",NCT02023450
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Parenteral Remodulin (treprostinil) injection|DRUG: Oral Treprostinil,PHASE2,"Incidence of Adverse Events (AEs) through 16 Weeks, 16 Weeks","Pulmonary Arterial Hypertension, Primary","Anticoagulant, Antihypertensive, Vasodilator, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT03016468
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: FDC macitentan | DRUG: tadalafil,PHASE3,"Change in Pulmonary Vascular Resistance (PVR) expressed as the ratio of geometric means of End of Double-Blind Treatment (EDBT) to baseline, PVR is the resistance in the pulmonary vasculature that has to be overcome to push blood from the right side of the heart to the lungs. PVR measured by Right Heart Catheterization (RHC) has diagnostic and prognostic value as well as offers an objective judgement on treatment response and efficacy., From baseline to EDBT (Week 16)",Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH),"Antihypertensive, Endothelin receptor antagonist | Antihypertensive, Impotence therapy, Phosphodiesterase V inhibitor ",NCT03904693
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: ubenimex,PHASE2,"Treatment-emergent Adverse Events (TEAEs), Number of Patients with TEAEs collected for all patients and recorded on the Adverse Event Case Report Form, At least 24 weeks of open-label treatment with ubenimex followed by 4 weeks follow-up","Pulmonary Arterial Hypertension, Primary","Antineoplastic, Immunomodulator",NCT02736149
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: EFI/ACT-385781A,PHASE3,"Change in Pulmonary Vascular Resistance From Baseline to End of Treatment (EOT)., Right heart catheterization was performed for cardiac hemodynamic assessment at Screening or Day 1, prior to switch from Flolan┬« to EFI/ACT-385781A and at EOT., Approximately 3 months|Change in Total Pulmonary Resistance From Baseline to End of Treatment (EOT)., Right heart catheterization was performed for cardiac hemodynamic assessment at Screening or Day 1, prior to switch from Flolan┬« to EFI/ACT-385781A and at EOT., Approximately 3 months|Change in Mean Pulmonary Arterial Pressure From Baseline to End of Treatment (EOT)., Right heart catheterization was performed for cardiac hemodynamic assessment at Screening or Day 1, prior to switch from Flolan┬« to EFI/ACT-385781A and at EOT., Approximately 3 months|Change in Mean Right Atrial Pressure From Baseline to End of Treatment (EOT)., Right heart catheterization was performed for cardiac hemodynamic assessment at Screening or Day 1, prior to switch from Flolan┬« to EFI/ACT-385781A and at EOT., Approximately 3 months|Change in Pulmonary Capillary Wedge Pressure From Baseline to End of Treatment (EOT)., Right heart catheterization was performed for cardiac hemodynamic assessment at Screening or Day 1, prior to switch from Flolan┬« to EFI/ACT-385781A and at EOT., Approximately 3 months|Change in Mean Cardiac Index From Baseline to End of Treatment (EOT)., Right heart catheterization was performed for cardiac hemodynamic assessment at Screening or Day 1, prior to switch from Flolan┬« to EFI/ACT-385781A and at EOT., Approximately 3 months","Pulmonary Arterial Hypertension, Primary","Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT01431716
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Benzbromarone,PHASE2,"Pulmonary vascular resistance (Wood units) assessed by right heart catheterization, 2 hours",Idiopathic Pulmonary Arterial Hypertension,"Gout suppressant, Uricosuric",NCT02790450
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Iloprost,PHASE4,"Change in six minute walk distance, 24 weeks",Sarcoidosis|Pulmonary Arterial Hypertension,"Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT00403650
ATP13A3,autosomal recessive,TGF-beta signaling pathway,"DRUG: 20 mg sildenafil citrate by mouth|DRUG: sodium tanshinone IIA sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth",PHASE2|PHASE3,"mPAP by right heart catheterization, To assess if sodium Tanshinone IIA sulfonate decreases mean pulmonary arterial pressure., At the end of 0- and 8-week trial",Pulmonary Hypertension|Pulmonary Arterial Hypertension|Cardiovascular Diseases|Lung Diseases|Tanshinone IIA Sulfonate,"Vasodilator, Impotence therapy, Phosphodiesterase V inhibitor",NCT01637675
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Metformin,PHASE2,The primary objective of this study will be to demonstrate the improvement of walk test distance in patients with pulmonary arterial hypertension (PAH) treated by metformin.,"Pulmonary Arterial Hypertension, Primary","Antidiabetic, Hypoglycemic, AMP kinase activator",NCT01352026
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: TPN171H||DRUG: Tadalafil,PHASE2,"Percentage of the maximum change in pulmonary vascular resistance(PVR) to the second baseline, Within 24 hours after drug administration","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Impotence therapy, Phosphodiesterase V inhibitor ",NCT04483115
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: bosentan,PHASE3,"exercise capacity, Baseline to end of study|cardiac hemodynamics, Baseline to end of study",Pulmonary Hypertension,"Antihypertensive, Endothelin receptor antagonist",NCT00091715
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Bosentan,PHASE3,"Treatment Emergent Adverse Events (AEs) up to 7 Days After Permanent Study Drug Discontinuation, This is the total number of subjects with at least one adverse event (serious or not serious) whether or not causally related to the study drug and presented cumulatively in the FUTURE 3 and FUTURE 3 Extension study. NOTE: FUTURE 3 extension study was exploratory and no primary efficacy and safety endpoints were defined in the protocol. So, this safety outcome measure was selected and reported as primary endpoint here., Up to 62 weeks in average",Pulmonary Arterial Hypertension,"Antihypertensive, Endothelin receptor antagonist",NCT01338415
ATP13A3,autosomal recessive,TGF-beta signaling pathway,"DRUG: Riociguat (Adempas, BAY63-2521)|DRUG: Riociguat (Adempas, BAY63-2521)|",PHASE3,"6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 12, 6-minute walking distance (6MWD) is a measure for the objective evaluation of a patient's functional exercise capacity., Baseline and week 12",Pulmonary Hypertension,"Vasodilator, Guanylate cyclase activator",NCT00810693
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Oxygen,PHASE2,"6-minute Walking distance, To determine the benefits for PH patients from a long-term oxygen therapy (LTOT) given continuously during ΓëÑ16h/day for 12 weeks, measured by improvement of exercise performance assessed by the 6 minute walking distance (6MWD)., Change from baseline to 6 months",Oxygen Deficiency|Pulmonary Arterial Hypertension|CTEPH,Medical gases,NCT04207593
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: bosentan,PHASE4,"Time to First Confirmed Morbidity/Mortality Event up to the End of Study, Kaplan-Meier estimate of percentage of participants without a morbidity/mortality event. A morbidity/mortality event is defined as the occurrence of a) death, b) hospitalization for worsening or complication of PAH or intravenous prostanoid initiation, c) atrial septostomy, d) lung transplantation, or e) worsening PAH, defined as ""moderately"" or ""markedly"" worsened PAH symptoms using a patient global self-assessment (PGSA) scale AND initiation of inhaled or subcutaneous prostanoids or the disease progression package (open-label bosentan). If a patient replied ""no change"" or ""mildly worse"" on the PGSA, a decrease in 6MWT of 20% versus last visit or 30% versus baseline is also required to confirm the event., From baseline to end of study, approximately 86 months",Pulmonary Arterial Hypertension,"Antihypertensive, Endothelin receptor antagonist",NCT00303459
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Spironolactone||RADIATION: PET/CT Scan: Two PET scans using 1. C-11 HED and 2. N-13 Ammonia or rubidium-82|DIAGNOSTIC_TEST: Cardiac MRI (Gadolinium enhanced),PHASE4,"Change in Ventricular Wall Stress, To determine if treatment with spironolactone is associated with a significant reduction in RV ventricular wall stress, as reflected by a reduction in serum NT-proBNP, in patients with chronic stable right HF when compared to placebo., Baseline and 12 weeks","Chronic Right-Sided Heart Failure|Pulmonary Arterial Hypertension|Pulmonary Hypertension, Primary, 2|Pulmonary Hypertension, Primary, 3|Pulmonary Hypertension, Primary, 4|Cardiomyopathy Right Ventricular","Antihypertensive, Diuretic, Aldosterone antagonist",NCT03344159
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: epoprostenol,PHASE4,NaN,"Hypertension, Pulmonary","Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT00004754
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Imatinib|DRUG: Sildenafil|DRUG: Bosentan,PHASE3,"Geometric Mean Ratio of Dose Normalized Area Under the Curve From Time Zero to Tau (AUCtau) for Bosentan Before and After Imatinib Administrations, AUCtau was the area under the curve calculated to the end of the dosing interval, tau. The effect of co-administration of imatinib at two doses (200 and 400 mg) on the pharmacokinetics of bosentan was performed on dose normalized AUCtau of bosentan. A mixed effects linear model was fitted to the log-transformed PK parameters. This model included treatment (i.e., dose of imatinib) as a fixed effect, and participant as a random effect. Estimates for the treatment differences and associated 90% confidence intervals were obtained from the above model. These estimates and confidence intervals were then ""back-transformed"" to the original scale, giving, for each dose level of imatinib, the ratio of imatinib + co-administered sildenafil and bosentan (test) relative to the co-administered drugs alone (sildenafil + bosentan) (reference)., Day 1: pre-dose, Day 8: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours post-dose, Day 9: pre-dose, Days 22 and 36: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose|Geometric Mean Ratio of Dose Normalized AUCtau for Sildenafil Before and After Imatinib Administrations, AUCtau was the area under the curve calculated to the end of the dosing interval, tau. The effect of co-administration of imatinib at two doses (200 and 400 mg) on the pharmacokinetics of sildenafil was performed on dose normalized AUCtau of sildenafil. A mixed effects linear model was fitted to the log-transformed PK parameters. This model included treatment (i.e., dose of imatinib) as a fixed effect, and participant as a random effect. Estimates for the treatment differences and associated 90% confidence intervals were obtained from the above model. These estimates and confidence intervals were then ""back-transformed"" to the original scale, giving, for each dose level of imatinib, the ratio of imatinib + co-administered sildenafil and bosentan (test) relative to the co-administered drugs alone (sildenafil + bosentan) (reference)., Day 1: pre-dose, Day 8: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours post-dose, Day 9: pre-dose, Days 22 and 36: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose|Geometric Mean Ratio of Dose Normalized Maximum Plasma Concentration (Cmax) for Bosentan Before and After Imatinib Administrations, Cmax was the maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after dose administration. The effect of co-administration of imatinib at two doses (200 and 400 mg) on the pharmacokinetics of bosentan was performed on dose normalized Cmax of bosentan. A mixed effects linear model was fitted to the log-transformed PK parameters. This model included treatment (i.e., dose of imatinib) as a fixed effect, and participant as a random effect. Estimates for the treatment differences and associated 90% confidence intervals were obtained from the above model. These estimates and confidence intervals were then ""back-transformed"" to the original scale, giving, for each dose level of imatinib, the ratio of imatinib + co-administered sildenafil and bosentan (test) relative to the co-administered drugs alone (sildenafil + bosentan) (reference)., Day 1: pre-dose, Day 8: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours post-dose, Day 9: pre-dose, Days 22 and 36: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose|Geometric Mean Ratio of Dose Normalized Cmax for Sildenafil Before and After Imatinib Administrations, Cmax was the maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after dose administration. The effect of co-administration of imatinib at two doses (200 and 400 mg) on the pharmacokinetics of sildenafil was performed on dose normalized Cmax of sildenafil. A mixed effects linear model was fitted to the log-transformed PK parameters. This model included treatment (i.e., dose of imatinib) as a fixed effect, and participant as a random effect. Estimates for the treatment differences and associated 90% confidence intervals were obtained from the above model. These estimates and confidence intervals was then ""back-transformed"" to the original scale, giving, for each dose level of imatinib, the ratio of imatinib + co-administered sildenafil and bosentan (test) relative to the co-administered drugs alone (sildenafil + bosentan) (reference)., Day 1: pre-dose, Day 8: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours post-dose, Day 9: pre-dose, Days 22 and 36: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose",Pulmonary Arterial Hypertension,"Antineoplastic, Tyrosine kinase inhibitor | Vasodilator, Impotence therapy, Phosphodiesterase V inhibitor | Antihypertensive, Endothelin receptor antagonist",NCT01392469
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Iloprost PD-6|DRUG: Iloprost PD-15,PHASE2,"Inhalation-times Rate - Iloprost PD-6 (Period I), Defined as the percentage of full doses (5 ┬╡g) of iloprost delivered within the recommended time frame for receiving a full dose of iloprost (4-10 minutes). Iloprost dosing information was available from the I-neb┬« device, which recorded the date and time of each inhalation, the duration of each inhalation, as well as the inhalation completion status (\< 12.5%, ΓëÑ 12.5% to \< 100%, and Full), 37 days prior to first dose of iloprost PD-15|Inhalation-times Rate - Iloprost PD-15 (Period II), Defined as the percentage of full doses (5 ┬╡g) of iloprost delivered within the recommended time frame for receiving a full dose of iloprost (4-10 minutes). Iloprost dosing information was available from the I-neb┬« device, which recorded the date and time of each inhalation, the duration of each inhalation, as well as the inhalation completion status (\< 12.5%, ΓëÑ 12.5% to \< 100%, and Full), 37 days following first dose of iloprost PD-15|Change in Inhalation-times Rate From Period I (Iloprost PD-6) to Period II (Iloprost PD-15), Change in the percentage of full doses (5 ┬╡g) of iloprost delivered within the recommended time frame for receiving a full dose of iloprost (4-10 minutes). Iloprost dosing information was available from the I-neb┬« device, which recorded the date and time of each inhalation, the duration of each inhalation, as well as the inhalation completion status (\< 12.5%, ΓëÑ 12.5% to \< 100%, and Full), 37 days prior to first dose of iloprost PD-15/37 days following first dose of iloprost PD-15",Pulmonary Hypertension,"Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT00467896
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Esuberaprost,PHASE3,"Number of Participants With Treatment Emergent Adverse Events (TEAEs), A TEAE is any untoward medical occurrence or undesirable event(s) experienced in a participant that begins or worsens following administration of study drug, whether or not considered related to study drug by Investigator. A serious adverse event (SAE) is an adverse event (AE) resulting in any of the following outcomes or deemed significant for any other reason, death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), or persistent or significant disability/incapacity. AEs included both SAEs and non-serious AEs. AEs were coded using Medical Dictionary for Regulatory Activities (MedDRA) Version 20.1. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module., Baseline up to Month 7","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Prostaglandin I2 receptor agonist",NCT03657095
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Apabetalone,PHASE2,"Placebo-corrected change from baseline in PVR at week 24, Right heart catheterization: Measuring PVR is performed in a standardized manner in catheterization laboratories of the participating centres, according to recommendations. Printed copies of waveforms will be kept for monitoring visits and documentation of the accuracy of the pressures and calculations., Baseline, and 24 weeks later","Pulmonary Arterial Hypertension, Primary","Anti-inflammatory, BET inhibitor",NCT04915300
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Remodulin (treprostinil sodium),PHASE4,"Six-minute walk distance, Placebo-corrected change in 6-minute walk distance from Baseline to Week 12., Twelve Weeks","Pulmonary Arterial Hypertension, Primary","Anticoagulant, Antihypertensive, Vasodilator, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT00494533
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Bisoprolol,PHASE1|PHASE2,"Effectivity, The primary efficacy endpoint is improvement in RV function as reflected by RVEF determined by means of cardiac MRI., 6 months|Safety, Safety of Bisoprolol treatment in iPAH patients is not taken as a primary endpoint but seen as a precondition for this study and will be closely monitored. Dose titration will be guided by possible side effects., continue",Idiopathic Pulmonary Arterial Hypertension,"Antihypertensive, beta1-Adrenergic receptor antagonist",NCT01246037
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Beraprost Sodium Modified Release,PHASE2,"Number of Subjects Reporting at Least One Treatment-Emergent Adverse Event (TEAE), A treatment-emergent adverse event (TEAE) is defined as an event not present prior to the initiation of the treatment or any event already present that worsens in either intensity or frequency following exposure to the treatment. AEs occurring more than 3 days after the last day study drug was taken in the study was not included in the statistical analyses or summaries (except for subjects with adverse events leading to study drug withdrawn). Only TEAEs that occurred during the treatment period of the BPS-MR-PAH-204 study were summarized. Any adverse event starting prior to the first dose of study drug was excluded from the summary analyses and only presented in the data listings. All efficacy results are descriptive; no statistical analysis was conducted, Up to 42 months|Number of Reported Treatment-Emergent Adverse Events, A treatment-emergent adverse event (TEAE) is defined as an event not present prior to the initiation of the treatment or any event already present that worsens in either intensity or frequency following exposure to the treatment. AEs occurring more than 3 days after the last day study drug was taken in the study was not included in the statistical analyses or summaries (except for subjects with adverse events leading to study drug withdrawn). Only TEAEs that occurred during the treatment period of the BPS-MR-PAH-204 study were summarized. Any adverse event starting prior to the first dose of study drug was excluded from the summary analyses and only presented in the data listings. All efficacy results are descriptive; no statistical analysis was conducted., Up to 42 months","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT00990314
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Iloprost Inhalation Solution (Ventavis),PHASE2,"Change from baseline in 6-minute walk distance measured post-inhalation (for patients ΓëÑ 8 years old) at Week 8 and Week 16|Change from baseline in Borg Dyspnea Scale measured following 6-MWT (for patients ΓëÑ 8 years old) at Week 8 and Week 16|Change from baseline in NYHA/WHO functional class at Week 8 and Week 16|Change from baseline in hemodynamic parameters measured at Week 16, and in patients who are able to undergo iloprost inhalation while consciously sedated, hemodynamic parameters measured prior to dosing and 15-30 minutes after dosing|Time to clinical worsening, defined as any one of the following: death due to underlying PAH, transplantation, atrial septostomy, hospitalization for PAH or right heart failure, >15% worsening in 6-minute walk distance in concert with a ΓëÑ 1 class deteri|Change from baseline in Child Health Questionnaire (CHQ-28) at Week 8 and Week 16|Change from baseline in exercise capacity, as measured by post-inhalation CPET, at Week 8 and Week 16 (if ΓëÑ 8 years old and > 130 cms in height. CPET testing will be conducted on NYHA/WHO Class IV patients at the discretion of the Principal Investigat","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT00453414
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Macitentan,PHASE3,"Incident Rate of Adverse Events (AEs)., Safety events are reported and documented as defined in study protocol from baseline to end of treatment period including safety follow-up visit., From Visit 1 to Post-treatment safety follow-up visit (30 days after discontinuation of the study drug).","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Endothelin receptor antagonist",NCT01847014
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Treprostinil|DIAGNOSTIC_TEST: Right Heart Catheterization (RHC) while exercising|DIAGNOSTIC_TEST: Optional Muscle Biopsy,PHASE2,"Change in cardiac output reserve (Qc), Cardiac output reserve (Qc) will be measured using the direct Fick method (L/min) during the RHC procedure., Baseline, approximately 35 minutes",Pulmonary Arterial Hypertension|Interstitial Lung Disease|Healthy Adults,"Anticoagulant, Antihypertensive, Vasodilator, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT05564637
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Q4W GMA301 (getagopzumab) IV injections (300 mg)|DRUG: Q4W GMA301 IV injections (600 mg)|DRUG: Q4W GMA301 IV injections (1000 mg)|DRUG: Q4W GMA301 IV injections (1800 mg)|OTHER: Q4W placebo IV injections,PHASE1,"The incidence of Treatment-emergent Adverse Events (TEAE) in subjects assigned to GMA301 compared with those assigned to placebo., Through study completion (up to 22 weeks)","Pulmonary Arterial Hypertension, Primary",antibody drug for PAH treatment,NCT04503733
ATP13A3,autosomal recessive,TGF-beta signaling pathway,PROCEDURE: PADN|PROCEDURE: sham PADN|DRUG: Sildenafil,PHASE4,"Pulmonary artery hypertension (PAH)- related events, Including all-cause death, lung transplantation, atrial septostomy, worsening of PAH, initiation of treatment with intravenous or subcutaneous prostacyclin, Baseline to month 6","Pulmonary Arterial Hypertension, Primary","Vasodilator, Impotence therapy, Phosphodiesterase V inhibitor",NCT02284737
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Imatinib (QTI571),PHASE3,"Serious Adverse Events, All Serious Adverse Events were evaluated and reported for all participants receiving QTI571. 16 individual SAEs were observed in 5 subjects., Approximately 2.9 years",Severe Pulmonary Arterial Hypertension,"Antineoplastic, Tyrosine kinase inhibitor",NCT02042014
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Pemziviptadil PB1046 Subcutaneous Injection,PHASE1,"Adverse Events, Incidence and severity of AEs (described descriptively) and their relationship to study drug, Pre-dose to 28 days after last dose|Vital Signs (Blood pressure), Changes from baseline in blood pressure and their relationship to study drug, Prior to eight weekly doses and 1 and 3 hours after the final dose and 1, 2, 3, 5, 7 and 28 days after final dose.|Vital Signs (Heart rate), Changes from baseline in heart rate and their relationship to study drug, Prior to eight weekly doses and 1 and 3 hours after the final dose and 1, 2, 3, 5, 7 and 28 days after final dose.|Laboratory Parameters (Lipids), Changes from baseline in lipids and their relationship to study drug, Pre-dose and 7 and 28 days after last dose|Laboratory Parameters (Serum chemistry), Changes from baseline in serum chemistry and their relationship to study drug, Pre-dose and prior to doses 2-8 and 7 and 28 days after last dose|Laboratory Parameters (Urinalysis), Changes from baseline in urinalysis and their relationship to study drug, Pre-dose and prior to doses 2-8 and 7 and 28 days after last dose|Laboratory Parameters (NT-pro-BNP), Changes from baseline in NT-pro-BNP and their relationship to study drug, Prior to doses 1-8 and 7 and 28 days after last dose|Mean Pulmonary Artery Pressure, Change from baseline in mean pulmonary artery pressure, Prior to eight weekly doses and 1 and 3 hours after the final dose and 1, 2, 3, 5, 7, 8 and 28 days after final dose|Cardiac Index, Change from baseline in cardiac index, Prior to eight weekly doses and 1 and 3 hours after the final dose and 1, 2, 3, 5, 7, 8 and 28 days after final dose|Total pulmonary resistance, Change from baseline in total pulmonary resistance, Prior to eight weekly doses and 1 and 3 hours after the final dose and 1, 2, 3, 5, 7, 8 and 28 days after final dose|Laboratory Parameters (Fasting Plasma Glucose), Changes from baseline in fasting plasma glucose and their relationship to study drug, Pre-dose and 7 and 28 days after last dose|Laboratory Parameters (Hematology), Changes from baseline in hematology and their relationship to study drug, Pre-dose and prior to doses 2-8 and 7 and 28 days after last dose",Pulmonary Arterial Hypertension,vasoactive intestinal peptide (VIP) receptor agonist,NCT03315507
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Selexipag,PHASE3,"Time to Disease Progression, Time to disease progression is the time from randomization up to 7 days after study treatment discontinuation. Disease progression is defined as the first occurrence of either of the following components: Death (all causes), Atrial septostomy or Potts' anastomosis, or registration on lung transplant list, Hospitalization due to worsening pulmonary arterial hypertension (PAH), Clinical worsening of PAH., From randomization up to 7 days after study treatment discontinuation (up to 5 years)","Hypertension, Pulmonary","Vasodilator, Prostaglandin I2 receptor agonist",NCT04175600
ATP13A3,autosomal recessive,TGF-beta signaling pathway,"DRUG: Macitentan 10 mg tablet, once daily.",PHASE3,"Change in Exercise Capacity as Measured by 6-minute Walking Distance (6MWD) Month 6 and 12, NOTE: The MAESTRO-OL study was exploratory in nature and no primary efficacy and safety endpoint were defined in the clinical protocol. This and the other exploratory efficacy outcome measures posted were selected to be reported as a primary endpoints. All efficacy analyses were considered exploratory. The analyses of the exploratory efficacy endpoints focused on the absolute values and on the change from DB baseline to Week 16 in the DB study and to Month 6 and Month 12 in the OL study. For missing 6MWD values in the OL study, the following imputation rules were applied: If the reason for missing data was death, a distance of zero (0) meters was imputed for all 6MWD visits from the date of death. For any other reasons, the last available value was carried forward., From baseline in DB parent study (AC-055-305, NCT01743001) up to month 12 in this OL study.|Change in WHO Functional Class (FC) at Month 6 and 12, Class I: no symptoms with exercise or at rest. No limitation of activity. Class II: No symptoms at rest but slight limitation with ordinary activities causing symptoms (e.g. short of breath with climbing stairs). Class III: may not have symptoms at rest but activities greatly limited by shortness of breath, fatigue, or near fainting. Class IV: symptoms at rest and inability to carry out any physical activity without symptoms. Patients in class IV manifest signs of right heart failure. For missing WHO FC values in the OL study, the following imputation rules were applied: If the reason for missing data was death, class IV was imputed for all WHO visits from the date of death. For any other reasons, the last available value was carried forward., From baseline in DB parent study (AC-055-305, NCT01743001) up to month 12 in this OL study.|Change in Borg Dyspnea Score at Month 6 and 12, The Borg dyspnea score rates the severity of dyspnea (difficult or labored breathing) on a scale from 0 ('Nothing at all') to 10 ('Very, very severe - maximal'). For missing Borg dyspnea index values in the OL study, the following imputation rules were applied: If the reason for missing data was death, a value of 10 was imputed for all Borg visits from the date of death. For any other reasons, the last available value was carried forward., From baseline in DB parent study (AC-055-305, NCT01743001) up to month 12 in this OL study.|Change in Peripheral Oxygen Saturation (SpO2) at Rest at Month 6 and 12, No imputation of missing data for SpO2 was applied. Oxygen saturation assessed by pulse oximetry: peripheral oxygen saturation (SpO2) at rest before the 6-minute walk test (6MWT), From baseline in DB parent study (AC-055-305, NCT01743001) up to month 12 in this OL study.","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Endothelin receptor antagonist",NCT01739400
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Treprostinil,PHASE2,"6 Minute Walk Distance, American Thoracic Society (ATS) Practice Guideline based 6-minute walk (6MW) distance, 3 months",Pulmonary Arterial Hypertension|Interstitial Lung Disease|Idiopathic Pulmonary Fibrosis,"Anticoagulant, Vasodilator, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT00705133
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Cicletanine,PHASE2,"Change from baseline in six-minute walk distance (6MWD) evaluated after 12 weeks of treatment, Baseline to Week 12","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Diuretic",NCT00832507
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Treprostinil Palmitil,PHASE2,"Number of Participants Who Experience a Treatment Emergent Adverse Event (TEAE), Day 1 up to Day 30","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Prostaglandin I2 receptor agonist",NCT04791514
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Slow Dose Titration Group of Subcutaneous Treprostinil|DRUG: Rapid Dose Titration Group of Subcutaneous Treprostinil,PHASE4,"Incidence of Adverse Events Among Subjects through 16 Weeks, The incidence of adverse events among subjects throughout the 16 week study will be measured by the number of subjects analyzed and the percentage of those subjects who experienced an adverse event., 16 Weeks|Change in Patient Reported Site Pain from Baseline to Week 16, The site pain questionnaire is a 10-point scale rating the worst site pain experienced on a measured day. Scores will range from 0 (no pain) to 10 (worst possible pain). The questionnaire will be completed each time a new infusion site is placed and until a subject's infusion site pain level reaches a score of zero for two consecutive days or they have completed 14 days. Changes from Baseline to Week 16 will be summarized and compared between treatment groups using descriptive statistics. No formal hypothesis testing will be performed., Baseline and Week 16|Incidence of Subject Discontinuations Among Participants through 16 Weeks, The incidence of subject discontinuations among subjects throughout the 16 week study will be measured by the number of subjects analyzed and the percentage of those participants who discontinued., 16 Weeks","Pulmonary Arterial Hypertension, Primary","Anticoagulant, Vasodilator, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT02893995
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: CXA-10,PHASE2,"Incidence of AEs, Adverse events occurring during the treatment period, 6 months|Changes in respiration, Change from baseline values at each post-baseline time point, 6 months|Changes in heart rate, Change from baseline values at each post-baseline time point, 6 months|Changes in blood pressure, Change from baseline values at each post-baseline time point, 6 months",PAH,nitro fatty acid compound,NCT04053543
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Selexipag,PHASE2,"Pulmonary vascular resistance, 16 weeks",Pulmonary Hypertension|Schistosomiasis,"Vasodilator, Prostaglandin I2 receptor agonist",NCT04589390
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: ambrisentan AMB new formulation (1 mg)|DRUG: Reference AMB (5 mg),PHASE1,"Maximum Observed Plasma Concentration (Cmax) After Administration of AMB Under Fasted Condition, Blood samples were collected at indicated time-points for PK analysis of AMB. PK parameters were calculated by standard non-compartmental analysis. PK Parameter Population included all participants who provided PK parameter data., Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose|Time to Cmax (Tmax) After Administration of AMB Under Fasted Condition, Blood samples were collected at indicated time-points for PK analysis of AMB. PK parameters were calculated by standard non-compartmental analysis., Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose|Time of Last Quantifiable Concentration (Tlast) After Administration of AMB Under Fasted Condition, Blood samples were collected at indicated time-points for PK analysis of AMB. PK parameters were calculated by standard non-compartmental analysis., Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose|Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time [(AUC(0-inf)] After Administration of AMB Under Fasted Condition, Blood samples were collected at indicated time-points for PK analysis of AMB. PK parameters were calculated by standard non-compartmental analysis., Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose|Area Under the Plasma Concentration-time Curve From Time Zero to Last Time of Quantifiable Concentration [AUC(0-t)] After Administration of AMB Under Fasted Condition, Blood samples were collected at indicated time-points for PK analysis of AMB. PK parameters were calculated by standard non-compartmental analysis., Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose|Apparent Terminal Phase Half-life (t1/2) After Administration of AMB Under Fasted Condition, Blood samples were collected at indicated time-points for PK analysis of AMB. PK parameters were calculated by standard non-compartmental analysis., Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose","Hypertension, Pulmonary","Antihypertensive, Endothelin A receptor antagonist",NCT04095286
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: ambrisentan,PHASE3,"Frequently Reported (15% or More Overall) Adverse Events by Severity, The primary endpoint of this study is the incidence and severity of adverse events associated with long-term exposure to AMB in participants with PAH. The most frequently occurring adverse events (occurring in 15% or more of the participants in the combined group) are presented, by severity, that began after entering this extension study. Adverse events that were serious are included. Adverse events are coded according to the Medical Dictionary for Regulatory Activities (MedDRA) Version 6.1 and are presented by MedDRA preferred term. Severity was graded as follows: mild (AE did not interfere with routine activities; subject may have experienced slight discomfort), moderate (AE interfered with routine activities; subject may have experienced significant discomfort), and severe (AE made it impossible to perform routine activities; subject may have experienced intolerable discomfort or pain)., Baseline to Week 295|Serum Aminotransferases Relative to the Upper Limit of the Normal Range (ULN), The number of participants with serum alanine aminotransferase (ALT) and serum aspartate aminotransferase (AST) falling into the following categories: \>3.0 and \</= 5.0 x ULN, \>5.0 and \</= 8.0 x ULN, and \>8.0 x ULN. Includes the highest value per participant across all visits as well as values from early termination visits., Baseline to Week 295","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Endothelin A receptor antagonist",NCT00578786
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Beraprost sodium modified release,PHASE2,"Maximum Tolerated Dose (MTD) of BPS-MR in Pulmonary Arterial Hypertension (PAH) Patients, Following Chronic, Twice-daily Administration., 10 Weeks","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT00781885
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Nitric Oxide,PHASE2,"Number of Participants With Side Effects and/or Adverse Events, A phone contact will be made to the subject 5 days after the trial to assess general health status and collect information on any reported side effects or adverse events., 5 days","Pulmonary Arterial Hypertension, Primary",pulmonary vasodilator,NCT01165047
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Imatinib,PHASE3,"Number of Participants With Adverse Events, Serious Adverse Events and Deaths, Adverse event monitoring was conducted throughout the study., 204 weeks","Pulmonary Arterial Hypertension, Primary","Antineoplastic, Tyrosine kinase inhibitor",NCT01117987
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Riociguat Oral Tablet,PHASE2,"change of PVR, Pulmonary hemodynamics by right heart catheterization, baseline to 24 weeks",Pulmonary Vascular Disorder|Primary Pulmonary Hypertension|Systemic Sclerosis|Other Systemic Involvement of Connective Tissue,"Vasodilator, Guanylate cyclase activator",NCT05339087
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Tocilizumab,PHASE2,"Safety - Incidence and severity of adverse events, Incidence and severity of treatment emergent adverse events, 6 months|Pulmonary vascular resistance- dynes (cm-5), Invasive haemodynamic assessment by right heart catheter, Change from baseline pulmonary vascular resistance to end of study at 6 months","Pulmonary Arterial Hypertension, Primary","Anti-inflammatory, Antirheumatic, Immunosuppressant, Anti-IL-6 receptor antibody",NCT02676947
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Sildenafil citrate,PHASE3,Safety|Standard safety data|Efficacy|6-Minute Walk Test|BORG Dyspnoea Score|WHO Functional Class|Quality of Life SF-36 and EQ-5D,Pulmonary Hypertension,"Vasodilator, Erectile dysfunction, Phosphodiesterase V inhibitor",NCT00159887
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: MK-8892,PHASE1,"Peak Percent Change From Baseline in Pulmonary Vascular Resistance (PVR) at the Highest Acutely Tolerated (HAT) Dose of MK-8892, PVR assessments were performed throughout the right heart catheterization (RHC). Peak PVR reduction was determined to occur if 2 consecutive PVR measurements were at least 20% greater than the nadir PVR measurement., Baseline and up to 5 hours post-dose","Pulmonary Arterial Hypertension, Primary",inhibitor of leukotriene synthesis.,NCT01934647
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Inhaled treprostinil,PHASE3,"Six-minute walk test, 6 months","Pulmonary Arterial Hypertension, Primary","Anticoagulant, Vasodilator, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT01557647
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Rituximab,PHASE4,"pulmonary vascular resistance (PVR), PVR as assessed by right heart catheterization, the gold standard method to assess cardiopulmonary haemodynamics. Standardized Fick-based pulmonary vascular resistance (PVRf, in Woods Units) are calculated as follows: PVR = TPG / CO, where TPG = Transpulmonary Gradient (mmHg), CO = Cardiac Output (L/min), 0-24 weeks",Systemic Lupus Erythematosus|Pulmonary Arterial Hypertension,"Antineoplastic, Anti-CD20 antibody",NCT05828147
ATP13A3,autosomal recessive,TGF-beta signaling pathway,"DRUG: Ventavis (Iloprost, BAYQ6256)",PHASE2,"Tolerability: Adverse events (AE) and safety variables, Variables to describe clinical effects: NYHA class, Walking distance (6-min walk), Mahler Dyspnea Index, EuroQoL, Karnofsky Index, Hemodynamic and gas exchange|Mortality and lung/heart-lung transplantation, Acute effects of iloprost inhalation on hemodynamics and gas exchange","Hypertension, Pulmonary","Antihypertensive, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT00414687
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: sildenafil citrate|DRUG: sildenafil citrate|DRUG: sildenafil citrate,PHASE4,"Overall Survival, In this outcome measure number of deaths during the study were reported., Day 1 of study treatment up to date of death (within a maximum duration of 2102 days)","Pulmonary Arterial Hypertension, Primary","Vasodilator, Erectile dysfunction, Phosphodiesterase V inhibitor",NCT02060487
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Treprostinil diethanolamine,PHASE1,"Treprostinil pharmacokinetics, Treprostinil pharmacokinetics in healthy volunteers following a single oral dose of 0.5 mg, 1 mg and 2.5 mg treprostinil diethanolamine sustained release tablets immediately prior to through 36 hours post treprostinil diethanolamine dosing., 36 hours","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Prostaglandin I2 receptor agonist",NCT01153386
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Ralinepag,PHASE3,"Number of subjects with treatment-emergent adverse events [Safety and Tolerability], The safety and tolerability of ralinepag will be evaluated by the Number of subjects with treatment-emergent adverse events, Up to 6 years","PAH|Pulmonary Hypertension|Pulmonary Arterial Hypertension|Hypertension|Connective Tissue Diseases|Familial Primary Pulmonary Hypertension|Vascular Diseases|Cardiovascular Diseases|Hypertension, Pulmonary|Lung Diseases|Respiratory Tract Disease","Antihypertensive, Prostaglandin I2 receptor agonist",NCT03683186
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: bosentan,PHASE4,Change from baseline to Week 16 in oxygen saturation at rest with room air|Change from baseline to Week 16 in indexed pulmonary vascular resistance,Pulmonary Arterial Hypertension Related to Eisenmenger Physiology,"Antihypertensive, Endothelin receptor antagonist",NCT00317486
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Hydroxyurea,EARLY_PHASE1,"The change in concentration of CD34+ circulating progenitors from baseline to 6 months (24 weeks (+/- 7 days)) on hydroxyurea., ongoing",Pulmonary Hypertension,"Antineoplastic, Antimetabolite",NCT01950585
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: bosentan,PHASE4,"Proportion of patients with a mean decrease in sperm concentration to 7.5 x 10[6]/mL or below, without a single sperm concentration ΓëÑ 20 x 10[6]/mL, at 3 or 6 months. This proportion is considered of clinical relevance if greater than 30%., From baseline to end of study.","Hypertension, Pulmonary","Antihypertensive, Endothelin receptor antagonist",NCT00082186
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Imatinib,PHASE3,"Number of Patients With Adverse Events, Serious Adverse Events and Deaths, Adverse event monitoring was conducted throughout the trial., 144 weeks",Pulmonary Arterial Hypertension,"Antineoplastic, Tyrosine kinase inhibitor",NCT01392495
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Bosentan|DRUG: Bosentam TRACLEER,PHASE1,"To investigate whether bosentan compared to placebo reduces hypoxia-induced increase in pulmonary artery pressure in healthy subjects and in subjects with past history of high-altitude pulmonary oedema, during the study",Hypoxia-Induced Pulmonary Artery Hypertension,"Antihypertensive, Endothelin receptor antagonist",NCT00260819
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Ambrisentan (GSK1325760A),PHASE3,"Number of Participants With Any Adverse Event, An adverse event was defined as any untoward medical occurrence in a participant, temporally associated with the use of an investigational product, whether or not considered related to the investigational product., For 140.57 weeks at maximum, starting from Week 24|Number of Participants With Adverse Events Categorized by Severity, The severity of adverse events was assessed by the investigator; events were assigned to one of the following categories: mild, an event that was easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities; moderate, an event that was sufficiently discomforting to interfere with normal everyday activities; and severe, an event that prevented normal everyday activities., For 140.57 weeks at maximum, starting from Week 24","Pulmonary Arterial Hypertension|Hypertension, Pulmonary","Antihypertensive, Endothelin receptor type A antagonist",NCT00554619
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: ambrisentan,PHASE3,Change from baseline in the six-minute walk distance evaluated after 12 weeks of therapy compared to placebo.,"Pulmonary Arterial Hypertension, Primary","Antihypertensive, Endothelin receptor type A antagonist",NCT00423748
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Sitaxentan|DRUG: Ritonavir|DRUG: Sitaxsentan|DRUG: Ritonavir,PHASE1,"The comparison of peak plasma concentration of sitaxsentan when coadministered with ritonavir versus sitaxsentan administered alone., 24 hours|The comparison of area under the curve of sitaxsentan when coadministered with ritonavir versus sitaxsentan administered alone., 24 hours|The comparison of peak plasma concentration of ritonavir when coadministered with sitaxsentan versus ritonavir administered alone., 24 hours|The comparison of area under the curve of ritonavir when coadministered with sitaxsentan versus ritonavir administered alone., 24 hours","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Endothelin receptor type A antagonist",NCT01251848
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: L606 (Liposomal Treprostinil) Inhalation Solution 51ug|DEVICE: L606 Inhalation System|OTHER: Placebo Solution,PHASE1,"The number of treatment-emergent adverse events for L606 and placebo, including abnormal laboratory events, Frequency, severity and seriousness of adverse events (AE) including physical examination, incident of laboratory abnormalities, 12-lead ECG parameter and vital sign assessment, From Pre-dose to Day 10","Pulmonary Arterial Hypertension, Primary","Anticoagulant, Vasodilator, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT04041648
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: (-)-Epicatechin,PHASE1,"Pulmonary Vascular Resistance Index, This study will assess acute hemodynamic effects, specifically effects on pulmonary vascular resistance index (PVRI), of a single dose of purified (-)-epicatechin in patients with patients with PAH., up to 5 hours after right heart catheterization","Pulmonary Arterial Hypertension, Primary","non-toxic compound that naturally occurs in foods such as tea, wine and chocolate",NCT01880866
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Inhaled treprostinil,PHASE4,"Number of Adverse Events, Overall safety of transitioning from inhaled iloprost to inhaled treprostinil was assessed by type and frequency of adverse events., up to 24 months","Pulmonary Arterial Hypertension, Primary","Anticoagulant, Vasodilator, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT00741819
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: BIA 5-1058 (zamicastat) |DRUG: Warfarin,PHASE1,"Cmax - Maximum observed concentration, Primary Pharmacokinetic Parameters: Samples for PK assessments of BIA 5-1058 and metabolites were collected at pre-dose (Treatment Period 1, Day 1) and post-dose at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours (15 samples); and at pre-dose (Treatment Period 3, Day 1) and post-dose at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours (15 samples). Samples for PK assessments of warfarin were collected at pre-dose (Treatment Period 2, Day 1 and Treatment Period 3, Day 1) and post-last dose at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 96, 120 and 144 hours (18 samples), Up to 2 months and 2 weeks|AUC0-t - Area under the plasma concentration-time curve (AUC) from time zero to the last quantifiable concentration, Primary Pharmacokinetic Parameters: Samples for PK assessments of BIA 5-1058 and metabolites were collected at pre-dose (Treatment Period 1, Day 1) and post-dose at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours (15 samples); and at pre-dose (Treatment Period 3, Day 1) and post-dose at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours (15 samples). Samples for PK assessments of warfarin were collected at pre-dose (Treatment Period 2, Day 1 and Treatment Period 3, Day 1) and post-last dose at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 96, 120 and 144 hours (18 samples), Up to 2 months and 2 weeks|AUC0-inf - AUC from time zero extrapolated to infinity, Primary Pharmacokinetic Parameters: Samples for PK assessments of BIA 5-1058 and metabolites were collected at pre-dose (Treatment Period 1, Day 1) and post-dose at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours (15 samples); and at pre-dose (Treatment Period 3, Day 1) and post-dose at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours (15 samples). Samples for PK assessments of warfarin were collected at pre-dose (Treatment Period 2, Day 1 and Treatment Period 3, Day 1) and post-last dose at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 96, 120 and 144 hours (18 samples), Up to 2 months and 2 weeks","Pulmonary Arterial Hypertension, Primary",dopamine β-hydroxylase (DβH) inhibitor,NCT04994119
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: QCC374| Matching,PHASE2,"Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 16 (Day 111), The efficacy of 16 weeks of QCC374 administration in subjects with Pulmonary Arterial Hypertension (PAH) was assessed by measuring changes from baseline in Pulmonary Vascular Resistance (PVR). PVR is derived from the CO measurement in dyn┬╖s/cm5 and can be calculated as 80 multiplied by (Mean Arterial Pressure - Mean Pulmonary Artery Wedge Pressure) divided by Cardiac Output. A higher negative number in Pulmonary Vascular Resistance indicates improvement. Only descriptive analysis performed., Baseline, Week 16 (Day 111)","Pulmonary Arterial Hypertension, Primary",prostacyclin receptor agonist,NCT02927366
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Sitaxsentan|DRUG: Sitaxsentan and Sildenafil,PHASE3,"Time to Clinical Worsening (TTCW), Clinical worsening defined as time between first dose of study drug and occurrence of death; or heart-lung/lung transplant; or hospitalization for worsening pulmonary atrial hypertension (PAH); or atrial septostomy; or withdrawal due to addition of chronic medications for treatment of worsening PAH: prostacyclin/prostacyclin analogues/phosphodiesterase-5inhibitors/alternative endothelin receptor antagonists/intravenous inotropes; or increase of calcium channel blockers or oxygen. TTCW measured as duration between study's first dose date in and date when first clinical worsening event occurs., Baseline, Weeks 12, 24 or Early Termination (ET)",Pulmonary Arterial Hypertension|Pulmonary Hypertension,"Antihypertensive, Endothelin receptor type A antagonist",NCT00796666
ATP13A3,autosomal recessive,TGF-beta signaling pathway,"DRUG: Adempas (Riociguat, BAY63-2521)",PHASE4,"Number of patients with treatment-emergent adverse events (TEAEs) as measure of safety and tolerability, Up to approx. 3 years","Hypertension, Pulmonary","Vasodilator, Guanylate cyclase activator",NCT02759419
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Sildenafil,PHASE2,"Change from baseline in PVR after 16 weeks of treatment, 16 weeks",Portopulmonary Hypertension,"Vasodilator, Impotence therapy, Phosphodiesterase V inhibitor",NCT01517854
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Rodatristat ethyl KAR5585 Capsules,PHASE1,"Number of participants with abnormal physical exam results, Healthy adult volunteers receiving single and multiple doses of KAR5585 administered orally will be monitored for adverse events via physical examination., From baseline to 4 days post-dose for single dose and baseline to 6 days post-dose for multiple doses|Number of participants with abnormal hematology values, Healthy adult volunteers receiving single and multiple doses of KAR5585 administered orally will be monitored for adverse events via lab evaluation of hematology., From baseline to 4 days post-dose for single dose and baseline to 6 days post-dose for multiple doses|Number of participants with abnormal electrocardiogram results, Healthy adult volunteers receiving single and multiple doses of KAR5585 administered orally will be monitored for abnormal ECG results., From baseline to 4 days post-dose for single dose and baseline to 6 days post-dose for multiple doses|Number of participants with abnormal clinical chemistry values, Healthy adult volunteers receiving single and multiple doses of KAR5585 administered orally will be monitored for adverse events via lab evaluation of clinical chemistries., From baseline to 4 days post-dose for single dose and baseline to 6 days post-dose for multiple doses|Number of participants with abnormal urinalysis values, Healthy adult volunteers receiving single and multiple doses of KAR5585 administered orally will be monitored for adverse events via lab evaluation of urinalysis., From baseline to 4 days post-dose for single dose and baseline to 6 days post-dose for multiple doses","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Tryptophan hydroxylase inhibitor",NCT02746237
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Nilotinib| to nilotinib,PHASE2,"Change in Pulmonary Vascular Resistance (PVR), Change in pulmonary vascular resistance is measured via right heart catheter assessment according to local hospital procedures. It assesses several prognostic hemodynamic variables in pulmonary hypertension, including Pulmonary Vascular Resistance (PVR). Study was prematurely terminated and not powered for efficacy., 168 days","Pulmonary Arterial Hypertension, Primary","Antineoplastic, Tyrosine kinase inhibitor",NCT01179737
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: GMA301 Injection|OTHER: GMA301 Placebo Injection|DRUG: GMA301 Injection,PHASE1,"Safety and Tolerability, To assess the safety and tolerability of GMA301 Injection following single escalating intravenous (IV) injections in healthy subjects., All AEs (adverse events) will be captured from the time the investigator received the signed ICF (informed consent form) of subjects until study completion ie Day 70","Pulmonary Arterial Hypertension, Primary",monoclonal antibody against endothelin receptor A,NCT04505137
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: MK-5475,PHASE1,"Number of Participants Who Experienced at Least 1 Adverse Event (AE): All Parts, An AE was defined as any untoward medical occurrence in a participant which may not necessarily have a causal relationship with the treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease that was temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The number of participants who experienced at least 1 AE was reported by dose separately for Part 1 plus Part 2 Period 1, for the RHC Period, and for the FRI Period., Up to ~14 days after last dose of treatment period (Up to ~32 weeks total)|Number of Participants Who Discontinued From the Study Due to an AE: All Parts, An AE was defined as any untoward medical occurrence in a participant which may not necessarily have a causal relationship with the treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease that was temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The number of participants who discontinued from the study due to an AE was reported by dose separately for Part 1 plus Part 2 Period 1, for the RHC Period, and for the FRI Period., Up to ~14 days after last dose of treatment period (Up to ~32 weeks total)|Percentage Change From Baseline in Minimum Pulmonary Vascular Resistance (PVR): Part 2 Right Heart Catheterization (RHC) Period, For each participant in the RHC Period, the percentage change from baseline for the minimum post-dose PVR value over the duration of the RHC procedure was calculated. The average of pre-dose measurements was set as the baseline. Mean (SD) percent change from baseline in PVR minimum were calculated and reported for each dose group that underwent RHC in Part 2. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1., Baseline: Pre-dose on Day 1 of RHC Period (up to 185 days) and up to 4.5 hours post-dose","Pulmonary Arterial Hypertension, Primary",inhaled soluble guanylate cyclase (sGC) ,NCT03744637
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Sotatercept,PHASE2,"Serum Trough Concentration (Ctrough) of Sotatercept, Ctrough was the lowest concentration of Sotatercept in serum just before the next dose. Blood samples will be collected at multiple time points to estimate the Ctrough of Sotatercept., Predose Day 1, Day 21, Day 42, Day 63, Day 84, Day105, Day 126, Day 147, Day 168, Day 189. Postdose Day 7, Day 14, Day 64, Day 69 and Day 76|Area Under the Curve at Steady State (AUCss) of Sotatercept, Blood samples will be collected at multiple time points to estimate the AUCss of Sotatercept., Predose Day 1, Day 21, Day 42, Day 63, Day 84, Day105, Day 126, Day 147, Day 168, Day 189. Postdose Day 7, Day 14, Day 64, Day 69 and Day 76|Area Under the Curve from 0 to 3 weeks (AUC0-3 weeks) of Sotatercept, Blood samples will be collected at Predose Day 1, Day 7, Day 14, and Predose Day 21 to estimate the AUC0-3 weeks of Sotatercept., Predose Day 1, Day 7, Day 14, and Predose Day 21|Percentage of Participants Who Experience at Least 1 Adverse Event (AE), An AE is any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The percentage of participants with 1 or more AEs will be assessed., Up to 24 weeks|Percentage of Participants Who Discontinue Study Drug Due to an AE, An AE is any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. The percentage of participants who discontinued the study drug due to an AE regardless of study completion status will be assessed., Up to 24 weeks|Laboratory Parameter (Hematology): Concentration of Hemoglobin, Hematological parameters will be investigated in blood samples from participants by means of clinical laboratory assays and evaluated by the investigator. The concentration of hemoglobin will be presented., Up to 24 weeks|Laboratory Parameter (Hematology): Hematocrit, Hematological parameters will be investigated in blood samples from participants by means of clinical laboratory assays and evaluated by the investigator. The hematocrit will be presented., Up to 24 weeks|Laboratory Parameter (Hematology): Red Blood Cell (RBC) Count, Hematological parameters will be investigated in blood samples from participants by means of clinical laboratory assays and evaluated by the investigator. The RBC count will be presented., Up to 24 weeks|Laboratory Parameter (Hematology): Reticulocyte Count, Hematological parameters will be investigated in blood samples from participants by means of clinical laboratory assays and evaluated by the investigator. The reticulocyte count will be presented., Up to 24 weeks|Laboratory Parameter (Hematology): Platelet Count, Hematological parameters will be investigated in blood samples from participants by means of clinical laboratory assays and evaluated by the investigator. The platelet count will be presented., Up to 24 weeks|Blood Pressure (BP), BP will be assessed while the participant was seated after a period of rest in a quiet setting with no distractions (eg, television and cell phones)., Up to 24 weeks|Titer of Anti-drug Antibody (ADA) to Sotatercept, ADA to Sotatercept will be assessed., Up to 24 weeks","Pulmonary Arterial Hypertension, Primary","Anti-anemic, Bone anabolic",NCT05587712
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: PF-00489791|DRUG: PF-00489791|DRUG: PF-00489791|DRUG: PF-00489791|DRUG: PF-00489791||DRUG: sildenafil,PHASE2,"Mean Change From Baseline in Pulmonary Vascular Resistance Index (PVRI) Over 4 Hours Post Dose, PVRI was calculated as: PVRI (in Wood units\*meter\^2 \[m\^2\]) = pulmonary vascular resistance (PVR) multiplied by body surface area (BSA). PVR (in Wood units) = (mean pulmonary artery pressure \[mean PAP\] minus pulmonary capillary wedge pressure \[PCWP\]) divided by cardiac output (CO, taken as the average of the triplicate measurements). BSA (m\^2) = (0.007184) multiplied by (height in centimeters \[cm\])\^0.725 multiplied by (weight in kilograms \[kg\])\^0.425. PVRI values were converted to dyne\*second (s)\*m\^2/centimeter (cm)\^5 from Woods units by multiplying by a factor of 79.9. The change from baseline in PVRI over 4-hour interval was calculated as the average of the change from baseline values at 1, 2, 3, and 4 hours post dose on Day 1., Baseline, up to 4 hours post-dose on Day 1","Hypertension, Pulmonary",phosphodiesterase type 5 (PDE5) inhibitor,NCT00853112
ATP13A3,autosomal recessive,TGF-beta signaling pathway,"DRUG: nab-sirolimus (also known as ABI-009, nab-rapamycin, albumin-bound rapamycin)",PHASE1,"MTD, Maximum-Tolerated Dose, 16 weeks|DLT, Dose-limiting toxicities, 16 weeks",Pulmonary Hypertension,"Antineoplastic, Immunosuppressant, mTOR inhibitor",NCT02587325
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: LIQ861 Inhaled Treprostinil,PHASE3,"Number of participants with treatment emergent adverse events (AEs)., Treatment-emergent adverse events and serious adverse events will be grouped by MedDRA System Organ Class, dose level at onset, time on drug at onset, and relationship to dose titration., Baseline until the end of study, approximately 2.5 years (Dec-2021).",Primary Pulmonary Hypertension,"Anticoagulant, Vasodilator, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT03992755
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: BIA 5-1058,PHASE1,"Maximum observed plasma concentration (Cmax), In all treatment periods, blood samples were taken at the following times: before BIA 5-1058 dosing, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose, Up to 9 weeks|Time of occurrence of Cmax (tmax), In all treatment periods, blood samples were taken at the following times: before BIA 5-1058 dosing, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose, Up to 9 weeks|Area under the plasma concentration-time curve (AUC), In all treatment periods, blood samples were taken at the following times: before BIA 5-1058 dosing, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose, Up to 9 weeks|Area under the plasma concentration-time curve (AUC) from time zero to the last sampling time at which the drug concentration was at or above the lower limit of quantification (AUC0-last), In all treatment periods, blood samples were taken at the following times: before BIA 5-1058 dosing, and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose, Up to 9 weeks","Pulmonary Arterial Hypertension, Primary",dopamine β-hydroxylase (DβH) inhibitor,NCT04991155
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Macitentan,PHASE3,"Fold Change in Pulmonary Vascular Resistance Index (PVRI), PVRI fold change at Week 24 is calculated as 100\*(PVRI at Week 24 divided by PVRI at baseline)., Week 24","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Endothelin receptor antagonist",NCT05167825
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Ambrisentan,PHASE4,"Change in Stroke Volume, Echocardiography is used to estimate the stroke volume, or the amount of blood ejected from the heart with each beat. An average over three beats is used for the estimate and is reported as ml/beat., Baseline and 24 Weeks","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Endothelin receptor type A antagonist",NCT02885012
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Treprostinil Palmitil,PHASE2|PHASE3,"Number of Participants Who Experience at Least one Treatment Emergent Adverse Event (TEAE) and TEAEs by Severity, From screening up to last follow up visit (Up to approximately 26 months)","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Prostaglandin I2 receptor agonist",NCT05649748
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: BSF 208075,PHASE2,Change from baseline to Week 12 in six minute walk distance,Pulmonary Hypertension,"Antihypertensive, Endothelin receptor type A antagonist",NCT00046319
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Carbon Monoxide,PHASE1|PHASE2,"Evidence of a 20% decrease in pulmonary vascular resistance post-therapy when compared to pre-therapy value, At baseline and after 16 weeks","Hypertension, Pulmonary",Immunomodulator,NCT01523548
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Ferric carboxymaltose,PHASE4,"six-minute walking distance, The primary endpoint is improvement in six-minute walking distance, 12 weeks",Idiopathic Pulmonary Arterial Hypertension,"Hematinic, Supplement (iron)",NCT01288651
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: escitalopram,PHASE3,"To evaluate the efficacy of oral escitalopram at the dosage of 30 mg/day on the 6-minute walking test in patients with pulmonary hypertension, for 16 weeks",Pulmonary Hypertension,"Antidepressant, Selective serotonin reuptake inhibitor (SSRI)",NCT00190333
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Bardoxolone methyl,PHASE3,"Long-term Safety, Long-term Safety as Measured by Incidence of Adverse Events During the maximum study duration of 5 years, Up to 5 years (December 2021)",Pulmonary Hypertension,Anti-inflammatory,NCT03068130
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Bosentan,PHASE3,"Change from Baseline to End of Study in 6MWT distance. A mean difference from placebo of at least 35 m is considered clinically relevant., 16 weeks",Pulmonary Hypertension,"Antihypertensive, Endothelin receptor antagonist",NCT00310830
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Intravenous Treprostinil,PHASE4,"Effect of Long-term Remodulin Therapy on the 6-Minute Walk Distance (6MWD), The intent of the 6-Minute Walk Test (6MWT) is to evaluate exercise capacity associated with carrying out activities of daily living., The 6MWD was assessed at each subject's last visit, which occurred up to approximately 9 years after first visit|Effect of Long-term Remodulin Therapy on the NYHA Functional Classification, The NYHA functional classification ranges from I (subject's disease does not affect daily activities) to IV (subject's disease causes severe impairment)., The NYHA functional classification was assessed at each subject's last visit, which occurred up to approximately 9 years after first visit","Pulmonary Arterial Hypertension, Primary","Anticoagulant, Vasodilator, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT03055221
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Ambrisentan - low dose|DRUG: Ambrisentan - high dose,PHASE2,"Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious Treatment-emergent Adverse Events (SAEs), AEs defined as any untoward medical occurrence in a patient or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAEs defined as any untoward medical occurrence that, at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, or is a congenital anomaly or birth defect, medical events that may not immediately life threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention as per medical or scientific judgement and events of drug-induced liver injury with hyperbilirubinaemia. Safety population comprised of all randomized participants who received at least 1 dose of study drug., Up to 24 Weeks|Number of Participants With Post Baseline Potential Clinical Importance (PCI) Value for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT), Total Bilirubin and Creatinine, Blood samples were collected from participants for analysis of following clinical chemistry parameters: ALT, AST, GGT, total bilirubin and creatinine. PCI ranges were \<3 times the upper limit of normal (ULN), \<34.2 Micromoles per liter (UMOL/L) for total bilirubin and \<176.8 (UMOL/L) for creatinine. Only those parameters having any time post-Baseline PCI values were presented. Day 1 was considered as Baseline., Up to 24 Weeks|Number of Participants With Post Baseline PCI Value for Hematology Parameter: Hemoglobin, Blood samples were collected from participants for analysis of following hematology parameters: hemoglobin. PCI ranges were Males: 98 to180 grams per liter (G/L), Females: 91 to 161 (G/L) for hemoglobin. Only those parameters having any time post-Baseline PCI values were presented. Day 1 was considered as Baseline., Up to 24 Weeks|Number of Participants With Post Baseline PCI Value for Hematology Parameter: Hematocrit, Blood samples were collected from participants for analysis of following hematology parameter: hematocrit. PCI ranges were males: \<0.32 to \>0.54, females: \<0.29 to \>0.506 proportion of red blood cells in blood for hematocrit. Only those parameters having any time post-Baseline PCI values were presented. Day 1 was considered as Baseline., Up to 24 Weeks|Number of Participants With Post Baseline PCI Value for Hematology Parameter: Platelet Count, Blood samples were collected from participants for analysis of following hematology parameter: platelet count. PCI ranges were 100 to 400 for Giga cells per liter platelet count. Only those parameters having any time post-Baseline PCI values were presented. Day 1 was considered as Baseline., Up to 24 Weeks|Number of Participants With Abnormal Value for Physical Examination Parameter: Liver Size, Physical examination included measurement of liver size. Any abnormal enlargement or reduction in the size of the liver is reported., Week 12 and 24|Number of Participants With Abnormal Value for Physical Examination Parameter: Jugular Venous Pressure, Physical examination of participants jugular venous pressure is measured., Week 12 and 24|Number of Participants With Abnormal Value for Physical Examination Parameter: Peripheral Edema, Physical examination of paricipants peripheral edema is measured. Day 1 was considered as Baseline., Week 12 and 24|Number of Participants With Abnormal Value for Physical Examination Parameter: Ascites, Physcial examination of paricipants ascites was measured. Day 1 was considered as Baseline., Week 12 and 24|Percentage of Physical Examination Parameter: Saturated Oxygen Level, Physical examination of participants saturated oxygen level was measured. Day 1 was considered as Baseline., Week 12 and 24|Number of Participants With Post Baseline PCI Value for Vital Signs Parameter: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP), SBP and DBP were measured in semi-supine position after 5 minutes rest for the participants at indicated time points. PCI ranges were \<80 to \>160 millimeters of mercury (mmHg) for SDP and \<40 to \>110 mmHg for DBP. Only those parameters having any time post-Baseline PCI values were presented. Day 1 was considered as Baseline., Up to 24 Weeks|Number of Participants With Post Baseline PCI Value for Vital Signs Parameter: Heart Rate, Heart rate was measured in semi-supine position after 5 minutes rest for the participants at indicated time points. PCI ranges were \<50 to \>120 beats per minute (beats/min). Only those parameters having any time post-Baseline PCI values were presented. Day 1 was considered as Baseline., Up to 24 Weeks|Number of Participants With Post Baseline PCI Value for Vital Signs Parameter: Weight, Weight of the participants was measured. PCI ranges were \<20 kilogram (kg) for weight. Only those parameters having any time post-Baseline PCI values were presented. Day 1 was considered as Baseline., Up to 24 Weeks|Change From Baseline of Pubertal Development: Men- Testicular Volume (TV) at Weeks 12 and 24, Testicular volume was assessed by Prader's orchiodometer and the assessment was performed by a pediatric endocrinologist using the Tanner's criteria. Only those parameters having status - overall were presented. Day 1 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value., Baseline, Week 12 and 24|Change From Baseline in Plasma Endocrine Parameter - Female : Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) at Weeks 12 and 24, FSH and LH level of participants were measured. Only those parameters having status - overall were presented. Day 1 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value., Baseline, Week 12 and 24|Change From Baseline in Plasma Endocrine Parameter - Female : Inhibin B at Weeks 12 and 24, Inhibin B level of participants were measured. Only those parameters having status - overall were presented. Day 1 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value., Baseline, Week 12 and 24|Change From Baseline in Plasma Endocrine Parameter - Female : Sex Hormone Binding Globulin at Weeks 12 and 24, Sex hormone binding globulin level of participants were measured. Only those parameters having status - overall were presented. Day 1 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value., Baseline, Week 12 and 24","Hypertension, Pulmonary","Antihypertensive, Endothelin receptor type A antagonist",NCT01332331
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: current marketed FLOLAN (epoprostenol sodium)|DRUG: new thermo stable formulation of epoprostenol sodium,PHASE4,"Change From Baseline in Medical Outcomes Study Short Form 36 (SF-36), Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations due to physical health problems, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health), 2 summary scores (physical component and mental component), and a self-evaluated change in health status. Subscale and summary scores range: 0-100. Higher subscale and summary scores was considered as better health status. Change from Baseline was calculated as score at observation minus score at baseline. Baseline was defined as Visit 2 i.e. Day-14 (+ or - 7 days)., Baseline (Visit 2 i.e. Day-14 [+ or - 7 days]) and Week 4 (Visit 3)|Change From Baseline in Study Specific Participant Acceptance Survey, Study-specific questionnaire comprised the pre-defined15 questions which included activities of daily living assessment. Participants rated the question on a scale of 1 to 10, where 1 was do not agree and 10 was strongly agree. Change from Baseline was calculated as score at observation minus score at Baseline. Changes from Baseline was assessed for Questions 2 to 12. Baseline was defined as Visit 2 i.e. Day-14 (+ or - 7 days)., Baseline (Visit 2 i.e. Day-14 [+ or - 7 days]) and Week 4 (Visit 3).|Change From Baseline in Dose of Thermo Stable Epoprostenol Sodium at Week 4, Dose titration requirement was assessed at the time of discharge. Change from Baseline was calculated as score at observation minus score at Baseline. Units- nanogram per kilogram per minute (ng/kg/min). Baseline was Visit 2 i.e . Day-14 (+ or - 7 days)., Baseline (Visit 2 i.e. Day-14 [+ or - 7 days]) and Week 4","Hypertension, Pulmonary","Antihypertensive, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT01462565
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Macitentan,PHASE1,"Trough Concentration of Macitentan and its Active Metabolite Aprocitentan at Week 4 in Steady-State, Trough concentration of macitentan and its active metabolite aprocitentan at week 4 in steady-state will be reported., Predose (at Week 4)","Arterial Hypertension, Pulmonary","Antihypertensive, Endothelin receptor antagonist",NCT05731492
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Inhaled dry powder treprostinil (LIQ861),PHASE2,"Change in Pulmonary Vascular Resistance (PVR), Calculated in Wood units, 2 hours (120 minutes) post-dose on Day 1 and Week 16|Change in Pulmonary Artery Pressure (PAP), Systolic, diastolic, and mean pressure measured in millimeters of mercury (mmHG), 2 hours (120 minutes) post-dose on Day 1 and Week 16|Change in Cardiac Output (CO), Measured in liters per minute (L/min), 2 hours (120 minutes) post-dose on Day 1 and Week 16|Change in Pulmonary Artery Oxygen Saturation (PAO2%), Measured as a percent oxyhemoglobin saturation, 2 hours (120 minutes) post-dose on Day 1 and Week 16",Pulmonary Arterial Hypertension,"Anticoagulant, Vasodilator, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT03884465
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Riociguat,PHASE4,"Change in RV (right ventricular) area, echocardiographic analysis right atrial (RA) area, measured by echocardiography., Baseline to 24 weeks|Change in RA (right atrial) area, echocardiographic analysis, Baseline to 24 weeks",Primary Pulmonary Arterial Hypertension|Chronic Thromboembolic Pulmonary Hypertension,"Vasodilator, Guanylate cyclase activator",NCT04954742
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Simvastatin|DRUG: Aspirin|,PHASE2,"Distance Walked in Six Minutes, Measured at 6 months","Hypertension, Pulmonary","Antihyperlipidemic, HMG-CoA reductase inhibitor",NCT00384865
ATP13A3,autosomal recessive,TGF-beta signaling pathway,"OTHER: Maximum Exercise Tests|DRUG: BH4, L-NMMA, Vitamin C, Vitamin E, ╬▒-Lipoic Acid and L-Ascorbate|DRUG: BQ-123|DRUG: Fexofenadine, Ranitidine|OTHER: Angiotensin-II, Valsartan|DRUG: Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine|DRUG: BQ-123, MitoQ, BH4",PHASE1,"Change in Limb Blood Flow, Change in local limb blood flow as measured by ultrasound Doppler in units of milliliters per minute (mL/min) from baseline to up to 1 hour following study interventions, Baseline and 1 hour",Chronic Obstructive Pulmonary Disease|Pulmonary Artery Hypertension|Heart Failure|Hypertension,Antihypertensive,NCT02966665
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Treprostinil Injectable Product|DRUG: Riociguat Pill,PHASE3,"Change in stroke volume/end systolic volume (SV/ESV), Change in stroke volume/end systolic volume (SV/ESV), Baseline to 3 months","Pulmonary Arterial Hypertension, Primary","Anticoagulant, Vasodilator, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT04062565
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: AER-901 Solution for Nebulization,PHASE1,"Number of Participants with Treatment Emergent Adverse Events (TEAEs), TEAEs will be summarized by treatment group using frequency and percent for each system organ class and preferred term within each system, organ and class (SOC), From randomization though study completion (up to 17 days following last treatment)|Number of Participants with Serious Adverse Events (SAEs), SAEs will be summarized by treatment group using frequency and percent for each system organ class and preferred term within each system, organ and class (SOC), From randomization though study completion (up to 17 days following last treatment)","Pulmonary Arterial Hypertension, Primary","Antineoplastic, Tyrosine kinase inhibitor",NCT04903730
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: MK-5475| to MK-5475,PHASE2|PHASE3,"Phase 2 Cohort: Change from Baseline in Pulmonary Vascular Resistance (PVR) at 12 Weeks, PVR is assessed by right heart catheterization (RHC)., At baseline and 12 weeks|Phase 3 Cohort: Change from Baseline in 6-Minute Walk Distance (6MWD) at 12 Weeks, 6MWD is assessed using the 6-minute walk test (6MWT)., At baseline and 12 weeks","Pulmonary Arterial Hypertension|Hypertension, Pulmonary",inhaled soluble guanylate cyclase (sGC) ,NCT04732221
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: CS1 Administration,PHASE2,"Patient reported adverse events, Safety and tolerability of 3 doses of CS1, 6 months","Pulmonary Arterial Hypertension, Primary",NaN,NCT05224531
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: ambrisentan,PHASE3,"Change From Baseline in 6-minutes Walk Test (6MWT) at Week 12, The 6MWT measures the distance that a participant can walk in a period of 6 minutes. Change from Baseline was calculated as the Week 12 value minus the Baseline value. Baseline 6MWT comprised of an average of the last two consecutive measurements prior to dosing that varied by not greater than 10 percent (%). If only one measurement was available, that measurement was used as the Baseline value. The last observation carried forward method was used to impute missing values., Baseline and Week 12",Vascular Disease,"Antihypertensive, Endothelin receptor type A antagonist",NCT01808313
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: ambrisentan,PHASE2,"Number of Participants With Pulmonary Arterial Hypertension (PAH) Who Completed the Phase II NCT00046319 Study and Who Experienced Severe Adverse Events (AEs) During Long-term Ambrisentan Exposure, The number of participants in the AMB-220-E analysis set who experienced AEs (including serious AEs) of severe severity (ie, made it impossible to perform routine activities and the subject may have experienced intolerable discomfort or pain) that began after entering AMB-220-E (treatment-emergent AEs) and that occurred in more than 1 participant are summarized by dose group. The AMB-220-E analysis set consisted of all participants who received at least 1 dose of study drug during the AMB-220-E study., Week 24 (AMB-220-E baseline) to Week 334|Number of Participants With PAH Who Completed the Phase II NCT00046319 Study and Who Experienced AEs of Moderate Severity During Long-term Ambrisentan Exposure, The number of participants in the AMB-220-E analysis set who experienced AEs (including serious AEs) of moderate severity (ie, interfered with routine activities and subject may have experienced significant discomfort) that began after entering AMB-220-E (treatment-emergent AEs) and that occurred in more than 1 participant are summarized by dose group. The AMB-220-E analysis set consisted of all participants who received at least 1 dose of study drug during the AMB-220-E study., Week 24 (AMB-220-E baseline) to Week 329.3|Number of Participants With PAH Who Completed the Phase II NCT00046319 Study and Who Experienced AEs of Mild Severity During Long-term Ambrisentan Exposure, The number of participants in the AMB-220-E analysis set who experienced AEs (including serious AEs) of mild severity (ie, did not interfere with routine activities and the subject may have experienced slight discomfort) that began after entering AMB-220-E (treatment-emergent AEs) and that occurred in more than 1 participant are summarized by dose group. The AMB-220-E analysis set consisted of all participants who received at least 1 dose of study drug during the AMB-220-E study., Week 24 (AMB-220-E baseline) to Week 329.3",Pulmonary Hypertension,"Antihypertensive, Endothelin receptor type A antagonist",NCT00424021
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: udenafil,PHASE2,"Phase IIa - Pulmonary vascular resistance index(PVRI), 4 hours|Phase IIb - 6-minute walk distance, 16weeks","Pulmonary Arterial Hypertension, Primary","Impotence therapy, Phosphodiesterase V inhibitor",NCT01553721
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: sapropterin dihydrochloride (6R-BH4),PHASE1,"To evaluate the safety of oral 6R-BH4, administered in escalating doses in addition to standard care, in subjects with pulmonary arterial hypertension (PAH)., Up to 14 weeks","Pulmonary Arterial Hypertension, Primary","Antihyperphenylalaninemia, Cofactor replacement (tetrahydrobiopterin)",NCT00435331
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Macitentan|DRUG: Tadalafil|DRUG: Selexipag,PHASE3,"Change From Baseline to Week 26 in Pulmonary Vascular Resistance (PVR), Change from baseline to Week 26 in PVR was expressed as the ratio of Week 26 to baseline PVR value (Week 26 divided by baseline) using re-calculated PVR. PVR was determined by right heart catheterization (RHC). A geometric least square mean ratio of Week 26 to baseline PVR less than (\<) 1 corresponds to a reduction in PVR from baseline. Missing values were imputed using a last observation carried forward (LOCF) approach., Baseline, Week 26","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Endothelin receptor antagonist",NCT02558231
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Macitentan|OTHER: Standard-of-care,PHASE3,"Participants Greater than or Equal to (>=) 2 Years: Observed Steady-state Trough Plasma Concentration of Macitentan and its Active Metabolite ACT-132577 at Week 12, Observed steady-state trough plasma concentration of macitentan and its active metabolite ACT-132577 will be reported., Week 12|Participants Less than (<) 2 Years: Observed Steady-state Trough Plasma Concentration of Macitentan and its Active Metabolite ACT-132577 at Week 4, Observed steady-state trough plasma concentration of macitentan and its active metabolite ACT-132577 will be reported., Week 4","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Endothelin receptor antagonist",NCT02932410
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Parenteral Treprostinil|DRUG: Oral Treprostinil,PHASE4,"Change From Baseline in Right Ventricular Ejection Fraction (RVEF), as Measured by Cardiac Magnetic Resonance Imaging (cMRI) at Month 12, Baseline, Month 12","Pulmonary Arterial Hypertension, Primary","Anticoagulant, Vasodilator, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT05203510
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Macitentan,PHASE3,"Development and Refinement of the Patient-reported Outcome Measure of Symptoms and Their Impact in PAH (the PAH-SYMPACT), Content validity of the PAH-SYMPACT was assessed using item performance, exploratory and confirmatory factor analysis. The final item content and domain structure of PAH-SYMPACT was determined based on these analyses from the Steering Committee (expert clinicians) and findings from the qualitative research done with patients previously., From Screening Visit (Day -14) to End of Treatment (EOT) Visit (Visit 4, Week 16)|Validation of the Patient-reported Outcome Measure of Symptoms and Their Impact in PAH (the PAH-SYMPACT), With Reliability Assessed Via Test-retest Reliability., The reliability of the PAH-SYMPACT is assessed by test-retest reliability. Intra-class correlation coefficients (ICCs) assess test-retest reliability for the symptom and impact part scores as well as domains. ICCs equal to or greater than 0.70 are considered to demonstrate good test-retest reliability for total and domain scores., From ePRO period 1 (Days -14 to -8) to ePRO period 2 (Days -7 to -1) in screening period.|Validation of the Patient-reported Outcome Measure of Symptoms and Their Impact in PAH (the PAH-SYMPACT), Assessing Internal Consistency Reliability., The reliability of the PAH-SYMPACT is assessed by internal consistency reliability. This was determined using Cronbach's alpha-a value on an internal level scale from 0 to 1.0 with higher scores indicating a more-reliable (precise) instrument., From ePRO period 1 (Days -14 to -8) to ePRO period 2 (Days -7 to -1) in screening period.","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Endothelin receptor antagonist",NCT01841762
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Prostacyclin Receptor Agonist,PHASE1,"Number of Participants with Treatment-emergent Adverse Events (TEAEs), An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment., Up to 114 days|Number of Participants With Serious TEAEs, A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Serious TEAEs are defined as serious events between administration of study drug and after the last dose that were absent before treatment or that worsen relative to pretreatment state., Up to 114 days|Number of Participants with TEAEs by Severity, Number of participants with TEAEs by severity will be evaluated. An assessment of severity grade will be made using the following general categorical descriptors, such as Mild (Awareness of symptoms that are easily tolerated, causing minimal discomfort, and not interfering with everyday activities), Moderate (Sufficient discomfort is present to cause interference with normal activity), and Severe (Extreme distress, causing significant impairment of functioning or incapacitation, and prevents normal everyday activities)., Up to 114 days|Number of Participants with TEAEs Leading to Discontinuation, Number of participants with TEAEs leading to discontinuation will be reported., Up to 114 days|Number of Participants With Change from Baseline in Clinical Laboratory Values, Number of participants with change from baseline in clinical laboratory values (chemistry, hematology, and urinalysis) will be evaluated., Up to 114 days|Number of Participants With Injection Site Reactions, Number of participants with injection site reactions will be evaluated., Up to 114 days","Pulmonary Arterial Hypertension, Primary",NaN,NCT05427162
ATP13A3,autosomal recessive,TGF-beta signaling pathway,BIOLOGICAL: Sotatercept||DRUG: Background PAH Therapy,PHASE3,"Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 24, The 6MWD is the distance walked in 6 minutes as a measure of functional capacity. This will be assessed using the 6-minute walk test (6MWT). The change from baseline in 6MWD at Week 24 will be reported., Baseline and Week 24|Number of Participants Who Experience an Adverse Event (AE), An AE is any untoward medical occurrence in a study participant administered a study drug, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug. The number of participants who experience an AE will be reported., Up to approximately 19 months|Number of Participants Who Discontinue Study Treatment Due to an AE, An AE is any untoward medical occurrence in a study participant administered a study drug, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug. The number of participants who discontinue study treatment due to an AE will be reported., Up to approximately 19 months","Pulmonary Arterial Hypertension, Primary","Anti-anemic, Bone anabolic",NCT04576988
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Intravenous/Subcutaneous Treprostinil; Oral Treprostinil,PHASE4,"Oral treprostinil dose, The percentage of subjects achieving an oral treprostinil dose of 4 mg three times daily (TID) (or a total daily dose of 12 mg) or higher at Week 16 (or a dose of 0.057 mg/kg TID \[total daily dose of 0.171 mg/kg\] or greater for subjects \<70 kg) will be calculated and summarized, Assessed at Week 16","Pulmonary Arterial Hypertension, Primary","Anticoagulant, Vasodilator, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT03497689
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Ralinepag,PHASE3,"Time from randomization to the first adjudicated protocol-defined clinical worsening event, Clinical worsening events are defined as death, nonelective hospital admission for worsening PAH (further defined in clinical study protocol), initiation of parenteral or inhaled prostacyclin pathway agent for treatment of worsening PAH, disease progression (further defined in clinical study protocol), or unsatisfactory long-term clinical response (further defined in clinical study protocol)., The study duration was event-based. This parameter was assessed from randomization until the conclusion of the study, up to 3 years","PAH|Pulmonary Hypertension|Pulmonary Arterial Hypertension|Hypertension|Connective Tissue Diseases|Familial Primary Pulmonary Hypertension|Vascular Diseases|Cardiovascular Diseases|Hypertension, Pulmonary|Lung Diseases|Respiratory Tract Disease","Antihypertensive, Prostaglandin I2 receptor agonist",NCT03626688
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Tadalafil|DRUG: Vardenafil,PHASE4,"Six minute walking distance, 12 weeks|Level of pro-NT BNP, 12 weeks","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Impotence therapy, Phosphodiesterase V inhibitor",NCT00705588
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Sildenafil citrate,PHASE3,"Categorized Change From Baseline in 6-Minute Walking Distance, Number of subjects with categorized change in 6-minute walking distance. Distance that a subject could walk in 6-minutes at a comfortable pace with as many breaks as needed. Performed as close to trough levels of sildenafil as possible (just before dosing; at least 4 hours after the previous dose of study drug). Scores for categorized changes for missing visits were imputed as the worse score of its non-missing neighbors. If a visit was missing and there was no subsequent score, the score was coded to missing., 1 Year, 2 Year, 3 Year",Pulmonary Hypertension,"Vasodilator, Erectile dysfunction, Phosphodiesterase V inhibitor",NCT00159861
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: treprostinil|DEVICE: Crono Five ambulatory pump,PHASE4,"Change From Baseline at Week 8 in 6-Minute Walk Distance (6MWD), The administration of the 6MWD test and specifications of the testing area were consistent with the American Thoracic Society guidelines and the usual practice of the investigative site \[American Thoracic Society (ATS) guidelines; 2002\]., Week 8",Pulmonary Arterial Hypertension,"Anticoagulant, Vasodilator, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT00439946
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Hyperpolarized 129Xe,PHASE2,"a pathology-based 129Xe MRI noninvasive signature of pulmonary vascular remodeling that could be validated in a larger cohort of Group 3 PH patients, Such a signature could then be tested in clinical trials in Group 3 PH. These studies will have an important positive impact because they lay the foundation for a precision medicine strategy in Group 3 PH through the identification of potential responders and non-responders to PAH-specific therapies, 2 yrs",Interstitial Lung Disease|COPD|Pulmonary Arterial Hypertension,NaN,NCT04778046
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: ambrisentan|DRUG: tadalafil,PHASE3,"Number of Participants With First Adjudicated Clinical Failure (CF) Event, Death, Hospitalisation for Worsening PAH, Disease Progression, Unsatisfactory Long-term Clinical Response, All Through FAV, Time to the first adjudicated CF event (death, hospitalization for worsening pulmonary arterial hypertension \[PAH\], disease progression, or unsatisfactory long-term clinical response) after initiating either first-line combination therapy with AMB and TAD or first-line monotherapy with either drug (AMB or TAD) in par. with PAH was assessed. If data was not available for some par. following a loss to follow-up, their event times were treated as censored at their last assessment time for the statistical analyses. FAV occurred approximately 4 weeks after the predicted 105th adjudicated first CF event was reached. Par. who had an FAV, and who had no adjudicated events or whose first adjudicated event occurred after their FAV, were censored at their individual FAV. Modified Intent-to-Treat (mITT) Population: all randomized par. who met the PAH diagnosis and inclusion/exclusion criteria defined in protocol amendment 2 and who also received at least one dose of investigational product (IP)., From Baseline up to the Final Assessment Visit (FAV) (average of 609 days)","Hypertension, Pulmonary","Antihypertensive, Endothelin receptor type A antagonist",NCT01178073
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Sitaxsentan|DRUG: Sitaxsentan and Sildenafil,PHASE3,"Overall Survival, Overall survival is the duration from first dose to death. For participants who are lost to follow-up, survival was censored at the last date of follow-up., Baseline and every 12 weeks up to Week 18",Pulmonary Arterial Hypertension|Pulmonary Hypertension,"Antihypertensive, Endothelin receptor type A antagonist",NCT00796510
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Ranolazine,PHASE3,"Improve Angina Symptoms, Assessed as average improvement in WHO Functional Class. The WHO Functional Class score ranges from 1 to 4, with higher scores indicating more impairment, 3 months|6-Minute Walk Test, Improve Exercise Capacity measured by 6-Minute Walk Test, 3 Months|Improve Quality of Life, The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. The scores are averaged and transformed to a range of 0-100, in which higher scores reflect better health status and was performed at the conclusion of the study., 3 Months",Angina|Pulmonary Arterial Hypertension,Vasodilator,NCT01174173
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Treprostinil Inhalation Powder,PHASE1,"Incidence and severity of treatment-related adverse events (safety and tolerability) of single ascending doses of Treprostinil Inhalation Powder, Incidence and severity of treatment-related adverse events determined by changes from screening (baseline) of findings from physical examinations, laboratory evaluations, vital signs measurements, pulmonary testing, and ECG measurements., At protocol-specified time points from the time of screening (day 0) to end of study (day 6)",Pulmonary Arterial Hypertension,"Anticoagulant, Vasodilator, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT03464864
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Bosentan administration,PHASE4,maximal exercise tolerance (walking distance in the 6-minute walking test)|peripheral oxygen saturation (SatO2)|pulmonary-systemic ratio of arterial resistance (Rp:Rs),Eisenmenger Syndrome,"Antihypertensive, Endothelin receptor antagonist",NCT00266162
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: JTT-251,PHASE2,"Change in six-minute walk distance (6MWD) compared to baseline, 24 Weeks|Change in World Health Organization (WHO) functional classification compared to baseline, 24 Weeks|Change in pulmonary vascular resistance (PVR) compared to baseline, Assessed by right heart catheterization (RHC), 4, 12, 24 and 28 Weeks",Pulmonary Arterial Hypertension,NaN,NCT03789643
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: ambrisentan,PHASE2,"The Incidence of Confirmed Serum Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) Concentrations > 3 x the Upper Limit of Normal (ULN) Considered to be Related to Ambrisentan and Resulted in Discontinuation of Study Drug., The number of participants in the safety analysis set with confirmed serum ALT or AST concentrations \> 3 x ULN during 12 weeks of ambrisentan therapy that were related to ambrisentan and resulted in discontinuation of study drug. Safety analysis set included all participants who received at least 1 dose of study drug., Week 12",Pulmonary Hypertension,"Antihypertensive, Endothelin receptor type A antagonist",NCT00423592
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DIAGNOSTIC_TEST: 18F-FGLN PET Imaging|DRUG: (18F)FPGLU,EARLY_PHASE1,"SUV or image-based threshold of 18F-FGNnon-diseased controls, Regional \[F-18\] fluoroglutamine (18F-FGN) utilization will be measured as standardized uptake values (SUV) of 18F-FGN in right ventricle wall, left ventricle wall, and perivascular tissue within the lung parenchyma., 90 minutes","Pulmonary Arterial Hypertension, Primary",NaN,NCT05452889
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: UT-15C SR,PHASE2,"Number of Participants That Were Succesfully Transitioned From Parenteral Remodulin to UT-15C., Successful transition was based on the number of participants that completely transitioned to oral treprostinil by the week 4 study visit and clinically maintained on oral treprostinil treatment through Week 24., Up to 24 weeks","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Prostaglandin I2 receptor agonist",NCT01588405
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: ACT-293987,PHASE3,"Number of Participants With Treatment-emergent Adverse Events (TEAEs) up to 3 Days After Study Intervention Discontinuation, An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. A TEAE is any AE temporally associated with the use of study drug (from study drug initiation until 3 days after study drug discontinuation), whether or not considered related to the study drug., Up to 3 days after study drug discontinuation (Up to 10.5 years)|Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) up to 3 Days After Study Intervention Discontinuation, An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above. Those SAEs occurring during study drug administration, that is, between study drug initiation and three days after study drug discontinuation, are defined as treatment-emergent SAEs., Up to 3 days after study drug discontinuation (Up to 10.5 years)|Number of Participants With TEAEs Leading to Permanent Discontinuation of Study Intervention, An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. A TEAE is any AE temporally associated with the use of study drug (from study drug initiation until 3 days after study drug discontinuation), whether or not considered related to the study drug., Up to 10.5 years","Pulmonary Arterial Hypertension, Primary",NaN,NCT01112306
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: MN-08 24 mg/day|DRUG: MN-08 60 mg/day,PHASE1,"Incidence and severity of TEAEs and SAEs, Incidence and severity of treatment emergent adverse events (TEAEs) and Serious Adverse Events (SAEs) after multiple doses of MN-08 administered for 6.5 consecutive days in healthy subjects., Through study completion, an average of 12 days|Incidence and severity of treatment-related adverse events, Incidence and severity of treatment-related adverse events determined by changes from screening (baseline) of findings from vital signs, ECG, and clinical laboratory parameters per the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5., Through study completion, an average of 12 days","Pulmonary Arterial Hypertension, Primary",NaN,NCT05660863
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: sildenafil|DRUG: sildenafil||DRUG: sildenafil,PHASE3,"Change from baseline in exercise capacity, as measured by distance walked in six minutes (6-Minute Walk test)., Week 12","Hypertension, Pulmonary","Vasodilator, Impotence therapy, Phosphodiesterase V inhibitor",NCT00644605
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: MK-8892| for MK-8892,PHASE1,"Percentage of Participants Who Report 1 or More Adverse Events (AEs)- Healthy Participants, An AE was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The percentage of participants that reported at least 1 AE was summarized. Adverse events were summarized by dose taken at the time of the event., up to 7 weeks|Percentage of Participants Who Were Discontinued From the Study Due to an AE- Healthy Participants, An AE was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, regardless of whether or not considered related to the medicinal product. The percentage of participants that were discontinued from the study due to an AE was summarized. Adverse events were summarized by dose taken at the time of the event., up to 7 weeks|Change in 24-hour Time-weighted Average (TWA0-24hr) for Central Diastolic Blood Pressure (cDBP)- Healthy Participants, Central diastolic blood pressure measurements were obtained at predose and at 2, 3, 4, 6, 8, 12, 16 and 24 hours postdose via applanation tonometry of the radial artery. The average central diastolic blood pressure over the 24-hour monitoring period was calculated for each dose of each panel by adjusting each time-point by the baseline, aggregating the area under the curve (AUC) by the trapezoidal method and then dividing the AUC by 24 hours. A negative number indicates a decrease., Predose (baseline) and 2, 3, 4, 6, 8, 12, 16 and 24 hours postdose (for each Dosing Period of Each Panel)|Percentage of Participants Who Report 1 or More Adverse Events (AEs) - Hypertensive Participants, An AE was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. The percentage of participants that reported at least 1 AE was summarized. Adverse events were summarized by dose taken at the time of the event., up to 7 weeks|Percentage of Participants Who Were Discontinued From the Due to an AE - Hypertensive Participants, An AE was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. The percentage of participants that were discontinued from the study due to an AE was summarized. Adverse events were summarized by dose taken at the time of the event., up to 7 weeks|Change in 24-hour Time-weighted Average (TWA0-24hr) for Central Diastolic Blood Pressure (cDBP) - Hypertensive Participants, Central diastolic blood pressure measurements were obtained at predose and 2, 3, 4, 6, 8, 12, 16 and 24 hours postdose via applanation tonometry of the radial artery. The average central diastolic blood pressure over the 24-hour monitoring period was calculated for each dose of each panel by adjusting each time-point by the baseline, aggregating the area under the curve (AUC) by the trapezoidal method and then dividing the AUC by 24 hours. A negative number indicates a decrease., Predose (baseline) and 2, 3, 4, 6, 8, 12, 16 and 24 hours postdose (for each Dosing Period)","Pulmonary Arterial Hypertension, Primary", leukotriene synthesis inhibitor,NCT01798849
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Tezosentan,PHASE2,"Change in PVR from Baseline to 30 minutes expresses as percent of the Baseline value., 30 minutes","Pulmonary Arterial Hypertension, Primary",NaN,NCT01077297
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Sulfasalazine|DRUG: Ambrisentan|DRUG: Sulfasalazine's placebo|DRUG: Ambrisentan's placebo,PHASE1|PHASE2,"Time to First Confirmed Clinical Adverse Event up to the End of Treatment, Clinical adverse event was defined as death., Up to end of treatment (data presented up to month 6)","Pulmonary Arterial Hypertension, Primary","Anti-inflammatory disease, Antirheumatic",NCT04528056
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: PAH Therapies,PHASE4,"Time to all Cause Death, Time to all cause death will be reported. All-cause death defined as deaths due to any cause., Up to 6 years|Time to Death due to Pulmonary Arterial Hypertension (PAH) or First Hospitalization due to PAH, Time to death due to PAH or first hospitalization due to PAH will be reported., Up to 6 years","Pulmonary Arterial Hypertension, Primary",NaN,NCT04955990
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: UT-15,PHASE3,NaN,Pulmonary Hypertension,"Antihypertensive, Prostaglandin I2 receptor agonist",NCT00004497
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: [11C]-GSK2256098 500 MBq,PHASE1,"Volume of Distribution of Radiolabeled GSK2256098 Measured by PET Scan, The PET scan was acquired to measure the uptake of radiolabeled GSK2256098 in the heart and lungs, assessed as the volume of distribution (VT). The analysis was performed on Safety Population which comprised of all participants who received a microdose of study treatment., Day 1|Standardized Uptake Values (SUV) of Radiolabeled GSK2256098 Measured by PET Scan, The PET scan was acquired to measure the uptake of radiolabeled GSK2256098 in the heart and lungs, assessed as the mean standardized uptake value (SUV) averaged over the 60 minute period between 30 and 90 minutes. The analysis was performed on Safety Population which comprised of all participants who received a microdose of study treatment., Day 1","Hypertension, Pulmonary",NaN,NCT02551653
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: inhaled treprostinil,PHASE3,"Long term safety of inhaled treprostinil, up to 5 years","Pulmonary Arterial Hypertension, Primary","Anticoagulant, Vasodilator, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT01557660
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Remodulin,PHASE4,"Number of Participants With Successful Completion of the 16 Week Treatment Period., Successful completion was defined as completion of the 16 week treatment period of the study without experiencing any serious adverse events considered by the investigator to be possibly related to Remodulin., Baseline to week 16","Pulmonary Arterial Hypertension, Primary","Anticoagulant, Antihypertensive, Vasodilator, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT02847260
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Nitric Oxide,PHASE2,"Difference in Ambulatory 6 Minute Walk Distance (6MWD) Pulmonary Artery (PA) Pressures (Systolic, Diastolic, Mean) Between the Post-intervention (iNO+) and Pre-intervention (iNO-) Condition as Measured by the CardioMems Device, Difference between baseline (t=0) and post-intervention (t=2h), 2 hours","Pulmonary Arterial Hypertension, Primary",pulmonary vasodilator,NCT02734953
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: treprostinil sodium,PHASE4,Primary Outcomes: Change in distance traversed during the six minute walk test at 8 weeks;|Adverse events,"Hypertension, Pulmonary","Anticoagulant, Vasodilator, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT00458042
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Riciguat Group|DRUG: Macitentan Group,PHASE2,"RV function, Evaluation of the therapeutic effect of both treatment groups as measured by the change in systolic and diastolic RV function within 12 weeks after starting medication to plan a larger Phase II study. Methods: RV Catheterisation and Conductance Catherterisation., 12 weeks","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Endothelin receptor antagonist",NCT03362047
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: DHEA tablet,PHASE2,"Right ventricular (RV) longitudinal strain, Change in global RV longitudinal strain measured by cardiac magnetic resonance imaging (MRI) between DHEA and placebo, 18 weeks, 40 weeks","Pulmonary Arterial Hypertension, Primary",NaN,NCT03648385
ATP13A3,autosomal recessive,TGF-beta signaling pathway,|DRUG: Sotatercept|OTHER: SOC,PHASE2,"Base Study: Change From Baseline in Pulmonary Vascular Resistance (PVR) at 24 Weeks, Each participant's PVR, at resting supine, was measured by right heart catheterization at baseline and at 24 weeks., Baseline and 24 weeks|Extension Period: Change From Baseline in PVR (Delayed-Start Analysis), Each participant's PVR, at resting supine, was measured by right heart catheterization at baseline and the timepoint at which the third right heart catheterization was performed, which occurred between Month 18 and Month 24., Baseline and timepoint at which third right heart catheterization was performed, which occurred between Month 18 and Month 24|Extension Period: Change From Baseline in PVR (Placebo-Crossed Analysis), Each participant's PVR, at resting supine, was measured by right heart catheterization at baseline and the timepoint at which the third right heart catheterization was performed, which occurred between Month 18 and Month 24., Baseline and the timepoint at which the third right heart catheterization was performed, which occurred between Month 18 and Month 24.|Extension Period: Number of Participants Who Experienced One or More Adverse Events (AEs), An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product., Up to approximately 32 months|Extension Period: Number of Participants Who Discontinued Study Treatment Due to an AE, An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product., Up to 30 months","Pulmonary Arterial Hypertension, Primary","Anti-anemic, Bone anabolic",NCT03496207
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Inhaled Nitric Oxide 75 mcg/kg IBW/hr,PHASE3,"Change in 6-minute Walk Distance (6MWD) From Baseline (Randomization) to End of Treatment Period (Week 18), The 6-minute walk distance test (6MWD) is a non-encouraged test performed in a 30 m long flat corridor, where the patient is instructed to walk as far as possible, back and forth around two cones, with the permission to slow down, rest, or stop if needed. All patients were required to complete two walks while on chronic oxygen therapy given at a standard rate during the test and throughout the study while using the investigational product (INOpulse device with nitric oxide or matching placebo). The average of two walks at Week 2 visit (2 weeks after Run-In) was used as the Baseline 6MWD., Change in 6MWD from Week 2 (2 weeks after randomization and run-in period) to Week 18 (end of blinded treatment period)","Pulmonary Arterial Hypertension, Primary",pulmonary vasodilator,NCT02725372
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Olaparib,EARLY_PHASE1,"Change in pulmonary vascular resistance (PVR) at week 16, At baseline and week 16, a cardiac catheterization and MRI will assess changes in pulmonary hemodynamics and RV function, 16 weeks","Pulmonary Arterial Hypertension, Primary","Antineoplastic, PARP inhibitor",NCT03251872
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Phenylephrine|DRUG: Epinephrine|DRUG: Arginine Vasopressin,PHASE4,"Change in Systemic Vascular Resistance Index (SVRI) to Pulmonary Vascular Resistance Index (PVRI) Ratio (Rp:Rs Ratio), In patients with pulmonary hypertension (PH) one anticipates a greater increase in pulmonary vascular resistance as opposed to systemic vascular resistance when vasopressors are administered., Day 1 (at baseline and up to 5 minutes following study drug administration) (Q: 2 minutes - 2 to 5 minutes?)","Pulmonary Arterial Hypertension, Primary","Vasoconstrictor, alpha1-Adrenergic receptor agonist",NCT05439460
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: BIA 5-1058,PHASE1,"Cmax: maximum observed concentration, PK parameters analysis, Day 1, Day 6 and Day 10|Cmin: minimum observed concentration at steady state, PK parameters analysis, Day 1, Day 6 and Day 10|Tlag: the elapsed time from dosing at which analyte was first quantifiable in a concentration vs time profile, PK parameters analysis, Day 1, Day 6 and Day 10|Tmax: the time from dosing at which Cmax was apparent, PK parameters analysis, Day 1, Day 6 and Day 10|AUC(0-t): area under the curve from 0 time to last measurable concentration, PK parameters analysis, Day 1, Day 6 and Day 10|AUC(0-tau): area under the curve during a dosing interval, PK parameters analysis, Day 1, Day 6 and Day 10|AUC(0-inf): area under the curve from 0 time extrapolated to infinity, PK parameters analysis, Day 1, Day 6 and Day 10|AUC%extrap: percentage of AUC(0-inf) extrapolated beyond last measured time point, PK parameters analysis, Day 1, Day 6 and Day 10|Lambda-z: the slope of the apparent elimination phase, PK parameters analysis, Day 1, Day 6 and Day 10|t1/2: the apparent elimination half-life, PK parameters analysis, Day 1, Day 6 and Day 10|Cl/F: clearance, the apparent volume cleared of parent drug per unit time after extravascular administration, PK parameters analysis, Day 1, Day 6 and Day 10|MRT: mean residence time, PK parameters analysis, Day 1, Day 6 and Day 10",Cardiovascular Disease+Pulmonary Disease|Pulmonary Arterial Hypertension,dopamine β-hydroxylase (DβH) inhibitor,NCT03708146
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Macitentan,PHASE4,"Change From Baseline in Right Ventricular Stroke Volume (RVSV) to Week 26, Change from baseline in RVSV assessed by cardiac magnetic resonance imaging (MRI) from pulmonary artery flow was reported at Week 26. Primary analysis were based on interim results as pre-planned and the primary outcome measures data table reported is finalized as is., Baseline and Week 26|Ratio of Week 26 to Baseline Pulmonary Vascular Resistance (PVR), Ratio of Week 26 to baseline PVR as assessed by RHC was reported. PVR represents the resistance against which the right ventricle needs to pump. PVR is determined by right heart catheterization (RHC). PVR was calculated as 80\*(Mean pulmonary arterial pressure \[mPAP\] -\[Pulmonary capillary wedge pressure {PCWP} or Left ventricular end diastolic pressure {LVEDP} if PCWP not available/cardiac output \[CO\]). Primary analysis were based on interim results as pre-planned and the primary outcome measures data table reported is finalized as is., Baseline and Week 26","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Endothelin receptor antagonist",NCT02310672
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Trimetazidine,PHASE2,"Changes in right ventricular (RV) function, Changes in RV function assessed by echo 3d (strain-strain rate), 3 months",Pulmonary Artery Hypertension,Vasodilator,NCT02102672
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: i.v. selexipag|DRUG: oral selexipag (Uptravi),PHASE3,"Number of Participants With at Least One Adverse Event (AE), AE is any untoward medical event that occurs in a participant during the course of the study whether or not considered by the investigator as related to the study treatment., From Day 1 to Day 37|Number of Participants With Prostacyclin-associated Adverse Events, Prostacyclin-associated AE include headache, diarrhea, nausea, vomiting, jaw pain, myalgia, pain in the extremity, flushing and arthralgia., From Day 1 to Day 37|Number of Participants With Adverse Event Related to Injection Site Reactions, This is the number of participants with at least one clinically significant reaction at the injection site (e.g., erythema/redness, tenderness, swelling, induration, hemorrhage at the injection site) occurring on the days of intravenous (iv) selexipag injection., From Day 2 to Day 3|Number of Participants With Prostacyclin-associated AEs Leading to Study Treatment Discontinuation, This is the number of subjects who discontinued the i.v. selexipag treatment due to prostacyclin-associated adverse events (headache, diarrhea, nausea, vomiting, jaw pain, myalgia, pain in the extremity, flushing and arthralgia)., From Day 2 to Day 3|Number of Participants With PAH-related Adverse Events, This is the number of participants with at least one AE considered to be related to pulmonary arterial hypertension during the course of the study., From Day 1 to Day 37","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Vasodilator, Prostaglandin I2 receptor agonist",NCT03187678
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Ralinepag,PHASE3,"Change from Baseline in peak VO2 assessed by CPET, Peak VO2 by CPET was measured at Baseline (prior to starting study drug) and Week 28, Baseline to Week 28","PAH|Pulmonary Hypertension|Hypertension|Connective Tissue Disease|Familial Primary Pulmonary Hypertension|Vascular Diseases|Cardiovascular Diseases|Hypertension, Pulmonary|Lung Diseases|Respiratory Tract Disease|Pulmonary Arterial Hypertension","Antihypertensive, Prostaglandin I2 receptor agonist",NCT04084678
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Carvedilol,PHASE1|PHASE2,"Absolute Change in Right Ventricular Ejection Fraction, Change in right ventricular ejection fraction is measured by cardiac magnetic resonance imaging, using the method of disks with the reading radiologist being blinded to before and after images. Cardiac magnetic resonance imaging was done at baseline and 6 months only, baseline, 6 months","Pulmonary Arterial Hypertension, Primary","Antihypertensive, alpha1/beta-Adrenergic receptor antagonist",NCT00964678
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Bosentan|DRUG: Sildenafil,PHASE4,"Number of Patients Reaching a 6-Minute Walk Test (6MWT) Distance ΓëÑ 380 Meters, The 6MWT is a non encouraged test, which measures the walking distance covered over a 6 minute period, at 16 weeks and at 28 weeks of a stepped approach to therapy","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Endothelin receptor antagonist",NCT00433329
ATP13A3,autosomal recessive,TGF-beta signaling pathway,"DRUG: Riociguat (Adempas, BAY63-2521)",PHASE3,"Change from baseline in 6 Minute Walking Distance (6MWD), 6MWD test was used to measure the subjects functional exercise capacity. Subjects were instructed to walk alone, not run, from one end to the other end of the walking course, at their own pace, while attempting to cover as much ground as possible in 6 minutes. No ""warm-up"" period was performed before the test. Investigators have not walked with the subjects. This was an encouraged test (the person conducting the test encouraged subjects to walk farther or faster by using only standardized phrases)., Baseline, Week 12 and Week 24","Hypertension, Pulmonary","Vasodilator, Guanylate cyclase activator",NCT02007629
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: APD811,PHASE2,"Change From Baseline in Pulmonary Vascular Resistance (PVR), Measurements of PVR from right heart catheterization were obtained prior to Day 1 of the dose titration period and at the end of the maintenance period (Week 22), approximately 4 hours after the last dose of study drug., Baseline and 22 Weeks|Change From Baseline in 6-minute Walk Distance (6MWD) in Patients With PAH, The 6MWT was conducted according to the modified guidelines issued by the American Thoracic Society prior to Day 1 of the dose titration period and at the end of the maintenance period (Week 22)., Baseline and 22 Weeks","Pulmonary Arterial Hypertension, Primary",NaN,NCT02279160
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: sildenafil,PHASE1,"Pharmacokinetic concentrations of plasma sildenafil and its metabolite, 6 hours|Adverse events, 28 days|Change in blood pressure and pulse rate from baseline (sitting and postural), 6 hours","Hypertension, Pulmonary","Vasodilator, Impotence therapy, Phosphodiesterase V inhibitor",NCT00800592
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Albuterol,PHASE2,"Change in Mean Pulmonary Artery Pressure (MPAP), Change in MPAP will be measured using echocardiogram, Baseline, up to 30 minutes after inhalation",Pulmonary Hypertension,"Bronchodilator, beta2-Adrenergic receptor agonist",NCT03270332
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: ambrisentan,PHASE3,Change from baseline in the six-minute walk distance evaluated after 12 weeks of therapy compared to placebo.,"Pulmonary Arterial Hypertension, Primary","Antihypertensive, Endothelin receptor type A antagonist",NCT00423202
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: tadalafil|DRUG: tadalafil,PHASE3,"Number of Participants With Adverse Events (AEs), A summary of serious and all other non-serious AEs, which include adverse events reported for laboratory tests and vital signs, is located in the Reported Adverse Event module., Baseline (Double-Blind Period) up to Week 243 (End of Open-Label Period)","Hypertension, Pulmonary","Antihypertensive, Impotence therapy, Phosphodiesterase V inhibitor",NCT00549302
ATP13A3,autosomal recessive,TGF-beta signaling pathway,"DRUG: Riociguat (Adempas, BAY63-2521)",PHASE2,"To investigate the safety, tolerability and feasibility of individual titration of BAY63-2521 according to peripheral systolic blood pressure, 3 months|To investigate the long term safety and tolerability of BAY63-2521, max. 84 months","Hypertension, Pulmonary","Vasodilator, Guanylate cyclase activator",NCT00454558
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Inhaled nitric oxide,PHASE3,"Death or Bronchopulmonary Dysplasia, At 36 weeks post-conceptional age","Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature|Respiratory Distress Syndrome (RDS)|Sepsis|Pneumonia|Hypertension, Pulmonary",pulmonary vasodilator,NCT00016523
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: ESR-specific PET scan,PHASE2,"To correlate lung ESR density with pulmonary vascular resistance (PVR), Positron emission tomography (PET) with ESR-targeting radiopharmaceuticals is a noninvasive method for assessing regional ESR expression in vivo. For example, multiple studies have shown that the detection of ESR positive tissue by 18F-FES PET is reliable and that 18F-FES uptake correlates well with immunohistochemical scoring for ESR density. We will determine the relationship, if any, between the density of ESR in the lungs of subjects, and pulmonary vascular resistance (PVR), measured in Woods Units, acquired at time of recent cardiac catheterization., Day 1","Pulmonary Arterial Hypertension, Primary",NaN,NCT04280523
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: ubenimex|OTHER: placebo,PHASE2,"Change in Pulmonary Vascular Resistance (PVR), Change from Baseline at End of Treatment in PVR Using Worst Case Imputation in the Modified Intent to Treat Population. PVR was assessed by hemodynamic measurements obtained via right heart catheterization., Baseline to Week 24","Pulmonary Arterial Hypertension, Primary","Antineoplastic, Immunomodulator",NCT02664558
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Macitentan,PHASE3,"Number of Participants With Treatment Emergent Adverse Events (TEAEs) up to 28 Days After Study Treatment Discontinuation, An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAE are defined as AEs with onset during the treatment period or that are a consequence of a pre-existing condition that has worsened since baseline., Up to 28 days after study treatment discontinuation (Up to 12 years)|Number of Participants With Death up to 28 Days After Study Treatment Discontinuation, Number of participants with deaths up to 28 days after study treatment discontinuation were reported., Up to 28 days after study treatment discontinuation (Up to 12 years)|Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs) up to 28 Days After Study Treatment Discontinuation, An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAE are defined as AEs with onset during the treatment period or that are a consequence of a pre-existing condition that has worsened since baseline. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically significant, or requires intervention to prevent at least one of the outcomes listed above., Up to 28 days after study treatment discontinuation (Up to 12 years)|Number of Participants With AEs Leading to Permanent Discontinuation of Study Treatment, Number of participants with AEs leading to permanent discontinuation of study treatment were reported. An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship., Up to 28 days after study treatment discontinuation (Up to12 years)|Number of Participants With Treatment Emergent Abnormal Liver Tests up to 28 Days After Study Treatment Discontinuation, Number of participants with treatment-emergent abnormal liver tests: Alanine aminotransferase (ALT) greater than (\>) 3\*upper limit of normal (ULN) or aspartate aminotransferase (AST) \>3\* ULN, ALT \>5\* ULN or AST \>5\*ULN, ALT \>8\*ULN or AST \>8\*ULN, total bilirubin (TBIL) \>2\*ULN, ALT \>3\*ULN or AST \>3\*ULN and TBIL \>2\*ULN at any time were reported., Up to 28 days after study treatment discontinuation (Up to12 years)|Number of Participants With Treatment Emergent Hemoglobin Abnormality up to 28 Days After Study Treatment Discontinuation, Number of participants with treatment-emergent hemoglobin (HGB) abnormality up to 28 days after study treatment discontinuation were reported. Participants assessed for different categories of HGB were \<=80 grams/Liter (g/L), \<=100g/L, decrease from baseline \>=20 g/L, and decrease from baseline \>=50 g/L., Up to 28 days after treatment discontinuation (Up to 12 years)","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Endothelin receptor antagonist",NCT00667823
ATP13A3,autosomal recessive,TGF-beta signaling pathway,"DRUG: ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)",PHASE4,"Change in right ventricular ejection fraction, The primary endpoint will be change in right ventricular ejection fraction (RVEF) during 2 years of follow-up., 4,12, 24 months of follow-up","Pulmonary Arterial Hypertension, Primary",Vasodilator and Antihypertensive,NCT03236818
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Sorafenib,PHASE1,"Monthly 6MW/B, 16 weeks","Pulmonary Arterial Hypertension, Primary","Antineoplastic, Tyrosine kinase inhibitor",NCT00452218
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: BPS-314d-MR,PHASE2,"Number of participants experiencing Adverse Events, To determine the overall safety of open label study drug by tabulating the number of patients experiencing Adverse Events, 2 years","Pulmonary Arterial Hypertension, Primary",NaN,NCT01966302
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: treprostinil sodium,PHASE4,NaN,"Pulmonary Arterial Hypertension, Primary","Anticoagulant, Vasodilator, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT00058929
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Inhaled Nitric Oxide,PHASE3,"Incidence of Serious Adverse Events, Incidence of Serious Adverse Events from baseline to end of study, Through Study Completion, anticipated 3 years|Incidence of INOpulse device malfunction and/or device failure leading to an AE, Incidence of INOpulse device malfunction and/or device failure leading to an AE from baseline to end of study, Through Study Completion, anticipated 3 years","Pulmonary Arterial Hypertension, Primary",pulmonary vasodilator,NCT02652429
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Terbogre,PHASE2,"Number of patients with adverse events, up to 18 months|Number of patients with clinically significant findings in laboratory tests, up to 18 months|Number of patients with clinically significant changes in ECG, up to 18 months","Hypertension, Pulmonary","Platelet aggregation inhibitor, Thromboxane A2 (TXA2) receptor antagonist, Thromboxane A2 (TXA2) synthase inhibitor",NCT02223494
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: tadalafil|DRUG: tadalafil|DRUG: tadalafil|DRUG: tadalafil,PHASE3,"6 minute walk distance change from baseline to Week 16, 16 weeks",Pulmonary Hypertension,"Antihypertensive, Impotence therapy, Phosphodiesterase V inhibitor",NCT00125918
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Atorvastatin,PHASE2,"The placebo-corrected change from baseline to week 24 in 6-minute walk distance, Measured at 6 months","Hypertension, Pulmonary","Antihyperlipidemic, HMG-CoA reductase inhibitor",NCT00615823
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Anakinra,PHASE1,"Change in exercise capacity, as determined by peak oxygen consumption and ventilatory efficiency on cardiopulmonary exercise testing, 14 days","Pulmonary Arterial Hypertension, Primary","Anti-inflammatory, Immunosuppressant",NCT03057028
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: tadalafil and ambrisentan upfront combination therapy,PHASE4,"Right Ventricular (RV) Mass, Assessment of change in Right ventricular mass was done via standard volumetric cine images of the right heart at baseline and comparing it to that at the end of 36 weeks using Cardiac Magnetic Resonance Imaging studies., baseline and 36 weeks|Pulmonary Vascular Resistance (PVR), Change in Pulmonary Vascular Resistance (PVR) was ascertained via Right Heart Catheterization (RHC) measurement of the difference between the PVR at baseline and 36 weeks, baseline 36 weeks",Pulmonary Arterial Hypertension|Systemic Sclerosis|Scleroderma Spectrum of Diseases|Connective Tissue Disease|Pulmonary Hypertension,"Antihypertensive, Impotence therapy, Phosphodiesterase V inhibitor, Endothelin receptor type A antagonist",NCT01042158
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Olaparib,PHASE1|PHASE2,"Occurrence of treatment-emergent AEs at week 24, Description of treatment-emergent AEs leading to premature discontinuation of the study treatment., Week 24","Pulmonary Arterial Hypertension, Primary","Antineoplastic, PARP inhibitor",NCT03782818
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Sitaxsentan,PHASE3,"Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs), All observed or volunteered AEs and SAEs regardless of treatment group or suspected causal relationship to the investigational product were reported., Day 1 up to 82 months|The Percentage of Participants Who Experience an Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) Value Greater Than (>) 3.0 Times (x) the Upper Limit of Normal Range (ULN), ALT and AST data were analyzed by several local laboratories. There were subtle differences in the reference ranges used for analysis., Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 62, 68, 72, 74, 80, 84, 88, 92, 96, 100, 104, 108 and every 4 weeks to Termination up to 82 months|The Percentage of Participants Who Experience an ALT and AST Value > 3.0 x ULN, ALT and AST data were analyzed by several local laboratories. There were subtle differences in the reference ranges used for analysis., Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 62, 68, 72, 74, 80, 84, 88, 92, 96, 100, 104, 108 and every 4 weeks to Termination up to 82 months|Percentage of Participants With Total Bilirubin > 1.5 x ULN, Total builirubin data were analyzed by several local laboratories. There were subtle differences in the reference ranges used for analysis., Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 62, 68, 72, 74, 80, 84, 88, 92, 96, 100, 104, 108 and every 4 weeks to Termination up to 82 months|Percentage of Participants With Laboratory Test Abnormalities (Hematology), Hematology data were analyzed by several local laboratories. There were subtle differences in the reference ranges used for analysis., Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 62, 68, 72, 74, 80, 84, 88, 92, 96, 100, 104, 108 and every 4 weeks to Termination up to 82 months|Percentage of Participants With Laboratory Test Abnormalities (Chemistry), Chemistry data were analyzed by several local laboratories. There were subtle differences in the reference ranges used for analysis., Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 62, 68, 72, 74, 80, 84, 88, 92, 96, 100, 104, 108 and every 4 weeks to Termination up to 82 months|Percentage of Participants With Laboratory Test Abnormalities (Urinalysis), Urinalysis data were analyzed by several local laboratories. There were subtle differences in the reference ranges used for analysis., Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 62, 68, 72, 74, 80, 84, 88, 92, 96, 100, 104, 108 and every 4 weeks to Termination up to 82 months|Percentage of Participants With Anticoagulant Use, Participants with anticoagulant use before first dose or participants with anticoagulant use from first dose of sitaxsentan., Baseline, Weeks 1 and 2, every 2 weeks up to Week 52, Amendment 4 visit, every 4 weeks up to 82 months|Percentage of Participants With Elevated International Normalize Ratio (INR), Elevated INR in participants who took warfarin, warfarin derivatives, other anticoagulant and no anticoagulants. Elevated INR defined as \> 3.5. Percentage calculated using number of participants with INR data as the denominator., Baseline, Weeks 1 and 2, every 2 weeks up to Week 52, Amendment 4 visit, every 4 weeks up to 82 months|Percentage of Participants With Electrocardiography (ECG) Results of Potential Clinical Importance, Standard 12-lead ECG results determined to be of potential clinical importance according to investigator clinical judgement., Weeks 28,60,72,84,96,104, Transition Visit up to 82 months|Percentage of Participants With Vital Sign Results of Potential Clinical Importance, Vital signs include sitting blood pressure, respiration rate, heart rate and temperature. Potential clinical importance determined according to investigator clinical judgement., Day 1, Weeks 28,60,72,84,96,104, Transition visit, every 6 months Post Transition, up to 82 months|Percentage of Participants With Abnormal Prothrombin Time (PT), PT data were analyzed by several local laboratories. There were subtle differences in the reference ranges used for analysis., Baseline, Weeks 1 and 2, every 2 weeks up to Week 52, Amendment 4 visit, every 4 weeks up to 82 months|Percentage of Participants With Abnormal Partial Thromboplastin Time (PTT), PTT data were analyzed by several local laboratories. There were subtle differences in the reference ranges used for analysis., Baseline, Weeks 1 and 2, every 2 weeks up to Week 52, Amendment 4 visit, every 4 weeks up to 82 months","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Endothelin receptor type A antagonist",NCT00811018
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Sildenafil,PHASE3,"To determine the distance of walking, which is performed during a 6- min walking test; oxygen saturation and relation of resistance Rp : Rs during the examination with ""Herzkatheter"", described as the difference between visit 1 (baseline) and visit 4, visit 1 and visit 4 (after 26 weeks)","Pulmonary Arterial Hypertension, Primary","Vasodilator, Impotence therapy, Phosphodiesterase V inhibitor",NCT00586794
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Inhaled Iloprost (5 ╬╝g)|DRUG: Inhaled Placebo|DRUG: Sildenafil|DRUG: Bosentan,PHASE3,"Absolute Change From Baseline to Week 16 in 6-Minute Walk Distance (6MWD) During the Double-blind Treatment Period, The 6MWD test is a non-encouraged test, performed in a 30-meter long flat corridor, where the patient is instructed to walk as far as possible, back and forth around two cones during 6 minutes. They can slow down, rest, or stop if needed. This test is used to assess exercise capacity. The test was performed about 30 minutes after study drug administration. Any increase in the walk distance was considered improvement from baseline., Day 1 and Week 16",Pulmonary Hypertension,"Antihypertensive, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT00302211
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Pemziviptadil (PB1046) Injection,PHASE2,"Incidence and Severity of Adverse Events, Duration of extension study - Starting the day of first dose and completing 28 days after last dose.|Incidence of Clinical Laboratory Abnormalities, Duration of extension study - Starting the day of first dose and completing 28 days after last dose.|Change in Diastolic Blood Pressure from baseline, Duration of extension study - Starting the day of first dose and completing 28 days after last dose.|Change in Systolic Blood Pressure from baseline, Duration of extension study - Starting the day of first dose and completing 28 days after last dose.|Change in Oral Body Temperature from baseline, Duration of extension study - Starting the day of first dose and completing 28 days after last dose.|Change in Respiratory Rate from baseline, Duration of extension study - Starting the day of first dose and completing 28 days after last dose.|Change in Heart Rate from baseline, Duration of extension study - Starting the day of first dose and completing 28 days after last dose.|12-Lead ECG - Incidence of clinically significant abnormal ECG findings as measured by 12 Lead ECG, Duration of extension study - Starting the day of first dose and completing 28 days after last dose.|Incidence of Immunogenicity, Incidence of positive immunogenicity results after receipt of study drug, Duration of extension study - Starting up to 30 days prior to first dose of study drug in original study (PB1046-PT-CL-0004/0005) and completing 28 days after last dose.","Pulmonary Arterial Hypertension, Primary",NaN,NCT03795428
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: GSK1325760A,PHASE2,"Mean Change From Baseline in Six Minutes Walk Distance (6MWD) at Week 12, Mean change from baseline was calculated as the Week 12 value minus the baseline value. 6MWD was measured by a 6 minute walk test. This test measures the distance that a subject can walk in a period of 6 minutes., Baseline and Week 12","Hypertension, Pulmonary","Antihypertensive, Endothelin receptor type A antagonist",NCT00540436
ATP13A3,autosomal recessive,TGF-beta signaling pathway,|DRUG: Selonsertib,PHASE2,"Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 24, as Measured by Right Heart Catheterization (RHC), PVR is a measure of the extent to which pulmonary circulation resists cardiac output. Change from Baseline was calculated as the value at Week 24 minus the value at Baseline. The Week 24 value was defined as the last assessment at or prior to Week 24., Baseline to Week 24","Pulmonary Arterial Hypertension, Primary",Apoptosis signal-regulating kinase 1 inhibitor,NCT02234141
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Lidocaine,PHASE4,"Pain Questionnaire, Short Form McGill Pain Questionnaire - Change from baseline over one week, 1 week|Daily Pain Diary, 10cm visual analogue scale (VAS) - Change in aggregated median/maximum scores over one week, 1 week","Pulmonary Arterial Hypertension, Primary","Antiarrhythmic, Sodium channel blocker",NCT01433328
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: 75mg CXA-10|DRUG: 150mg CXA-10|OTHER: Placebo,PHASE2,"Right Ventricular Ejection Fraction (RVEF), ΓÇó To determine the efficacy of oral doses of CXA-10 on stable background therapy administered for 6 months in subjects with PAH assessed by right ventricular ejection fraction (RVEF) as measured by Cardiac MRI, 6 months|Pulmonary Vascular Resistance (PVR), ΓÇó To determine the efficacy of oral doses of CXA-10 on stable background therapy administered for 6 months in subjects with PAH assessed by pulmonary vascular resistance (PVR) as measured by right heart catheterization (RHC), 6 months",PAH,nitro fatty acid compound,NCT03449524
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: macitentan|DRUG: tadalafil,PHASE4,"pulmonary vascular resistance (PVR), Change from Baseline to Week 16 in percentage of patients with clinically meaningful improvement of PVR (decrease of 30% from baseline to Week 16), 16 weeks","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Endothelin receptor antagonist",NCT02968901
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: NX1011,PHASE2,"To evaluate the safety, tolerability, and activity of inhalation therapy with NX1011 based on right heart catheterization (RHC) measures, pulse oximetry, and hemodynamic response|To establish maximum tolerated dose (MTD) levels of NX1011 based on predefined criteria for dose-limiting toxicity (DLT)|To qualify the delivery apparatus|To generate descriptive data on the concentration-response relationship in order to choose a range of concentrations (e.g., low, medium, high) for the follow-up, fixed-dose, placebo-controlled study|To summarize correlation data between echocardiography and RHC measures with respect to activity and methemoglobin levels documented via the visible light spectroscopy",Pulmonary Hypertension,NaN,NCT00323024
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Ambrisentan,PHASE4,"Changes From Baseline in Peak Exercise Mean Pulmonary Artery Pressure (mPAP), Transpulmonary Pressure Gradient (TPG), and Pulmonary Capillary Wedge Pressure (PCWP), mPAP is measure of the blood pressure found in the main artery of the lung. TPG is the difference between mean pulmonary arterial pressure and left atrial pressure. PCWP is the pressure measured by wedging a pulmonary catheter with an inflated balloon into a small pulmonary arterial branch., Baseline to Week 24|Change From Baseline in Peak Exercise Pulmonary Vascular Resistance (PVR), PVR is the resistance offered by the pulmonary circulatory system., Baseline to Week 24|Change From Baseline in Peak Exercise Pulmonary Vascular Compliance (PVC ), PVC is a measure of a pulmonary vein's ability to expand., Baseline to Week 24|Change From Baseline in Peak Exercise Cardiac Output (CO), CO is the amount of blood pumped by the heart per minute., Baseline to Week 24|Change From Baseline in Peak Exercise Maximum Oxygen Uptake (VO2max), VO2max is the measurement of the maximum amount of oxygen that an individual can utilize during intense or maximal exercise., Baseline to Week 24",Exercise-induced Pulmonary Arterial Hypertension,"Antihypertensive, Endothelin receptor type A antagonist",NCT01338636
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Bosentan|DRUG: Sitaxsentan||BIOLOGICAL: Endothelin-3,EARLY_PHASE1,"Plasma ET-1 after 7-day administration of bosentan, sitaxsentan and placebo, 7 days|Responses to ET-3 (maximum vasodilation after ET-3 administration and area under the curve of vasodilation) after bosentan compared with the results from sitaxsentan and placebo., 60 mins",Pulmonary Arterial Hypertension|Vasodilation|Vasoconstriction,"Antihypertensive, Endothelin receptor antagonist",NCT01100736
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Treprostinil Diolamine,PHASE3,"Time to First Clinical Worsening Event, Clinical worsening was assessed continuously from randomization until the subject's last study visit. Clinical worsening events were defined as death (all causes), hospitalizations due to worsening pulmonary arterial hypertension (PAH), initiation of an inhaled or infused prostacyclin (PGI2) for the treatment of worsening PAH, disease progression, or unsatisfactory long-term clinical response. All clinical worsening events reported by the study sites were reviewed by the Sponsor Medical Monitors. Once a clinical worsening event occurred, it was entered in the eCRF and a narrative was submitted for review by the Sponsor's Medical Monitor within 48 hours after the event became known to the Investigator or designee. Subsequently, the narratives for subjects with the reported clinical worsening events were sent to an independent adjudication committee. The independent adjudication committee reviewed and adjudicated all clinical worsening events throughout the study., From randomization to approximately 4 years",Pulmonary Arterial Hypertension,"Anticoagulant, Vasodilator, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT01560624
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Dichloroacetate Sodium|DRUG: Dichloroacetate Sodium|DRUG: Dichloroacetate Sodium,PHASE1,"Assessment of safety and tolerability of DCA in patients with pulmonary arterial hypertension., December 2010","Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)","Antineoplastic, Nootropic",NCT01083524
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Sildenafil,PHASE3,NaN,"Hypertension, Pulmonary","Vasodilator, Impotence therapy, Phosphodiesterase V inhibitor",NCT00780728
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Aerosolized iloprost,PHASE4,6 minute walk test,Hypertension,"Antihypertensive, Platelet aggregation inhibitor, Prostaglandin I2",NCT00120380
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: selexipag (Uptravi),PHASE2,"Area Under the Plasma Concentration-time Curve Over a Dose Interval at Steady State of Selexipag and Its Metabolite ACT-333679 Combined (AUC╧ä, ss, Combined), AUC╧ä, ss, combined was defined as the area under the plasma concentration-time curve over one dosing interval at steady state. AUC╧ä,ss,combined was calculated as 1/38 AUC╧ä,ss,selexipag plus 37/38 AUC╧ä,ss,ACT-333679., Week 1,Week 12: pre-dose, 1, 2, 4, 6, 8 and 12 h post-morning dose. Week 2, 4 and 6: pre-dose (Up to Week 12)","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Vasodilator, Prostaglandin I2 receptor agonist",NCT03492177
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Ambrisentan plus Spironolactone|DRUG: Ambrisentan plus Placebo,PHASE4,"Effect of Combination Ambrisentan + Spironolactone on Peak Volume of Oxygen Consumption (pVO2) and Cardiac Output, Study the effect of combination ambrisentan (5-10 mg/d) + spironolactone (50 mg/d) on pVO2 and cardiac output. The pVO2 refers to a measure of general physical fitness measured during exercise., Up to average of 20 min","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Endothelin receptor type A antagonist",NCT02253394
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: macitentan,PHASE3,"Incident Rate of Treatment-emergent Adverse Event, An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. A treatment-emergent AE is any AE temporally associated with the use of study treatment., From Day 1 to End of study (EoS) visit (an average of 3 years)|Incident rate of treatment-emergent adverse events (AEs) leading to premature discontinuation of study treatment, Any AE will be recorded that 1) is (temporally) associated with the use of study treatment whether or not considered by the investigator as related to study treatment and 2) leads to premature discontinuation of study medication., From Day 1 to EoS visit (an average of 3 years)|Incident rate of treatment-emergent serious adverse events (SAEs), Any SAE as defined by the ICH guidelines will be recorded. Any hepatic AE that leads to discontinuation of study treatment will be defined as SAE., From Day 1 to EoS visit (an average of 3 years)|Number of pregnancies with maternal exposure to macitentan, Pregnancies with maternal exposure to macitentan will be recorded., From Day 1 to EoS visit (an average of 3 years)",Pulmonary Arterial Hypertension|Chronic Thromboembolic Pulmonary Hypertension,"Antihypertensive, Endothelin receptor antagonist",NCT03422328
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Nitric Oxide for inhalation|DRUG: Oxygen|DRUG: Nitric Oxide plus Oxygen,PHASE3,"Number of Participants With Reversible Pulmonary Hypertension (Vasoreactivity), A composite of hemodynamic measurements were used to identify reversible pulmonary hypertension (vasoreactivity), on Day 1",Idiopathic Pulmonary Arterial Hypertension|Cardiomyopathy,pulmonary vasodilator,NCT00626028
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Elafin,PHASE1,"Incidence of Treatment-Emergent Adverse Events in healthy controls., Safety and tolerability will be determined on the basis of adverse events reported and the severity of adverse events., 28 day time period","Pulmonary Arterial Hypertension, Primary",elastase inhibitor,NCT03522935
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Sitaxsentan alone|DRUG: Sitaxsentan|DRUG: Rifampin,PHASE1,"Comparison of Peak Plasma Concentrations of sitaxsentan co-administered with rifampin versus sitaxsentan administered alone., 24 hours|Comparison of Area Under the Curve of sitaxsentan co-administered with rifampin versus sitaxsentan administered alone., 24 hours","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Endothelin receptor type A antagonist",NCT01251835
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: treprostinil diethanolamine,PHASE1,"Plasma treprostinil concentrations, Pharmacokinetic blood sampling will occur twice for each subject. Pharmacokinetic parameters will be derived from treprostinil concentration-time data, 1 month","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Prostaglandin I2 receptor agonist",NCT01172496
ATP13A3,autosomal recessive,TGF-beta signaling pathway,"DRUG: lloprost(Ventavis,BAYQ6252, 20 ┬╡g/mL)|DRUG: lloprost(Ventavis,BAYQ6252, 10 ┬╡g/mL)",PHASE1|PHASE2,"The proportion of patients with a meaningful maximum increase (i.e. >=25%) in heart rate AND/OR a meaningful maximum decrease (i.e. >=20%) in systolic blood pressure within the 30 minutes after the start of inhalation, multiple measurements within 30 minutes after iloprost inhalation","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT02032836
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Iloprost Inhalation Solution (Ventavis),PHASE2,Safety,Pulmonary Fibrosis|Pulmonary Hypertension,"Antihypertensive, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT00109681
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: bosentan,PHASE3,"The primary outcome is the change in the following hemodynamics during exercise: pulmonary vascular resistance (PVR), mean pulmonary arterial pressure (mPAP), cardiac outputΓêòcardiac input (COΓêòCI), mean right arterial pressure (mRAP), 6 months","Hypertension, Pulmonary|Connective Tissue Disease","Antihypertensive, Endothelin receptor antagonist",NCT00864201
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: PRX-08066,PHASE2,Systolic Pulmonary Artery Pressure,Pulmonary Hypertension|Chronic Obstructive Pulmonary Disease,NaN,NCT00345774
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Oral Ifetroban|DRUG: Oral Placebo,PHASE2,"Incidence of adverse events (AEs) and Serious AEs (SAEs), Safety is measured using AEs, including clinical significant changes in vital signs, laboratory test abnormalities and clinical tolerability of ifetroban., 56 weeks","Scleroderma, Diffuse|Scleroderma, Systemic|Scleroderma, Limited|Sclerosis, Progressive Systemic|Skin Diseases|Connective Tissue Diseases|Pathologic Processes|Autoimmune Diseases","Antithrombotic, Thromboxane A2 (TXA2) receptor antagonist",NCT02682511
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: AIR001,PHASE2,"To evaluate the intermediate/long-term safety of inhaled nebulized AIR001, The primary objective of this study is to evaluate the intermediate/long-term safety of inhaled nebulized AIR001 administered according to 3 treatment arms (80 milligrams (mg) 4 times daily, 46 mg 4 times daily, or 80 mg once daily) in subjects with World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH) who have completed the 16-week AIR001-CS05 study., minimum of 6 months","Pulmonary Arterial Hypertension, Primary",NaN,NCT01725269
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: rodatristat ethyl 300 mg tablet BID|DRUG: rodatristat ethyl 600 mg BID|,PHASE2,"Percent change from baseline of pulmonary vascular resistance (PVR) as measured by right heart catheterization between active and placebo, From initiation of treatment to Week 24","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Tryptophan hydroxylase inhibitor",NCT04712669
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: AV-101,PHASE2|PHASE3,"Phase 2b: Change from Baseline in Pulmonary Vascular Resistance (PVR), 24 weeks|Phase 3: Change from Baseline in Six Minute Walk Distance (6MWD), 24 weeks","Pulmonary Arterial Hypertension, Primary",NaN,NCT05036135
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Anastrozole,PHASE2,"Plasma Estradiol (E2) Level, Baseline, 3 months|Tricuspid Annular Plane Systolic Excursion (TAPSE), Baseline, 3 months","Pulmonary Arterial Hypertension, Primary","Antineoplastic, Estrogen biosynthesis inhibitor",NCT01545336
ATP13A3,autosomal recessive,TGF-beta signaling pathway,"DRUG: Riociguat (Adempas, BAY63-2521)||DRUG: Sildenafil",PHASE2,"Maximum Change From Baseline in Supine Systolic Blood Pressure (SBP) Within 4 Hours Post-dose at Visit 6 (Week 12), Systolic blood pressure (SBP) was measured as standard vital sign parameter. Range allowed in this study: \<= 180 mmHg. In addition, SBP must be \>=95 mmHg in the first 2 hours after intake of background treatment with sildenafil. The maximum change from baseline at each visit was defined as the within-subject maximum decrease from baseline (or zero if baseline was lower than all subsequent SBP measurements in that profile) within 4 hours post-dose. Baseline was the last SBP recorded at and within 30 minutes before intake of study drug., Pre-dose (baseline) and within 4 hours post-dose at visit 6 (week 12)",Pulmonary Hypertension,"Vasodilator, Guanylate cyclase activator",NCT01179334
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Treprostinil diethanolamine|OTHER: Standardized meals,PHASE1,"Treprostinil pharmacokinetics in healthy volunteers following a single oral dose of a 1 mg treprostinil diethanolamine sustained release tablet after four different meal types., Immediately prior to through 36 hours post treprostinil diethanolamine dosing for each treatment period (4 treatment periods each separated by a 7-day washout period)|Adverse event monitoring, From the first dose of treprostinil diethanolamine through study end (Study Day 23/24)","Hypertension, Pulmonary|Pulmonary Arterial Hypertension","Anticoagulant, Vasodilator, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT00963001
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Ambrisentan,PHASE3,"Change From Baseline to 12 weeks and 24weeks in 6-minute Walk Distance, The 6-minute walk test (6MWT) is a non-encouraged test, performed in a 30 m long flat corridor, where the patient is instructed to walk as far as possible, back and forth around two cones, with the permission to slow down, rest, or stop if needed. These guidelines were provided to all sites. For patients who had never performed a 6MWT previously, a training test was required before the qualifying tests for inclusion were performed., Baseline, week 12 and week 24","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Endothelin receptor type A antagonist",NCT05437224
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Udenafil,PHASE2|PHASE3,"Safety (Adverse Events, Physical Examination, Vital Sign, Electrocardiography, Laboratory test, etc), Adverse Events, Physical Examination, Vital Sign, Electrocardiography, Laboratory test, etc, during 48-weeks","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Impotence therapy, Phosphodiesterase V inhibitor",NCT02304198
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: sitaxsentan sodium,PHASE3,,Pulmonary Hypertension,"Antihypertensive, Endothelin receptor type A antagonist",NCT00080457
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Tadalafil,PHASE4,"All Cause Mortality, 16 weeks|Adverse Events Are no Greater Than With Treprostinil Infusion Alone, 16 weeks|WHO Functional Class Will Improve or Remain Stable, 16 weeks|Hospitalizations, 16 weeks","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Impotence therapy, Phosphodiesterase V inhibitor",NCT01302444
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: BIA 5-1058|DRUG: treprostinil,PHASE1,"Maximum observed plasma concentration - Cmax, Primary Pharmacokinetic Parameters - BIA 5 1058, Pre-dose (Treatment Period 1, Day 1 and Treatment Period 3, Day 6) and post-dose at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours|Area under the plasma concentration-time curve (AUC) from time zero to the last quantifiable concentration - AUC0-t, Primary Pharmacokinetic Parameters - BIA 5 1058, Pre-dose (Treatment Period 1, Day 1 and Treatment Period 3, Day 6) and post-dose at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours|AUC from time zero extrapolated to infinity - AUC0-inf, Primary Pharmacokinetic Parameters - BIA 5 1058, Pre-dose (Treatment Period 1, Day 1 and Treatment Period 3, Day 6) and post-dose at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours|Maximum observed plasma concentration at steady state - Cmax,ss, Primary Pharmacokinetic Parameters - Treprostinil, Pre-last dose (Treatment Period 2, Day 6 and Treatment Period 3, Day 6) and post-last dose at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours.|AUC over the dosing interval at steady state - AUC0-╧ä,ss, Primary Pharmacokinetic Parameters - Treprostinil, Pre-last dose (Treatment Period 2, Day 6 and Treatment Period 3, Day 6) and post-last dose at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours.","Pulmonary Arterial Hypertension, Primary","dopamine β-hydroxylase inhibitor | Anticoagulant, Vasodilator, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT04675944
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: QCC374,PHASE2,"Number of Participants Who Experienced Adverse Events (AEs), Serious Adverse Events (SAEs) in Patients With PAH Over a Two Year Period, Patients with all (serious and non-serious) adverse events, serious adverse events and death were reported, Two years","Pulmonary Arterial Hypertension, Primary",prostacyclin receptor agonist,NCT02939599
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: L-Citrulline Malate,EARLY_PHASE1,"the change in exercise capacity, The primary measure of efficacy was the change in exercise capacity, as measured by the total distance walked in six minutes, from baseline to week 2. (15), 2 weeks",Idiopathic Pulmonary Arterial Hypertension|Eisenmenger Syndrome,Hepatoprotectant,NCT01683981
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Bardoxolone methyl,PHASE2,"Change From Baseline Though Week 16 in 6-Minute Walk Distance (6MWD) for Bardoxolone Methyl Compared to Placebo, Overall treatment effect in exercise capacity, as measured by the total distance walked in 6 minutes (6MWD) mean change from baseline though Week 16. A lower 6MWD reflects greater severity thus, a positive change from baseline suggests an improvement., Baseline through Week 16",Pulmonary Arterial Hypertension|Pulmonary Hypertension|Interstitial Lung Disease|Idiopathic Interstitial Pneumonia|Idiopathic Pulmonary Fibrosis|Sarcoidosis|Respiratory Bronchiolitis Associated Interstitial Lung Disease|Desquamative Interstitial Pneumonia|Cryptogenic Organizing Pneumonia|Acute Interstitial Pneumonitis|Idiopathic Lymphoid Interstitial Pneumonia|Idiopathic Pleuroparenchymal Fibroelastosis,"Anti-inflammatory, Antineoplastic",NCT02036970
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Satralizumab (Genetical Recombination),PHASE2,"Percent change in total pulmonary vascular resistance (PVR) from baseline to 24 weeks., 24 weeks","Pulmonary Arterial Hypertension, Primary","Anti-inflammatory, Immunosuppressant, Anti-IL-6 receptor antibody",NCT05679570
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Treprostinil diethanolamine,PHASE1,"Treprostinil pharmacokinetics, Treprostinil pharmacokinetics in healthy volunteers following a single oral dose of 1mg treprostinil diethanolamine collecting pre and post-dose levels to 36 hours., 36 hours","Pulmonary Arterial Hypertension, Primary","Anticoagulant, Vasodilator, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT01165476
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Macitentan|DRUG: Selexipag|DRUG: FDC of Macitentan and Tadalafil,PHASE3,"Frequency of Treatment Emergent Adverse Events (TEAEs), An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment., Baseline until End of Study (EOS) (Up to 61 months)|Frequency of TEAEs Leading to Discontinuation, Frequency of TEAEs leading to discontinuation of study intervention will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment., Baseline until EOS (Up to 61 months)|Frequency of Serious Adverse Events (SAEs), SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product and is medically important., Baseline until EOS (Up to 61 months)|Frequency of Deaths from Baseline Until EOS, Frequency of deaths will be reported., Baseline until EOS (up to 61 months)","Hypertension, Pulmonary","Antihypertensive, Endothelin receptor antagonist",NCT05179876
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: iloprost|DRUG: iloprost,PHASE3,"Treatment-emergent Adverse Events, Number of adverse events, Double-blind period: from first inhalation of study drug to end of 12-week treatment period. Open-label period: from the start to end of open-label medication, mean duration of exposure was 284.5 days.|Treatment-emergent Serious Adverse Events, Number of serious adverse events, Double-blind period: from first inhalation of study drug to end of 12-week treatment period. Open-label period: from the start to end of open-label medication, mean duration of exposure was 284.5 days.|Adverse Events Leading to Premature Discontinuation of Study Drug, Number of adverse events leading to discontinuation of study treatment, Double-blind period: from the first inhalation of study drug to discontinuation. Open-label period: from the start of open-label medication to discontinuation, mean duration of exposure was 284.5 days.|Patients With Adverse Events Leading to Premature Discontinuation of Study Drug, Number of patients with adverse events leading to discontinuation of study treatment, Double-blind period: from the first inhalation of study drug to discontinuation. Open-label period: from the start of open-label medication to discontinuation, mean duration of exposure was 284.5 days.","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT00709098
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Ambrisentan,PHASE3,Change from baseline at Week 12 of six minute walk distance,Pulmonary Hypertension,"Antihypertensive, Endothelin receptor type A antagonist",NCT00091598
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: GB002 (seralutinib)||DEVICE: Generic Dry Powder Inhaler,PHASE2,"Change from Baseline to Week 24 in Pulmonary Vascular Resistance (PVR), Change in PVR using right heart catheterization (RHC), Baseline, 24 weeks","Pulmonary Arterial Hypertension, Primary",Receptor tyrosine kinase inhibitor,NCT04456998
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Sildenafil citrate|DRUG: Sildenafil citrate|DRUG: Sildenafil citrate,PHASE3,"Number of Participants Reporting at Least One Adverse Event, Safety was measured according to standard adverse event collection as described in the adverse event section of the results. Complete tables of the adverse events according to the A1481156 treatment groups are provided in the reported adverse event section., Up to Follow-Up visit (30 to 40 days after study completion or treatment discontinuation)|Number of Participants Reporting Treatment-related Adverse Events, Safety was measured according to standard adverse event collection as described in the adverse event section of the results., Up to Follow-Up visit (30 to 40 days after study completion or treatment discontinuation)|Number of Participants Reporting at Least One Serious Adverse Event, Safety was measured according to standard adverse event collection as described in the adverse event section of the results. Complete tables of the serious adverse events according to the A1481156 treatment groups are provided in the reported adverse event section., Up to Follow-Up visit (30 to 40 days after study completion or treatment discontinuation)|Number of Participants Reporting Treatment-related Serious Adverse Events, All serious adverse events regardless of treatment group or suspected relationship to study drug were reported. Investigators were to provide independent determination of possible causality of any serious adverse event., Up to Follow-Up visit (30 to 40 days after study completion or treatment discontinuation)|Number of Deaths Reported in the Study Prior to the Data Monitoring Committee (DMC) Recommendation of Dose Down Titration, Deaths were reported immediately independent of the circumstances or suspected cause at any time during the study through the last follow-up visit or 30 days after the last administration of study drug, whichever comes later., Pre-DMC Recommendation dose down titration (04 August 2011)|Number of Deaths Reported During This Study, Deaths were reported immediately independent of the circumstances or suspected cause at any time during the study through the last follow-up visit or 30 days after the last administration of study drug, whichever comes later., Last follow-up visit or 30 days after the last administration of study drug|Discontinuation Due to Intolerability, Participant who experienced drug-related intolerance, the participant's dose was reduced by 50%. If, after a dose reduction, the participant continued to appear intolerant, they were discontinued from study treatment., Throughout the treatment duration (median treatment duration 1689 to 1744 days)|Downtitration in Dose Due to Intolerability., Based on review of the survival data, DMC concluded that the high dose of sildenafil was associated with a harmful effect on survival when compared to the low dose. The DMC also expressed concern as to the potential dose-response relationship between increasing dose and mortality. Therefore, on 04 August 2011, the DMC recommended discontinuation of the 40 mg and 80 mg three times a day (TID) doses, as well as the 20 mg TID dose in children with body weight Γëñ20 kg. The protocol was amended per DMC recommendations., Pre-DMC recomendation (04 August 2011)|Number of Participants With Deterioration Post Baseline in Visual Acuity Safety Tests, Visual Acuity is measured either using the reduced Snellen test or via Teller cards, and was assessed in the left and right eyes separately. There were 9 lines on the reduced Snellen chart which were coded as 6/60, 6/36, 6/24, 6/18, 6/12, 6/9, 6/6, 6/5, 6/4 (where 6/60 was the easiest to read and 6/4 was the most difficult to read). If a participant experienced a visual adverse event the investigator was asked to perform additional ocular assessments either at the visit when the participant reported the visual adverse event or at an unplanned visit., Week 36|Number of Participants With Deterioration Post Baseline in Color Vision Monitoring Safety Tests., Colour vision was measured where appropriate via the Farnsworth-Munsell D-15 Hue test. This test was performed in both eyes simultaneously or just in a single specific eye. If using a single eye the same eye was used throughout the study. In case of young participants an age-and-ability-appropriate evaluation such as the Ishihara Test for Unlettered Persons were conducted., Week 36|Pediatric Cognitive Development Status at Week 16., Participant's cognitive development status was assessed at A1481156 baseline (Week 16 in A1481131; NCT00159913) using the physician assessment questions. Assessment question (i.e., compared to other children the participant's age group is this participant's cognitive development limited?) included the following criteria : severely limited, moderately limited, mildly limited and not limited., Week 16|Pediatric Cognitive Development Status at Week 52., Participant's cognitive development status was assessed at Week 52 using the physician assessment questions. Assessment question (i.e., compared to other children the participant's age group is this participant's cognitive development limited?) included the following criteria : severely limited, moderately limited, mildly limited and not limited., Week 52|Pediatric Motor Development Status at Week 16., Participant's motor development status was assessed at A1481156 baseline (Week 16 in A1481131; NCT00159913) using the physician assessment questions. Assessment question (i.e., compared to other children the participant's age group is this participant's motor development limited?) included the following criteria : severely limited, moderately limited, mildly limited and not limited., Week 16|Pediatric Motor Development Status at Week 52, Participant's motor development status was assessed at Week 52 using the physician assessment questions. Assessment question (i.e., compared to other children the participant's age group is this participant's motor development limited?) included the following criteria : severely limited, moderately limited, mildly limited and not limited., Week 52","Pulmonary Arterial Hypertension, Primary","Vasodilator, Impotence therapy, Phosphodiesterase V inhibitor",NCT00159874
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Epoprostenol,PHASE3,"Treatment-emergent Adverse Events, On average 2.72 years","Pulmonary Arterial Hypertension, Primary","Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT01470144
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Treprostinil,PHASE4,"Assessment of Treprostinil effects on right ventricular structure and function using echocardiography, Assessment of RV structure and function by echocardiography, through study completion, an average of 5 years|Assessment of Treprostinil effects on right ventricular structure and function using Cardiac Magnetic Resonance Imaging (CMR)., Assessment of RV structure and function by cardiac magnetic resonance imaging (CMR)., through study completion, an average of 5 years",Pulmonary Hypertension,"Anticoagulant, Antihypertensive, Vasodilator, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT03835676
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Morphine Sulfate,PHASE2,"Change in Borg Dyspnea Score, Change in peak Borg dyspnea score (morphine versus control), The Peak Borg Dyspnea Score will be determined over 6 minutes of observation during the conduct of each 6-minute walk test. The 6-minute walk tests and assessments of the peak Borg Dyspnea Score will be recorded within 1 and 7 days of each other.","Pulmonary Arterial Hypertension, Primary","Analgesic (narcotic), Opioid receptor agonist",NCT03401476
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Terbogrel low dose|DRUG: Terbogrel high dose,PHASE2,"Change in distance walked in 6 minutes, baseline, after 3 months of treatment|Change in pulmonary vascular resistance (PVR), baseline, after 3 months of treatment","Hypertension, Pulmonary","Platelet aggregation inhibitor, Thromboxane A2 (TXA2) receptor antagonist, Thromboxane A2 (TXA2) synthase inhibitor",NCT02223481
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Anastrozole| Oral Tablet,PHASE2,"Difference in changes in distance walked in six minutes between anastrozole and placebo groups, 6 months","Pulmonary Arterial Hypertension, Primary","Antineoplastic, Estrogen biosynthesis inhibitor",NCT03229499
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Carvedilol,PHASE2,"Mean Change in Right Ventricular Ejection Fraction as Measured by Cardiac MRI, 6 months","Pulmonary Arterial Hypertension, Primary","Antihypertensive, alpha1/beta-Adrenergic receptor antagonist",NCT02507011
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Imatinib mesylate,PHASE2|PHASE3,"Number of Patients With Adverse Events (AEs), Serious Adverse Events (SAEs) and Death During the Core, In this analysis patients with all (serious and non -serious) adverse events, and death were reported. See Safety Section., 6 months|Number of Patients With Adverse Events (AEs), Serious Adverse Events (SAEs) and Death During the Extension, In this analysis patients with all (serious and non -serious) adverse events, and death were reported. See Safety Section., 72 months|Change From Baseline of Six Minute Walk Test - Total Distance Walked at Different Time Periods, The Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. Distance \<500 meters suggests considerable exercise limitation; Distance 500-800 meters suggests moderate limitation; Distance \>800 meters (with no rests) suggests mild or no limitation., Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)|Change From Baseline of Six Minute Walk Test - Number of Stops at Different Time Periods, The Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. Number of stops were recorded for each patient., Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)|Change From Baseline of Six Minute Walk Test - Total Duration of Stops at Different Time Periods, The Six Minute Walk test was carried out along a course, such as a hospital corridor, measuring at least 20 meters delineated by markers. Patients were instructed to walk at a comfortable speed as far as they could manage in six minutes, resting whenever they needed to. If the patient stopped the duration of each stop was recorded., Baseline, Day 32, Week 8, Week 12, Week 16, Week 20 and Study completion (Week 24)","Pulmonary Arterial Hypertension, Primary","Antineoplastic, Tyrosine kinase inhibitor",NCT00477269
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: Sildenafil citrate|DRUG: Sildenafil citrate||DRUG: Sildenafil citrate,PHASE3,"Percent Change From Baseline in Peak Volume of Oxygen (VO2) Consumed : Intent To Treat Population, Peak VO2 (normalized for body weight) at trough plasma levels assessed by CPX testing (bicycle ergometry)at the end of treatment (Week 16 for those who completed the study). Mean Percent change = \[(week 16 value minus baseline mean)/mean at baseline\]\*100%., Baseline, Week 16|Percent Change From Baseline in Peak Volume of Oxygen (VO2) Consumed : Per Protocol Population, Peak VO2 (normalized for body weight) at trough plasma levels assessed by CPX testing (bicycle ergometry)at the end of treatment (Week 16 for those who completed the study). Mean Percent change = \[(week 16 value minus baseline mean)/mean at baseline\]\*100%., Baseline, Week 16","Pulmonary Arterial Hypertension, Children","Vasodilator, Impotence therapy, Phosphodiesterase V inhibitor",NCT00159913
ATP13A3,autosomal recessive,TGF-beta signaling pathway,"DRUG: Iloprost (Ventavis inhaled, BAYQ6256)",PHASE3,"Change in Pulmonary vascular resistance (PVR) from screening (baseline) to week 12 (after inhalation), At baseline and 12 weeks|Number of participants with adverse events as a measure of safety and tolerability, Up to 52 weeks|Area under the plasma concentration vs time curve from start of inhalation to infinity after single inhalation (AUC), At baseline, 12 weeks, 52 weeks and over 52 weeks|Maximum drug concentration in plasma after start of inhalation (Cmax), Up to 12 weeks|Number of participants with adverse events as a measure of safety and tolerability, Over 52 weeks","Hypertension, Pulmonary","Antihypertensive, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT01469169
ATP13A3,autosomal recessive,TGF-beta signaling pathway,DRUG: bosentan,PHASE4,"6 minute walk distance, ATS Guideline 6MW distance before and after intervention, monthly assessement until date of lung transplantation",Pulmonary Arterial Hypertension|Idiopathic Pulmonary Fibrosis,"Antihypertensive, Endothelin receptor antagonist",NCT00625469
ATP13A3,autosomal recessive,TGF-beta signaling pathway,"DRUG: Riociguat (Adempas, BAY63-2521)",PHASE3,"Number of Participants With Any Treatment-emergent Adverse Events, An adverse event (AE), including AE in relation to a medical device (i.e. Raumedic dosing pipette), is any untoward medical occurrence in a participant administered with a pharmaceutical product and does not necessarily have to have a causal relationship with this treatment. A serious AE (SAE) is any untoward medical occurrence that at any dose is resulting in death, is lifethreatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity. AEs occurring between start of study drug and up to 2 days after the last dose were defined as treatment-emergent AEs (TEAEs)., From start of study drug up to 2 days after the last dose of study drug in the main study part, up to 24 weeks plus/minus 5 days.|Change in Heart Rate From Baseline, Mean change in heart rate from baseline is reported., Baseline and Week 24 (plus/minus 5 days)|Change in Blood Pressure From Baseline, Mean changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP) from baseline are reported., Baseline and Week 24 (plus/minus 5 days)|Change in Respiratory Rate From Baseline, Mean change in respiratory rate from baseline is reported., Baseline and Week 24 (plus/minus 5 days)|Number of Subjects With Transitions From Baseline in Bone Age Compared to Chronological Age, X-ray of left hand was performed for each participant and bone age was determined centrally by a specialist. For each participant, the bone age was compared to the chronological age and assigned to one of the categories - ""delayed"", ""in accordance"" or ""advanced"", indicating the advancement or delay in the growth of the bone. Number of participants who transitioned to another category different from baseline was calculated and is reported., Baseline and Week 24 (plus/minus 5 days)|Change in Hematology Parameters (Platelets) From Baseline, Hematology parameters were collected. Parameters with a decrease or increase in the mean value compared to baseline are reported in this data set., Baseline and Week 24 (plus/minus 5 days)|Change in Hematology Parameters (Lymphocytes/Leucocytes Ratio) From Baseline, Hematology parameters were collected. Parameters with a decrease or increase in the mean value compared to baseline are reported in this data set., Baseline and Week 24 (plus/minus 5 days)|Change in Hematology Parameter (Neutrophils/Leucocytes Ratio) From Baseline, Hematology parameters were collected. Parameters with a decrease or increase in the mean value compared to baseline are reported in this data set., Baseline and Week 24 (plus/minus 5 days)|Change in Clinical Chemistry (Alanine Aminotransferase) From Baseline, Clinical chemistry parameters were collected and analyzed. Parameters with a trend to lower or higher mean values from baseline are reported in this data set., Baseline and Week 24 (plus/minus 5 days)|Change in Clinical Chemistry (Aspartate Aminotransferase) From Baseline, Clinical chemistry parameters were collected and analyzed. Parameters with a trend to lower or higher mean values from baseline are reported in this data set., Baseline and Week 24 (plus/minus 5 days)|Change in Clinical Chemistry (Sodium) From Baseline, Clinical chemistry parameters were collected and analyzed. Parameters with a trend to lower or higher mean values from baseline are reported in this data set., Baseline and Week 24 (plus/minus 5 days)|Change in Clinical Chemistry (Blood Urea Nitrogen) From Baseline, Clinical chemistry parameters were collected and analyzed. Parameters with a trend to lower or higher mean values from baseline are reported in this data set., Baseline and Week 24 (plus/minus 5 days)|Change in Clinical Chemistry (eGFR) From Baseline, Clinical chemistry parameters were collected and analyzed. Parameters with a trend to lower or higher mean values from baseline are reported in this data set. eGFR = estimated glomerular filtration rate, Baseline and Week 24 (plus/minus 5 days)|Change in Clinical Chemistry (Urea) From Baseline, Clinical chemistry parameters were collected and analyzed. Parameters with a trend to lower or higher mean values from baseline are reported in this data set., Baseline and Week 24 (plus/minus 5 days)|Change in Clinical Chemistry (Gamma Glutamyl Transferase) From Baseline, Clinical chemistry parameters were collected and analyzed. Parameters with a trend to lower or higher mean values from baseline are reported in this data set., Baseline and Week 24 (plus/minus 5 days)|Plasma Concentration of Riociguat at Week 0, For each participant, one blood sample was collected at one given time point. Values below lower limit of quantification (LLOQ) were substituted by 1/2 LLOQ for the calculation in statistics. Means at any time were only calculated if at least 2/3 of the individual data were measured and were above the limit of quantification (LOQ). Geometric mean and percentage geometric coefficient of variation (%CV) are reported. W = Week., Week 0 (30-90 minutes post-dose; 2.5-4 hours post-dose)|Plasma Concentration of Riociguat at Week 4, For each participant, one blood sample was collected at one given time point. Values below lower limit of quantification (LLOQ) were substituted by 1/2 LLOQ for the calculation in statistics. Means at any time were only calculated if at least 2/3 of the individual data were measured and were above the limit of quantification (LOQ). Geometric mean and percentage geometric coefficient of variation (%CV) are reported., Week 4 (pre-dose)|Plasma Concentration of Riociguat at Week 8, For each participant, one blood sample was collected at one given time point. Values below lower limit of quantification (LLOQ) were substituted by 1/2 LLOQ for the calculation in statistics. Means at any time were only calculated if at least 2/3 of the individual data were measured and were above the limit of quantification (LOQ). Geometric mean and percentage geometric coefficient of variation (%CV) are reported., Week 8 (pre-dose)|Plasma Concentration of BAY60-4552 at Week 0, BAY60-4552 is riociguat's active metabolite. For each participant, one blood sample was collected at one given time point and in that sample both riociguat and BAY60-4552 were measured. Values below lower limit of quantification (LLOQ) were substituted by 1/2 LLOQ for the calculation in statistics. Means at any time were only calculated if at least 2/3 of the individual data were measured and were above the limit of quantification (LOQ). Geometric mean and percentage geometric coefficient of variation (%CV) are reported. W = Week, Week 0 (30-90 minutes post-dose; 2.5-4 hours post-dose)|Plasma Concentration of BAY60-4552 at Week 4, BAY60-4552 is riociguat's active metabolite. For each participant, one blood sample was collected at one given time point and in that sample both riociguat and BAY60-4552 were measured. Values below lower limit of quantification (LLOQ) were substituted by 1/2 LLOQ for the calculation in statistics. Means at any time were only calculated if at least 2/3 of the individual data were measured and were above the limit of quantification (LOQ). Geometric mean and percentage geometric coefficient of variation (%CV) are reported., Week 4 (pre-dose)|Plasma Concentration of BAY60-4552 at Week 8, BAY60-4552 is riociguat's active metabolite. For each participant, one blood sample was collected at one given time point and in that sample both riociguat and BAY60-4552 were measured. Values below lower limit of quantification (LLOQ) were substituted by 1/2 LLOQ for the calculation in statistics. Means at any time were only calculated if at least 2/3 of the individual data were measured and were above the limit of quantification (LOQ). Geometric mean and percentage geometric coefficient of variation (%CV) are reported., Week 8 (pre-dose)","Hypertension, Pulmonary","Vasodilator, Guanylate cyclase activator",NCT02562235
BMPR2,heterozygous mutation in the BMPR2 gene (600799) on chromosome 2q33,TGF-beta signaling pathway,DRUG: Iloprost,NaN,"Cardiopulmonary exercise test parameters, after 3 months active follow-up","Pulmonary Arterial Hypertension, Primary","Antihypertensive, Platelet aggregation inhibitor, Prostaglandin I2 receptor agonist",NCT01054105
BMPR2,heterozygous mutation in the BMPR2 gene (600799) on chromosome 2q33,TGF-beta signaling pathway,PROCEDURE: Salt loading|DRUG: Hydrochlorothiazide (HCTZ),NaN,"Blood Pressure Change During Salt Loading, Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured every 15 minutes for 4 hours.",Hypertension,"Antihypertensive, Diuretic, Na+-Cl- symport inhibitor",NCT00896389
BMPR2,heterozygous mutation in the BMPR2 gene (600799) on chromosome 2q33,TGF-beta signaling pathway,NaN,NaN,Primary Pulmonary Hypertension 1,"Pulmonary Arterial Hypertension, Primary",NaN,OMIM: 178600
CAV1,heterozygous mutation in the CAV1 gene (601047) on chromosome 7q31,TGF-beta signaling pathway,DRUG: Para-aminohippuric Acid|DRUG: Angiotensin II|DRUG: Norepinephrine,PHASE1,"Genetic Variation at the Caveolin-1 Locus, We are testing our hypothesis that genetic variation at the cav-1 locus is a determinant of vascular phenotypes in hypertensive subjects. We will recruit hypertensive subjects who will be classified into two groups according to genotype status at rs926198 of CAV-1. Vascular function status will be determined using four markers: renal blood flow (primary endpoint), brachial artery reactivity, aortic compliance, and blood pressure levels. We will assess these endpoints before and after two provocations: low vs. high salt intake and AngII infusion., 5 years",Primary pulmonary hypertension|Insulin Resistance,"Antihypotensive, Vasoconstrictor, Adrenergic receptor agonist",NCT01426529
CAV1,heterozygous mutation in the CAV1 gene (601047) on chromosome 7q31,TGF-beta signaling pathway,NaN,NaN,"PULMONARY HYPERTENSION, PRIMARY, 3","PULMONARY HYPERTENSION, PRIMARY",NaN,OMIM: 615343
CYP11B2,autosomal recessive,Aldosterone synthesis and secretion and Aldosterone-regulated sodium reabsorption,DRUG: Osilodrostat (LCI699),PHASE2,"Systolic blood pressure over a 7-week forced titration treatment period, 7 weeks",Primary Hyperaldosteronism,Aldosterone Synthase Inhibitor,NCT00732771
DRD1,G protein-related kinase 4 gene variants,Calcium signaling pathway|cAMP signaling pathway|Neuroactive ligand-receptor interaction|Gap junction|Dopaminergic synapse|Parkinson disease|,DRUG: fenoldopam,PHASE1,"Urine sodium excretion, 7 days",Essential Hypertension,"Antihypertensive, Dopamine D1 receptor agonist",NCT00592150
KCNJ5,Autosomal dominant,Aldosterone synthesis and secretion,DRUG: Clarithromycin,NaN,"Study 1: Change in Relative Aldosterone Secretion Index (RASI)., Within-patient change from baseline of the RASI in adrenal vein blood draining the gland with and without the APA., Baseline and after 45min clarithromycin infusion.|Study 2: Change in plasma aldosterone concentration (PAC)., Within-patient change from baseline of PAC in peripheral venous blood in patients undergoing screening for PA., Baseline and after 60 and 120 minutes roxitromycin administration",Hyperaldosteronism,"Antibacterial, Protein biosynthesis inhibitor",NCT03414918
NR3C2,"heterozygous mutation in the mineralocorticoid receptor gene (MCR, NR3C2; 600983) on chromosome 4q31",Aldosterone-regulated sodium reabsorption,DRUG: Eplerenone (-based therapy) arm|DRUG: Valsartan (-based therapy) arm,PHASE4,"Difference in change of ABPM from baseline, in the eplerenone arm versus the valsartan arm as monotherapy at 8 weeks, as combined dual treatment with amlodipine at 16 weeks and as combined triple treatment with amlodipine and indapamide at 24 weeks., Ambulatory blood pressure measurements (metric unit: mmHg) at baseline and 8,16 and 24 weeks and evaluation of the difference of mean ambulatory systolic and diastolic blood pressure measurements between baseline and each time frame in all participants, 8, 16 and 24 weeks",Hypertension|Obesity,"Antihypertensive, Aldosterone antagonist",NCT03476616
NR3C2,"heterozygous mutation in the mineralocorticoid receptor gene (MCR, NR3C2; 600983) on chromosome 4q31",Aldosterone-regulated sodium reabsorption,DRUG: Eplerenone 50mg,PHASE4,"Reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) Cycle threshold (Ct) value of mineralocorticoid receptor-regulated gene messenger ribonucleic acid (mRNA), Cycle threshold of urinary mRNA biomarker following treatment with placebo and following treatment with eplerenone will be measured using RT-qPCR., Week 6 (after first study treatment)|RT-qPCR Ct value of mineralocorticoid receptor-regulated gene mRNA, Cycle threshold of urinary mRNA biomarker following treatment with placebo and following treatment with eplerenone will be measured using RT-qPCR., Week 12 (after second study treatment)",Hypertension,"Antihypertensive, Aldosterone antagonist",NCT04746495
NR3C2,"heterozygous mutation in the mineralocorticoid receptor gene (MCR, NR3C2; 600983) on chromosome 4q31",Aldosterone-regulated sodium reabsorption,DRUG: Eplerenone|DRUG: Chlorthalidone|DRUG: Potassium,PHASE4,"Change in myocardial flow reserve, Change in myocardial flow reserve (ratio of hyperemic stress myocardial blood flow to rest myocardial blood flow), 9 months",Hypertension|Left Ventricular Hypertrophy,"Antihypertensive, Aldosterone antagonist",NCT05593055
NR3C2,"heterozygous mutation in the mineralocorticoid receptor gene (MCR, NR3C2; 600983) on chromosome 4q31",Aldosterone-regulated sodium reabsorption,DRUG: Eplerenone|DRUG: Chlorthalidone with potassium chloride,PHASE4,"Change in stress myocardial perfusion reserve on cardiac MRI, Change in myocardial perfusion, one year",Metabolic Syndrome|Hypertension|Overweight and Obesity,"Antihypertensive, Aldosterone antagonist",NCT04519164
NR3C2,"heterozygous mutation in the mineralocorticoid receptor gene (MCR, NR3C2; 600983) on chromosome 4q31",Aldosterone-regulated sodium reabsorption,DRUG: KBP-5074,PHASE3,"Change in seated trough cuff SBP from baseline to Week 12, Efficacy of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP for KBP-5074 dose regimen compared to placebo, will be evaluated., From baseline to Week 12|Change in seated trough cuff SBP from Week 48 to Week 52, Durability of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP for the KBP-5074 dose regimen compared to placebo, will be evaluated., Week 48 to Week 52",Chronic Kidney Diseases,NaN,NCT04968184
NR3C2,"heterozygous mutation in the mineralocorticoid receptor gene (MCR, NR3C2; 600983) on chromosome 4q31",Aldosterone-regulated sodium reabsorption,DRUG: Finerenone|DRUG: Spironolactone,PHASE4,"Hypertension remission rate., The proportion of patients with blood pressure\<140/90 mmHg at 12 weeks., 12 weeks.",Primary Aldosteronism|Hypertension,"Diuretic, Aldosterone antagonist",NCT05814770
NR3C2,mutation in the mineralocorticoid receptor gene (600983),Aldosterone-regulated sodium reabsorption,NaN,NaN,Hypertension exacerbated in pregnancy,Secondary hypertension,NaN,OMIM: 605115
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,PROCEDURE: Renal denervation|DRUG: Metoprolol|DRUG: Lisinopril,PHASE2,"cardiovascular death, 1 year|myocardium infarction, 1 year|stroke, 1 year|repeat revascularization, 1 year",Acute Coronary Syndrome|Arterial Hypertension,"Antihypertensive, Vasodilator, beta1-Adrenergic receptor antagonist",NCT01901549
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Everolimus,PHASE4,"Molecular profile of cytokines, To characterize the molecular profile of cytokines in kidneys obtained from deceased donors such as ""standard"" (SCD) and extended criteria (ECD) in biopsies taken before and after transplantation and to evaluate the effect of treatment with everolimus (EVL) in the expression of these molecules., 12 months",Delayed Function of Renal Transplant,"Antineoplastic, Immunosuppressant, mTOR inhibitor",NCT01663805
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Spironolactone|DRUG: Chlorthalidone,PHASE2,"Change in Systolic Automated Office Blood Pressure from baseline to 12 weeks between arms, Baseline to 12 Weeks",Renal Insufficiency|Chronic Hypertension,"Antihypertensive, Diuretic, Aldosterone antagonist",NCT05222191
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Benazepril hydrochloride,PHASE3,"microalbuminuria excretion rate (spot or 24h), Baseline; 1 week + 24 weeks after treatment start|eGFR, Baseline; 1 week + 24 weeks after treatment start",Renal Alteration,"Antihypertensive, Angiotensin-converting enzyme inhibitor",NCT01095939
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet|DRUG: Valsartan 80 mg Oral Tablet,PHASE2|PHASE3,"Change in mean nocturnal systolic blood pressure, Change in mean nocturnal systolic blood pressure will be analyzed in the two study arms (morning vs. evening dose of sacubitril/valsartan or valsartan) from baseline and after 28 days of intervention., At Baseline and after 28 days of intervention.",Obesity|Cardiovascular Diseases|Hypertension|Nocturnal Blood Pressure|Natriuretic Peptides|Renin-Angiotensin-Aldosterone System,Renin-angiotensin system inhibitor,NCT04971720
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,PROCEDURE: renal sympathetic denervation|DRUG: antihypertensive drugs,PHASE2,"office-based measurements of systolic blood pressure, Between-group change in average office-based measurements of systolic blood pressure from baseline to 12 months after randomization and One-time standard bilateral renal sympathetic denervation by catheter-based radiofrequency ablation., baseline and 12 months (day 360Â±14)",Autosomal Dominant Polycystic Kidney Disease|Hypertension,NaN,NCT01932450
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Ng-monomethyl-L-arginine (drug),PHASE1,,Hypertension,NaN,NCT00345150
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Vasopressin - Very Low Dose|DRUG: Vasopressin - Low Dose| Comparator,PHASE2,"Change in Mean Interdialytic 44-hour Ambulatory Systolic Blood Pressure Over a 2 Week Follow-up Period, This is designed to measure if the administration of intradialytic AVP will result in change in systolic blood pressure., Baseline and Two Weeks",Hypertension|End Stage Renal Disease,"Antidiuretic, Antihypotensive, Arginine vasopressin receptor agonist",NCT01247090
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Gonadotropin-Releasing Hormone Agonist|DRUG: Androgen receptor inhibitor,PHASE4,"Change in Cardiovagal Baroreflex Sensitivity, The change in cardiovagal baroreflex sensitivity will be assessed the modified Oxford procedure, Before and after 9 weeks of androgen deprivation therapy or placebo|Change in blood pressure reactivity to the cold pressor test, The change in blood pressure will be assessed from quiet rest to sympathetic activation using the cold pressor test, Before and after 9 weeks of androgen deprivation therapy or placebo|Change in exercise pressor reflex, The change in blood pressure will be assessed from quiet rest to isometric handgrip exercise, Before and after 9 weeks of androgen deprivation therapy or placebo|Change in ambulatory blood pressure variability, Ambulatory blood pressure variability will be determined from 24-hour ambulatory blood pressure monitoring., Before and after 9 weeks of androgen deprivation therapy or placebo|Change in beat-to-beat blood pressure variability, Beat-to-beat blood pressure variability will be using finger photoplethysmography measured in the laboratory., Before and after 9 weeks of androgen deprivation therapy or placebo|Change in renal vascular resistance, Renal blood flow will be determined using ultrasound and blood pressure will be determined using finger photoplethysmography. These measures will be used to estimate renal vascular resistance., Before and after 9 weeks of androgen deprivation therapy or placebo|Change in Renal dysfunction biomarkers, Neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule (KIM)-1, interleukin (IL)-18, and vanin-1 will be quantified in urine using commercially available assay kits. Concentrations will be normalized to urinary flow rate., Before and after 9 weeks of androgen deprivation therapy or placebo",Androgen Deprivation Therapy|Prostate Cancer|Hypertension|Autonomic Dysfunction|Renal Disease,"Ovulation inducing agent, Luteinizing hormone/choriogonadotropin receptor agonist, Follicle stimulating hormone receptor agonist",NCT05700903
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Linagliptin,PHASE3,"Albumin/Creatinine Ratio (UACR) in 24h urine change between Baseline and Visit 4, up to 14 weeks of study drug intake",Arterial Hypertension|Albuminuria,"Antidiabetic, Dipeptidyl peptidase-4 (DPP-4) inhibitor",NCT02376075
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Aliskiren|DRUG: Amlodipine,PHASE4,"Vascular stiffness, Vascular stiffness will be measured by pulse wave velocity and augmentation index and compared between anlodipine and aliskiren., 8 weeks|Endothelial function, Access endothelial function by peripheral arterial tonometry and brachial flow-mediated vasodilation and compare it between anlodipine and aliskiren., 8 weeks|Renin activity and concentration, Access plasma renin activity and concentration and compare it between anlodipine and aliskiren., 8 weeks",Hypertension|Diabetes Mellitus,"Antihypertensive, Renin-inhibitors",NCT01409408
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Pioglitazone|DRUG: Metformin,PHASE4,"Effects of Pioglitazone on Renal Hemodynamics, At the end of each treatment diet phase, renal clearances were performed for the determination of GFR and RBF, 2008|Effects of Pioglitazone on Sodium and Lithium Clearances, At the end of each treatment and diet phase, 24 urine collections were collected for the determination of sodium and lithium clearances, 2007|Effects of Pioglitazone on 24h Blood Pressure Control, 24 hour blood pressure measurements were performed after each treatment/diet phase, march 2009",Diabetes|Hypertension,Antidiabetic,NCT01090752
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Eplerenone,PHASE4,"Change in LV mass index (g/m2) in ClC-Ka Gly/Gly83 patients and ClC-Ka Gly/Gly83 patients, 12 months",Hypertension,"Antihypertensive, Aldosterone antagonist",NCT01275352
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: ACE Inhibition|DRUG: Intensified Blood Pressure Control|DRUG: Add-on Angiotensin Receptor Blockade,PHASE3,"Time interval to renal 'loss' as defined by an absolute decrease in creatinine clearance by 50 % or attainment of renal replacement therapy., two-monthly",Children|Chronic Renal Failure|Hypertension|Acquired Kidney Disease|Congenital Kidney Disease,NaN,NCT00221845
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Olmesartan medoxomil|DRUG: Losartan|DRUG: Furosemide oral tablets,PHASE3,"Change in mean sitting diastolic blood pressure (dBP), assessed by conventional blood pressure measurements after 12 weeks of treatment, Baseline to 12 weeks",Essential Hypertension|Renal Impairment,"Antihypertensive, Angiotensin II receptor antagonist",NCT00151827
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,OTHER: MAP goal less than or equal to 92 mm Hg|OTHER: MAP goal 102-107 mm Hg|DRUG: Ramipril|DRUG: Amlodipine|DRUG: Metoprolol,PHASE3,"Rate of change in GFR, GFR slope was determined separately during the first 3 months after randomization (acute phase) and during the remainder of follow-up (chronic phase), Up to 3 years",Hypertensive Nephrosclerosis|Chronic Renal Insufficiency,"Antihypertensive, Angiotensin-converting enzyme inhibitor",NCT04364139
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: trandolapril/verapamil|DRUG: Lotrel (amlodipine/benazepril),PHASE4,"Changes in urinary albumin:creatinine ratio, 36 weeks",Hypertension|Diabetes|Proteinuria,Antihypertensive,NCT00234871
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Allopurinol,PHASE1|PHASE2,"Systolic Blood Pressure, 2 months",Hypertension|Renal Transplant,"Gout suppressant, Uric acid biosynthesis inhibitor, Xanthine oxidase inhibitor",NCT00288171
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: hydrocortisone|DRUG: dextrose solution 5%,PHASE2,"renal function, 10 days",Cirrhosis With Ascites,Anti-inflammatory,NCT00657306
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: UT-15C SR (treprostinil diethanolamine),PHASE1,"Treprostinil pharmacokinetics in volunteers with varying degrees of renal function following a single oral dose of a 1 mg treprostinil diethanolamine sustained release., 48hrs post dose (60 hours for ESRD)",Pulmonary Arterial Hypertension|Renal Dysfunction,"Antihypertensive, Prostaglandin I2 receptor agonist",NCT01131845
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Lisinopril|DRUG: Telmisartan,PHASE3,"Number of Participants With 50% Reduction of Baseline eGFR, End Stage Renal Disease (ESRD, Initiation of Dialysis or Preemptive Transplant), or Death., Patients followed for 5-8 years with average of 6.5 years follow up","Kidney, Polycystic","Antihypertensive, Angiotensin-converting enzyme inhibitor",NCT01885559
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: mycophenolate mofetil (CellCept),PHASE2,"The Number of Subjects With a 10% Decrease in PRA Level at Month 8., Enrollment to month 8","Kidney Failure, Chronic|Diabetic Nephropathies|Glomerulonephritis, IGA|Hypertension, Renal","Immunosuppressant, Inosine monophosphate dehydrogenase inhibitor",NCT00446459
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,"DRUG: Beta-blocker, ACE-inhibitor|DRUG: Calcium Channel Blockers, ACE-Inhibitor",PHASE4,"Change in glomerular filtration rate between the two treatment arms., Measured at baseline and after 18 months of treatment",Chronic Kidney Insufficiency|Hypertension|Vasodilation,NaN,NCT01380717
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: fimasartan,PHASE1,"pharmacokinetic characteristic of fimasartan, AUC, Cmax, Tmax, T1/2, and CL/F of fimasartan, 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 32, 48h",Renal Impairment,"Antihypertensive, Angiotensin II receptor antagonist",NCT01148368
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: 6R-BH4|OTHER: 6R-BH4 placebo|DIETARY_SUPPLEMENT: Folic acid|OTHER: Exercise training|OTHER: Stretching|DIETARY_SUPPLEMENT: Histidine and beta-alanine supplementation|OTHER: Histidine and beta-alanine placebo,PHASE2,"Change in functional sympatholysis, Muscle oxygenation during exercise and sympathoexcitation will be measured., Baseline, Week 12|Change in vascular alpha 1 adrenergic responsiveness, Changes in vascular diameter in response to phenylephrine will be measured., Baseline, Week 12|Change in exaggerated pressor responses during exercise, Blood pressure and sympathetic responses during exercise will be measured., Baseline, Week 12","Renal Insufficiency, Chronic","Antihyperphenylalaninemia, Cofactor replacement (tetrahydrobiopterin)",NCT02947750
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,"DRUG: amlodipine, hydralazine, terazosin or hydrochlorothiazide",PHASE4,"Change in urine microalbumin creatinine ratio, Kidney function will be assessed throughout the study to assess changes in function prior to the washout of ACE/ARB medication and reintroduction of the ACE/ARB medication., Visit 1 (screening visit and the beginning of the washout period may be combined -day -30), Visit 2 (day 30 of the washout period and the beginning of the test period), Visit 3 (day 30 of the test period), Visit 4 day (60) and Visit 5 (day 90)",Type 2 Diabetes|Hypertension,"Antihypertensive, Vasodilator, Calcium channel blocker",NCT02046395
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Optimal medical therapy|PROCEDURE: revascularization,PHASE4,"Glomerular filtration rate in the ischemic kidney after revascularization by means of percutaneous renal angioplasty (PTRAS) or optimal medical treatment., The Primary Objective of the study is to determine if revascularization by means of PTRAS is superior or equivalent to optimal medical treatment for preserving glomerular filtration rate in the ischemic kidney as assessed by 99TcDTPA sequential renal scintiscan, 24 months",Renal Artery Stenosis,NaN,NCT01208714
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: TPN171H single dose,PHASE1,"Area under the curve (AUC), Area under the curve (AUC) for plasma and urine following a single dose of TPN171H in subjects with renal insuffiency and healthy subjects., 72 hours or 120 hours after dosing|Time to maximum plasma concentration (Tmax), Time to maximum plasma concentration (Tmax) for plasma and urine following a single dose of TPN171H in subjects with renal insuffiency and healthy subjects., 72 hours or 120 hours after dosing|Maximum plasma concentration (Cmax), Maximum plasma concentration (Cmax) for plasma and urine following a single dose of TPN171H in subjects with renal insuffiency and healthy subjects., 72 hours or 120 hours after dosing|Terminal half-life (t 1/2), Terminal half-life (t 1/2) for plasma and urine following a single dose of TPN171H in subjects with renal insuffiency and healthy subjects., 72 hours or 120 hours|Apparent distribution volume (Vd), Apparent distribution volume (Vd) for plasma and urine following a single dose of TPN171H in subjects with renal mpairment and healthy subjects., 72 hours or 120 hours after dosing|Clearance rate (CL), Clearance rate (CL) for plasma and urine following a single dose of TPN171H in subjects with renal insuffiency and healthy subjects., 72 hours or 120 hours after dosing|Oral bioavailability (F), Oral bioavailability (F) for plasma and urine following a single dose of TPN171H in subjects with renal insuffiency and healthy subjects., 72 hours or 120 hours after dosing|Adverse events, Number of Participants With treatment-related Adverse Events and Serious Adverse Events., From administration of study drug through 8 days after administration of study drug",Pulmonary Arterial Hypertension|Erectile Dysfunction,"Antihypertensive, Impotence therapy, Phosphodiesterase V inhibitor ",NCT05208814
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: aliskiren 300 mg once daily|/sugar pill,PHASE4,"Change in Flow-mediated Dilation, Flow-mediated dilation of the brachial artery assessed by ultrasound to evaluate improvement of arterial functioning by % of dilation after non-invasive occlusion, Baseline to 3 months",Diabetes|Pre-hypertension|Hypertension,"Antihypertensive, Renin inhibitor",NCT01349114
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Sodium nitrite|DRUG: Sodium chloride,PHASE1,"Fractional urinary sodium excretion (FENa), 1 day",Hypertension,Antidote (cyanide poisoning),NCT02527837
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: losartan potassium|DRUG: Comparator: Placebo,PHASE4,"Incidence of chronic allograft nephropathy, 24 months post treatment",High Blood Pressure,"Antihypertensive, Angiotensin II receptor antagonist",NCT00140907
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Aliskiren|DRUG: Amlodipine| of Aliskiren| of amlodipine,PHASE2,"Part 1: Aliskiren Concentrations From Interstitial Fluid (Microdialysis)at the End of Aliskiren Treatment Period, Interstitial fluid was obtained from subcutaneous adipose and skeletal muscle tissues by microdialysis using the zero-flow method. Interstitial fluid was collected for measurements of drug concentrations on the last day of the aliskiren treatment periods (Day 42)., Day 42|Part 1: Amlodipine Concentrations From Interstitial Fluid (Microdialysis) at the End of Amlodipine Treatment Period, Interstitial fluid was obtained from subcutaneous adipose and skeletal muscle tissues by microdialysis using the zero-flow method. Interstitial fluid was collected for measurements of drug concentration on the last day of the amlodipine treatment periods (Day 98)., Day 98|Part 1: Angiotensin II Levels in Interstitial Fluid of Fat and Skeletal Muscle (Microdialysis) During Aliskiren Treatment Period, Interstitial fluid was obtained from subcutaneous adipose and skeletal muscle tissues by microdialysis using the zero-flow method to determine Ang II concentration., Day 42|Part 1: Angiotensin II Levels in Interstitial Fluid of Fat and Skeletal Muscle (Microdialysis) During Amlodipine Treatment Period, Interstitial fluid was obtained from subcutaneous adipose and skeletal muscle tissues by microdialysis using the zero-flow method to determine Ang II concentration., Day 98|Part 1: Aliskiren Concentrations From Tissue at the End of Aliskiren Treatment Period, Biopsies were taken from abdominal adipose and skeletal muscle tissue to determine aliskiren concentration. Tissue biopsy samples for drug concentrations analyses were taken on the last day of the aliskiren treatment periods (Day 42)., Day 42|Part 1: Angiotensin II Levels From Tissue During Aliskiren Treatment Period, Biopsies were taken from abdominal adipose and skeletal muscle tissue to determine Ang II concentration., Day 42|Part 1: Renin Activity and Concentrations From Adipose and Skeletal Tissues During Aliskiren Treatment Period, Day 42|Part 1: Aliskiren Concentrations From Plasma at the End of Aliskiren Treatment Period, Plasma samples were obtained for measurement of aliskiren or amlodipine concentrations. All blood samples were taken by an indwelling cannula inserted in a forearm vein or direct venipuncture. The plasma samples for drug concentrations analyses were taken on the last day of the aliskiren treatment periods (Day 42)., Day 42|Part 1: Amlodipine Concentrations From Plasma at the End of Amlodipine Treatment Period, Plasma samples were obtained for measurement of aliskiren or amlodipine concentrations. All blood samples were taken by an indwelling cannula inserted in a forearm vein or direct venipuncture. The plasma samples for drug concentrations analyses were taken on the last day of the amlodipine treatment periods (Day 98)., Day 98|Part 1: Angiotensin II Levels in Plasma During Aliskiren Treatment Period, Interstitial fluid was obtained from subcutaneous adipose and skeletal muscle tissues by microdialysis using the zero-flow method to determine Ang II concentration., Day 42|Part 1: Angiotensin II Levels in Plasma During Amlodipine Treatment Period, Interstitial fluid was obtained from subcutaneous adipose and skeletal muscle tissues by microdialysis using the zero-flow method to determine Ang II concentration., Day 98|Part 1: Renin Concentrations From Plasma During Aliskiren Treatment Period, Renin concentrations from plasma were measured as: plasma renin concentration (PRC), prorenin concentration and total renin concentration (renin + prorenin concentration)., Day 42|Part 1: Renin Concentrations From Plasma During Amlodipine Treatment Period, Renin concentrations from plasma were measured as plasma renin concentration (PRC), prorenin concentration and total renin concentration (renin + prorenin concentration)., Day 98|Part 1: Renin Activity From Plasma During Aliskiren Treatment Period, Plasma Renin activity (PRC) was measured by a trapping PRA (tPRA) assay., Day 42|Part 1: Renin Activity From Plasma During Amlodipine Treatment Period, Plasma renin activity (PRC) was measured by a trapping PRA (tPRA) assay., Day 98|Part 2: Change From Baseline in Angiotensin II Levels in Interstitial Fluid of Fat and Skeletal Muscle (Microdialysis) During Double Blind Treatment Period, Interstitial fluid was obtained from subcutaneous adipose and skeletal muscle tissues by microdialysis using the zero-flow method to determine Ang II concentration., Placebo Baseline (Day 14), Active Treatment (Day 98)|Part 2: Change From Baseline in Plasma Angiotensin II Levels During Double Blind Treatment Period, Plasma Ang II was measured prior to and 1 hour after the Insulin modified-frequently sampled intravenous glucose tolerance test (IM-FSIGT) during placebo treatment (Days 14) and active treatment(Day 98)., Placebo Baseline (Day 14), Active Treatment (Day 98)|Part 2: Plasma Renin Activity (PRA) Concentration During Double Blind Treatment Period, Day 98|Part 2: Plasma Renin Concentration (PRC) Levels During Double Blind Treatment Period, Day 98",Hypertension|Abdominal Obesity,"Antihypertensive, Renin inhibitor",NCT00498433
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Aliskiren,PHASE4,"The Change of Blood Pressure, The change of systolic blood pressure and diastolic blood pressure, baseline and 6 month|The Change of Heart Function Confirmed by Echocardiograph, Left ventricular ejection fraction (LVEF)were measured by echocardiogram at baseline and 6 month. Plasma BNP level were measured by the radioimmunoassay (RIA) method at baseline and 6month., baseline and 6 month|The Change of BNP, Plasma BNP level were measured by the radioimmunoassay (RIA) method at baseline and 6month., baseline and 6month|The Change of eGFR, eGFR was calculated at baseline and at 6 month using a modified version of the Modification of Diet in Renal Disease (MDRD) formula of the Japanese Society of Nephrology as follows: eGFR (ml/min/1.73 m2) = 194 Ã— age-0.287 Ã— serum creatinine-1.094 (multiplied by 0.739 for females)., baseline and 6 month|The Change of Urine Albumin/ Creatinine Ratio (UACR)., The UACR was measured at baseline, Week12 and Week24, baseline and 6 months",Hypertension|Chronic Kidney Disease,"Antihypertensive, Renin inhibitor",NCT01284114
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,OTHER: Lower body negative pressure (LBNP)|DRUG: Candesartan cilexetil,PHASE4,"sodium excretion, sodium excretion will be compared to control group (healthy volunteers) after one hour of lower negative pressure. The protocol includes 2 hours of baseline measure, one hour of lower negative pressure and 2 hours of recovery, after one hour of lower body negative pressure",Hypertension|Obesity|White Coat Hypertension|Resistant Hypertension,"Antihypertensive, Angiotensin II receptor antagonist",NCT01734096
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: valsartan,PHASE4,"Cardiovascular events, 2 years|End-stage renal dysfunction, 2 years|50% reduction of creatinine clearance, 2 years",Hypertension,"Antihypertensive, Angiotensin II receptor antagonist",NCT00140790
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Digoxin immune fab,PHASE4,"Blood pressure, Screening, and 24-hour period after first infusion and after second infusion",Hypertension|Hemodialysis,Cardiotonic,NCT00852787
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Telmisartan|DRUG: Ramipril,PHASE4,"Change from baseline of renal plasma flow (RPF) in response to L-NMMA infusion at the end of treatment., 9 weeks","Diabetes Mellitus, Type 2|Hypertension","Antihypertensive, Angiotensin II receptor antagonist",NCT00240422
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: CS-3150,PHASE3,"Change from baseline in sitting systolic and diastolic blood pressure, Change from baseline in sitting systolic and diastolic blood pressure, Baseline to end of Week 12",Hypertension With Moderate Renal Impairment,"Antihypertensive, Aldosterone antagonist",NCT02807987
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Eplerenone,PHASE4,"Significant drop in blood pressure with Eplerenone when compared to placebo., days",Hypertension|Dialysis|Hyperaldosteronism,"Antihypertensive, Aldosterone antagonist",NCT00553722
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Lisinopril|DRUG: Telmisartan||OTHER: Standard Blood Pressure Control|OTHER: Low Blood Pressure Control,PHASE3,"Study A: Percent Annual Change in Total Kidney Volume, Annual percentage change in total kidney volume as assessed by abdominal magnetic resonance imaging (MRI) at baseline, 2 years, 4 years, and 5 years follow-up., Baseline and 2-, 4- and 5-year follow-up","Kidney, Polycystic","Antihypertensive, Angiotensin-converting enzyme inhibitor",NCT00283686
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Aprocitentan 25 mg,PHASE3,"Change from Baseline to Week 4 of double-blind treatment in mean trough sitting systolic blood pressure measured by automated office blood pressure measurement., From baseline to Week 4 after treatment initiation","Hypertension|Renal Insufficiency, Chronic","Antihypertensive, Endothelin Receptor Antagonist",NCT04162366
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,BIOLOGICAL: Blood sampling|PROCEDURE: Blood Pressure Measurement|DEVICE: electrocardiogram|PROCEDURE: orthostatic test|DRUG: Administration of Aprepitant|DRUG: Administration of placebo,PHASE2,"Difference from baseline in Plasma aldosterone concentration, Plasma aldosterone concentration is analyzed, Baseline and Day 14",Type 2 Diabetes|Hypertension,"Anti-emetic, Antidepressant, Antipsychotic, Neurokinin NK1 antagonist",NCT02811055
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Vasopressor Agent|DRUG: Crystalloid Solutions|PROCEDURE: Invasive Blood Pressure Monitoring|PROCEDURE: Intra-Abdominal Pressure Monitoring|OTHER: Abdominal Perfusion Pressure,PHASE4,"Change of the Level of Acute Kidney Injury, Kidney damage will be monitored according to the KDIGO (Kidney Disease Improving Global Outcomes) classification., up to 90 days|Mortality, Mortality in first 30 days, at 30th day of admission|Mortality, Mortality in first 90 days, at 90th day of admission",Septic Shock|Septicemia|Intraabdominal Hypertension|Renal Injury,NaN,NCT05358912
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Rituximab|DRUG: Mycophenolate mofetil (MMF),PHASE2,"The Number of Subjects Who Experience a Decrease in Their Panel of Reactive Antibodies (PRA) at 6 Months Post Rituximab Infusion., the number of subjects who experience a decrease in their Panel of Reactive Antibodies (PRA) at 6 months and 12 months post Rituximab infusion, Month 6 from start of study","Kidney Failure, Chronic|Diabetic Nephropathies|Glomerulonephritis, IGA|Hypertension, Renal","Antineoplastic, Anti-CD20 antibody | Immunosuppressant, Inosine monophosphate dehydrogenase inhibitor",NCT00446251
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Rilmenidine|DRUG: Nitrendipine,PHASE4,"sympathetic activation for the development and progression of chronic renal failure, 3 months",Chronic Kidney Disease|Hypertension,"Antihypertensive, alpha2-Adrenergic receptor agonist",NCT00892892
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: CIN-107,PHASE1,"Maximum plasma concentration (Cmax), This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data, as the data permit., up to Day 8|Time to maximum plasma concentration (Tmax), This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data, as the data permit., up to Day 8|Area under the curve from time 0 to the time of last quantifiable plasma concentration (AUC[0-last]), This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data, as the data permit., up to Day 8|Area under the curve from time 0 to infinity (AUC[0-inf]), This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data, as the data permit., up to Day 8|Percent of AUC extrapolated, This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data, as the data permit., up to Day 8|Terminal phase elimination half-life, This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data, as the data permit., up to Day 8|Apparent plasma clearance (CL/F), This PK parameter will be determined for CIN-107 using plasma concentration data., up to Day 8|Apparent volume of distribution, This PK parameter will be determined for CIN-107 using plasma concentration data., up to Day 8|The cumulative amount of CIN-107 and CIN-107-M excreted in the urine (Ae), This PK parameter will be calculated using the urine concentrations of CIN-107 and its primary metabolite (CIN-107-M), up to Day 8|Renal clearance (CLR) of CIN-107 and CIN-107-M of CIN-107 and CIN-107-M, Calculated as Ae/AUC. This PK parameter will be calculated using the urine concentrations of CIN-107 and its primary metabolite (CIN-107-M), up to Day 8|The fraction of the dose excreted renally, This PK parameter will be calculated using the urine concentrations of CIN-107, up to Day 8|Number of patients experiencing adverse events (AEs), up to Day 11|Number of patients experiencing adverse drug reactions, up to Day 11|Number of patients experiencing serious adverse events (SAEs), up to Day 11",Hypertension,NaN,NCT05470725
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Aliskiren|DRUG: Aliskiren plus placebo|DRUG: Aliskiren|DRUG: Aliskiren plus placebo,PHASE3,"Renal plasma flow following 3 single doses of aliskiren in healthy volunteers on a low sodium(10 mEq/day)diet, baseline and hourly intervals.",Hypertension,"Antihypertensive, Renin inhibitor",NCT00518765
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Febuxostat,PHASE4,"Change in Renal Plasma Flow in Response to Infused Angiotensin II, Baseline to 6 weeks",Hypertension,"Gout suppressant, Uric acid biosynthesis inhibitor, Xanthine oxidase inhibitor",NCT01328769
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Indapamide|DRUG: Hydrochlorothiazide,PHASE4,"renal function, Effects of indapamide SR 1.5 mg on renal function by comparison with hydrochlorothiazide 25 mg, in patients with Mild to Moderate Renal Insufficiency and Hypertension., 1 year",Hypertension|Renal Insufficiency,"Antihypertensive, Diuretic, Na+-Cl- symport inhibitor",NCT01172431
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,PROCEDURE: PVI+renal denervation|PROCEDURE: PVI + GP ablation|DRUG: Optimal medial therapy (OMT),PHASE2,"Freedom of AF or other atrial arrhythmias, 12 months",Atrial Fibrillation|Hypertension,NaN,NCT01898910
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Aliskiren/ Valsartan|DRUG: Telmisartan/ Ramipril,PHASE2,"Compare the effects of aliskiren + valsartan vs ramipril + telmisartan on 24-hour urinary aldosterone, 56 days",Hypertension,"Antihypertensive, Renin inhibitor",NCT00939588
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,"DRUG: Atacand/HCT, Caduet|PROCEDURE: GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting)",PHASE3,"Composite Endpoint: Death From Cardiovascular or Renal Causes, Stroke, Myocardial Infarction, Hospitalization for CHF, Progressive Renal Insufficiency, or Permanent Renal Replacement Therapy, Only the first event per participant is included in the composite, Measured at every 3 months for the first year and annually thereafter|Cardiovascular or Renal Death, Measured at every 3 months for the first year and annually thereafter|Myocardial Infarction, Measured at every 3 months for the first year and annually thereafter|Hospitalization for Congestive Heart Failure, Measured at every 3 months for the first year and annually thereafter|Stroke, Measured at every 3 months for the first year and annually thereafter|30% Reduction of eGFR From Baseline, Persisting for Greater Than or Equal to 60 Days, Measured at every 3 months for the first year and annually thereafter|Need for Renal Replacement Therapy, Measured at every 3 months for the first year and annually thereafter","Atherosclerosis|Cardiovascular Diseases|Hypertension, Renovascular|Renal Artery Obstruction","Antihypertensive, Angiotensin II receptor antagonist",NCT00081731
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Medical treatment|PROCEDURE: PTRS|DEVICE: renal artery stent|DEVICE: renal artery stent,PHASE4,"Death, Initiation of dialysis therapy or either serum creatinine increase more than 20% or reduction by > 20% in estimated clearance of creatinine (with MDRD formula), 0.5, 1 and 2 years follow up plus extended 4 yrs","Atherosclerosis|Chronic Kidney Disease|Hypertension, Renovascular|Ischemic Nephropathy|Renal Artery Stenosis",NaN,NCT01023373
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,"DEVICE: Renal artery Angioplasty plus stenting.|DRUG: Anti hypertensive, statin and antiplatelet medication.",PHASE4,"Mean change in diurnal systolic blood pressure assessed by ambulatory BP monitoring (ABPM), Baseline to 6 months",Hypertension|Hypertension Resistant to Conventional Therapy|Angiographically Proven Grade III Unilateral or Bilateral Atherosclerotic Renal Artery Stenosis (ARAS) Greater Than or Equal to 60 Percent,NaN,NCT02539810
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Aliskerin/Valsartan and Rampiril,PHASE1,"Mean Change in SBP from baseline to 10 weeks (2 weeks on initial dose & 6 weeks on higher dose), 2 weeks on initial dose & 6 weeks on higher dose",Hypertension|Metabolic Syndrome,"Antihypertensive, Renin inhibitor",NCT01432106
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Aliskiren|DRUG: Aliskiren|DRUG: Comparator: Losartan|DRUG: Comparator: Placebo to Aliskiren|DRUG: Comparator: Placebo to Losartan,PHASE1,"change in renal plasma flow as measured by PAH clearance and on renal blood flow as measured by ASL MRI after single-dose Aliskiren, 2-5 hours post dose of study drug",Hypertension,"Antihypertensive, Renin inhibitor",NCT00856960
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Tadalafil,PHASE3,"Change in renal function, Between-group differences in changes from baseline in: (1a) eGFR using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation and (1b) spot urine albumin-to-creatinine ratio (UACR), Baseline to 48 months|Incidence of acute kidney injury (AKI) events (clinical and subclinical), Impact of treatment on (2a) incidence of AKI events (adjudicated) based on new Kidney Disease Improving Global Outcomes criteria; and (2b) changes from baseline in the urine biomarkers of subclinical kidney injury: Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Marker 1 (KIM-1)., Baseline to 48 months",Heart Failure|Pulmonary Hypertension,"Antihypertensive, Impotence therapy, Phosphodiesterase V inhibitor",NCT01960153
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Aliskiren 150 mg||DRUG: HCTZ|DRUG: Aliskiren 300 mg,PHASE4,"Difference in Peak Plasma PAI-1 Level, baseline to 18 weeks|Difference in Mean Plasma PAI-1 Level, baseline to 18 weeks",High Blood Pressure,"Antihypertensive, Renin inhibitor",NCT03115853
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: calcitriol,EARLY_PHASE1,"Compare plasma renin activity (PRA) and plasma renin concentration (PRC) in hypertensive patients (JNC VII stage I) following 14 days treatment with calcitriol (1Î±, 25-[OH]2 vitamin D3) or matched placebo., 13 MONTHS (MAY 2007-JUNE 2008)",Hypertension|Vitamin D Deficiency,"Osteoporosis agent, Vitamin D receptor agonist",NCT00585442
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,"DRUG: Spironolactone|DRUG: Furosemide,|DRUG: Amiloride|DRUG: Ramipril|DRUG: Bisoprolol",PHASE4,"Reduction of Systolic BP, diastolic BP, mean BP and pulse pressure levels will be used to compare sequential nephron blockade versus dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol, Systolic BP (mmHg), Diastolic BP (mmHg), Mean BP (mmHg) and Pulse Pressure (mmHg), Twenty weeks",Hypertension Resistant to Conventional Therapy,"Antihypertensive, Diuretic, Aldosterone antagonist",NCT02832973
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: LCZ696,PHASE3,"Percentage of Participants With Reported Adverse Events (Total Adverse Events, Serious Adverse Events and Death), Percentage of patients with total adverse events, serious adverse events and death were reported., 8 weeks",Hypertension With Renal Dysfunction,NaN,NCT01593787
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: valsartan,PHASE4,Change from baseline in urine albumin excretion after 24 weeks|Change from baseline in an ultrasound measurement of blood flow after 24 weeks,Hypertension,"Antihypertensive, Angiotensin II receptor antagonist",NCT00171353
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Bisoprolol Fumarate 5-10 mg|DRUG: Amlodipine 5-10 mg,PHASE4,"Change in Left Ventricular Mass Index, 6 months","Hypertension, Renal","Antihypertensive, Vasodilator, beta1-Adrenergic receptor antagonist",NCT04085562
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,"DRUG: MK0954, losartan potassium/Duration of Treatment: 20 weeks|DRUG: Comparator: amlodipine / Duration of Treatment: 20 weeks",PHASE4,24h proteinuria,Renal Disorder,"Antihypertensive, Angiotensin II receptor antagonist",NCT00140985
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Aliskiren,PHASE3,Adverse events after 8 weeks,Hypertension,"Antihypertensive, Renin inhibitor",NCT00299832
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DEVICE: stent|DRUG: Aspirine|DRUG: Clopidogrel|DRUG: Lercanidipine,PHASE4,"Glomerular filtration rate, 12 months|Blood pressure, 12 months",Hypertension,"Anticoagulant, Platelet aggregation inhibitor, Purinergic receptor P2Y12 antagonist | Antihypertensive, Calcium channel blocker",NCT02594410
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Bendavia,PHASE1|PHASE2,"Change in Mean Glomerular Filtration Rate (GFR), as Measured by Iothalamate Clearance, at Baseline (Pre-percutaneous Renal Artery Angioplasty and 8 Weeks Post-PTRA., Change in mean glomerular filtration rate (GFR), as measured by iothalamate clearance, from baseline (pre-percutaneous renal artery angioplasty, or pre-PTRA) and 8 weeks post-PTRA.., Baseline (pre-PTRA) and 8 weeks post-PTRA","Renal Artery Obstruction|Hypertension, Renovascular|Ischemia Reperfusion Injury",NaN,NCT01755858
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,"DEVICE: Radiofrequency ablation catheter|DRUG: Amlodipine, losartan potassium and hydrochlorothiazide",PHASE3,"Change in average 24-hour systolic blood pressure by ambulatory blood pressure monitoring from baseline, 3 months post-randomization",Hypertension,"Antihypertensive, Angiotensin II receptor antagonist",NCT02900729
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: valsartan|DRUG: Conventional antihypertensive drugs,PHASE4,"Course of renal and cardiac function, every month for renal function and every year for cardiac function",Chronic Kidney Disease|Hypertension,"Antihypertensive, Angiotensin II receptor antagonist",NCT00190580
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Chlorthalidone,PHASE2,"Change From Baseline to 12 Weeks in Systolic Ambulatory Blood Pressure in the Chlorthalidone Group Compared to Placebo., Baseline to 12 weeks","Renal Insufficiency, Chronic|Hypertension","Antihypertensive, Diuretic, Na+-Cl- symport inhibitor",NCT02841280
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: CS-3150,PHASE2,"Change from baseline in sitting systolic and diastolic blood pressure, Baseline to end of Week 12",Hypertension,"Antihypertensive, Aldosterone antagonist",NCT02448628
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,BEHAVIORAL: USUAL - take your BP Meds as you usually do|BEHAVIORAL: HS DOSING|DRUG: ADD On Dosing,PHASE2|PHASE3,"Night Time Blood Pressure, Night time blood pressure from APBM at weeks 6, 12, and 18",Hypertensive Renal Disease,NaN,NCT00582777
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,"DRUG: New Medication: Enalapril, Isradipine, Propranolol",PHASE2|PHASE3,"Number of Participants Who Are Non Dippers, Percentage of subjects in each of the treatment arms who are nondippers, defined as systolic or diastolic nocturnal dip \<10%, 6 months",Hypertension Secondary to Kidney Transplant,"Antihypertensive, Vasodilator, Angiotensin-converting enzyme inhibitor",NCT01007994
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,PROCEDURE: Renal denervation|DRUG: adenosine infusion treatment,PHASE4,"Change in coronary atheroma, Evaluation of the change in coronary atheroma (change in percent atheroma volume (PAV) and the change in nominal atheroma volume in the 10-mm subsegment with the greatest disease severity at baseline), analyzed by an IVUS, between baseline and 2-year IVUS in the patients with CAD) for RENEWAL-REGRESS trial, change in coronary atheroma for 24 months after renal denervation",Resistant Hypertension,NaN,NCT01918111
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Amlodipine|DRUG: Valsartan,PHASE4,"Flow mediated dilatation, 12 weeks after",Diabetes|Hypertension|Proteinuria,Renin-angiotensin system inhibitor,NCT00921570
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Aliskiren|DRUG: Hydrochlorothiazide,PHASE4,"Renal Oxygenation Changes After Chronic Treatment With Aliskiren or Hydrochlorothiazide, Changes in R2\* at between week 0 and week 8 as measured by BOLD MRI in the cortex and medulla of the kidney, week 0 vs week 8",Hypertension,"Antihypertensive, Renin inhibitor",NCT01519635
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Losartan 100Mg Tab|DRUG: Qianyangyuyin 20g Granule|,PHASE2|PHASE3,"albumin-to-creatinine ratio(UACR), UACR tested at baseline and each month. Microalbuminuria was defined as urinary ACR of at least 30mg/g., 6 months",Hypertension|Renal Injury,"Antihypertensive, Angiotensin II receptor antagonist",NCT04078711
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: aliskiren,PHASE4,"Renal function (Creatinine clearance), One year (every 6 months)|Urinary protein, One year (every 6 months)","Glomerulonephritis, IGA|Hypertension","Antihypertensive, Renin inhibitor",NCT01184599
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Arterial infusion of autologous mesenchymal stem cells,PHASE1,"Renal blood flow and function in the treated kidneys., Individual kidney blood flow, measured by multidetector CT contrast transit times, will be measured before and after MSC infusion., 2 years",Atherosclerotic Renal Artery Stenosis|Ischemic Nephropathy|Renovascular Hypertension,NaN,NCT01840540
REN,homozygous or compound heterozygous mutation in genes encoding components of the renin-angiotensin system: renin (179820) on chromosome 1q32,Renin-angiotensin system,DRUG: Glyceryl trinitrate vs phentolamine for prophylaxis against renal impairment,PHASE4,"kidney function tests, creatinine in micromoles per liter and urea in millimole per liter, 96 hours after intervention",Pre-Eclampsia; Complicating Pregnancy|Pre-eclampsia Aggravated,"Antihypertensive, Vasodilator (coronary)",NCT05687669
ACVRL1,Autosomal dominant,Cytokine-cytokine receptor interaction,NaN,NaN,"Telangiectasia, hereditary hemorrhagic, type 2",Primary Hypertension,NaN,OMIM: 600376
AGT,Multifactorial,Renin-angiotensin system,NaN,NaN,"Hypertension, essential","Hypertension, essential",NaN,OMIM: 145500
CUL3,heterozygous mutation in the CUL3 gene (603136) on chromosome 2q36,"	Aldosterone-regulated sodium reabsorption",NaN,NaN,genetic heterogeneity of pseudohypoaldosteronism type II | aldosterone resistance is due to heterozygous mutations in the mineralocorticoid receptor gene,Secondary hypertension,NaN,OMIM: 603136
CYP11B1,homozygous or compound heterozygous mutation in the CYP11B1 gene (610613) on chromosome 8q24,Steroid hormone biosynthesis,NaN,NaN," Adrenal hyperplasia, congenital, due to 11-beta-hydroxylase deficiency",Primary Hypertension,NaN,OMIM: 202010
CYP11B1,anti-Lepore-type fusion of the CYP11B2 (124080) and CYP11B1 genes (see 610613.0002),Steroid hormone biosynthesis|Aldosterone synthesis and secretion|Cortisol synthesis and secretion,NaN,NaN,"Aldosteronism, glucocorticoid-remediable",Primary Hypertension,NaN,OMIM: 103900
CYP17A1,mutation in the gene encoding steroid 17-monooxygenase (CYP17A1; 609300),Steroid hormone biosynthesis,NaN,NaN,"17,20-lyase deficiency",Secondary hypertension,NaN,OMIM: 202110
EIF2AK4,autosomal recessive,TGF-beta signaling pathway,NaN,NaN,Pulmonary venoocclusive disease 2,Primary Hypertension,NaN,OMIM: 234810
HSD11B2,autosomal recessive,Steroid hormone biosynthesis,NaN,NaN,Apparent mineralocorticoid excess,Primary Hypertension,NaN,OMIM: 218030
KCNK3,heterozygous mutation in the KCNK3 gene (603220) on chromosome 2p23,TGF-beta signaling pathway,NaN,NaN,"PULMONARY HYPERTENSION, PRIMARY, 4",PULMONARY HYPERTENSION,NaN,OMIM: 615344
SCNN1A,"heterozygous mutation in the SCNN1A gene (600228), encoding the alpha subunit of the renal epithelial sodium channel (ENaC), on chromosome 12p13",Aldosterone-regulated sodium reabsorption,NaN,NaN,Liddle Syndrome 3,Secondary hypertension,NaN,OMIM: 618126
SCNN1B,"heterozygous mutation in the SCNN1B gene (600760), encoding the beta subunit of the renal epithelial sodium channel (ENaC), on chromosome 16p12.",Aldosterone-regulated sodium reabsorption,NaN,NaN,Liddle Syndrome 1,Secondary hypertension,NaN,OMIM: 177200
SCNN1G,"heterozygous mutation in the SCNN1G gene (600761), encoding the gamma subunit of the renal epithelial sodium channel (ENaC), on chromosome 16p12",Aldosterone-regulated sodium reabsorption,NaN,NaN,Liddle Syndrome 2,Secondary hypertension,NaN,OMIM: 618114
WNK1,autosomal recessive,"	Aldosterone-regulated sodium reabsorption",NaN,NaN,"Neuropathy, hereditary sensory and autonomic, type II",Secondary hypertension,NaN,OMIM: 201300
WNK4,autosomal recessive,"	Aldosterone-regulated sodium reabsorption",NaN,NaN,"Pseudohypoaldosteronism, type IIB",Secondary hypertension,NaN,OMIM: 614491
SMAD9,heterozygous truncating mutation in the SMAD9 gene,TGF-beta signaling pathway,NaN,NaN,Primary Pulmonary Hypertension 2,Primary Pulmonary Hypertension,NaN,OMIM: 615342
